DocTrack

DOCTRACK SOLUTIONS LIMITED

(Previously known as Docmode Health Technologies Limited)

CIN: L74999MH2017PLC297413

2025 - 2026

ANNUAL REPORT

Registered Office Address:
201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road,
Malad West, Mumbai – 400064, Maharashtra, India

INDEX

1. COMPANY OVERVIEW:

I am pleased to present the Annual Report of Doctrack Solutions Limited for the financial year 2025-26. This report sets out the manner in which your Company has consolidated its established lines of business, restructured the way in which those businesses are taken to market, and prioritised the protection of operating margins and the generation of cash over the pursuit of headline revenue growth during the year under review.

Originally incorporated as "Docmode Health Technologies Private Limited" in Mumbai, Maharashtra in 2017, the company was subsequently converted to a Public Limited company in December 2022 and its name was changed to "Docmode Health Technologies Limited." Thereafter, the name of the Company was further changed from “Docmode Health Technologies Limited” to “Doctrack Solutions Limited” pursuant to the approval granted by the Registrar of Companies (ROC) vide approval letter dated 28th July, 2026. Under the experienced leadership of our founders with over 25 years of collective expertise in healthcare advertising, health IT, healthcare communications, and event management, Doctrack has evolved into a multi-faceted organization serving diverse stakeholders across the global healthcare ecosystem

Doctrack is engaged in the business of offering integrated learning solutions through online and offline learning models to healthcare professionals and learners across the world, spanning the education value chain. The Company's offline learning model includes conferences and workshops, while the online courses are developed and presented by the in-house content development team, medical institutions, associations, subject matter experts, and key opinion leaders.

Doctrack's primary focus is on providing tech-driven online learning solutions that allow healthcare professionals and learners to engage in self-paced, inclusive, and individualized learning experiences. The Company's online learning model comprises notes, recorded videos, live conferences, and workshops. Additionally, Doctrack provides a platform for inter-professional, cross-industrial learning via panel discussions and courses, as well as leverages its performance assessment tools to enhance the clinical acumen of its users.

Beyond learning, the Company operates a network-powered surveys, studies and research offering that enables practising and certified healthcare professionals to participate in and contribute to marketing surveys, clinical studies and research; a knowledge marketing services line that supports medico-marketing organisations with scientific promotional literature, medical writing and customised learning initiatives; clinical research support services delivered under the oversight of an Ethics Committee registered with the Central Drugs Standard Control Organisation; and an online store for healthcare professionals offering books, journals, articles, event passes and memberships.

The Company is led by its experienced promoters, who have a collective experience of over 25 years in the fields of healthcare advertising, health IT, healthcare communications, and event management. Doctrack's promoters founded the Company with the vision of "Transforming Learning & Practice" in the medical fraternity, and they actively oversee the business development and strategic aspects of the Company.

The Company is supported by a team of qualified and experienced professionals who have demonstrated their ability to manage and grow the Company's operations, adapt and diversify its offerings, and leverage market opportunities. The Company is registered as ISO 27001:2013 for Information Security Management System and has also received a "ready" status from Skill India.

Contributors: Doctrack collaborates with international medical associations, key opinion leaders, and subject matter experts to develop certified courses for its users.

The Year in Review:

The financial year 2025-26 was, by deliberate choice, a year of consolidation rather than expansion. No new business lines and no new products were introduced during the year. Management's attention was directed instead towards three objectives: deepening the business already being secured from existing clients, restructuring the route to market so as to reduce the fixed cost of selling, and restoring operating profitability.

The most significant structural development of the year was the conclusion of reseller and distributor tie-ups covering a majority of the Company's current services and products. Under these arrangements, appointed partners undertake front-end market development, client engagement and, in defined cases, first-line service support within agreed territories and market segments. The Company retains ownership of its content and platforms and continues to be responsible for delivery standards and quality. The commercial effect of the arrangement is that a layer of largely fixed selling and market development cost is replaced by variable partner compensation, and that the Company's market coverage extends into territories and client segments that it was not addressing economically through its own sales effort.

Your directors consider it appropriate to state plainly the consequence of this decision for the reported results. Where business is transacted through a partner rather than billed directly, the Company's share of the end-customer value is lower. Reported topline may therefore be affected in the near term. In exchange, the Company removes a substantial fixed cost from its structure, and the margins on the business it does record are both higher in quality and more predictable. On the business the Company is already securing, your directors regard this as the better trade.

In parallel, the Company placed renewed emphasis on growing its traditional, directly billed business with pharmaceutical and healthcare clients. These engagements are repeat in nature, are supported by documented service arrangements, and provide reasonable revenue visibility. During the year, management concentrated on renewing and expanding mandates from existing clients rather than pursuing new categories of business, and exercised pricing discipline on renewals. Where an engagement did not meet the Company's revised margin thresholds, it was not pursued.

The Company also undertook a review of its online portal business. This line has not generated returns commensurate with the resources deployed on it. The Company is accordingly evaluating its options, including operating the business through reseller arrangements and the monetisation or divestment of certain components of the platform. No binding commitment has been entered into as at the date of this report, and any transaction will be undertaken in accordance with applicable law and with such approvals as may be required.

Alongside these measures, management implemented a structured cost rationalisation programme covering manpower deployment, delivery costs, technology and infrastructure spends and discretionary overheads. Delivery was consolidated around fewer and better-utilised teams and third-party costs were renegotiated. The objective of the programme was the restoration of operating profitability, and the Company's operating margin for the first half of the financial year improved over the corresponding period of the previous year.

Business Model:

The Company's business model is asset-light and technology-driven. Content, once developed, can be delivered repeatedly and across geographies without proportionate incremental cost, and the Company's platforms support additional volume without corresponding infrastructure investment. Following the cost rationalisation undertaken during the year, incremental volumes can be absorbed at a materially lower marginal cost than before, which is central to the Company's margin recovery.

The Company's registered base of healthcare professionals, built and verified over several years, is the foundation upon which the learning, survey and studies businesses rest. It is this network, rather than any single product, that constitutes the Company's principal asset, and its maintenance and verification continued to receive management attention throughout the year.

2. COMPANY'S UNIQUE SELLING PROPOSITIONS (USPs):

The Company's competitive position rests on an established base of long-standing client relationships, a large verified network of healthcare professionals, a breadth of service lines delivered within a single compliance framework, and, with effect from the year under review, a distribution network that extends reach without a corresponding increase in fixed cost. The Company's underlying value proposition has not changed during the year; what has changed is the manner in which it is taken to market and the discipline with which it is priced.

Integrated Service Offering Across the Value Chain

The Company offers medical education and professional development, surveys and studies, knowledge marketing support and clinical research support services from within a single organisation. Few competitors are able to address more than one or two of these requirements, and clients that engage the Company for one service line frequently extend the engagement to others.

This integration has a direct commercial effect. The cost of securing incremental business from an existing client is a fraction of the cost of acquiring a new one, and a broader service footprint allows the Company to be considered for a larger share of a client's annual spend. In a year in which the Company deliberately reduced its market development expenditure, this characteristic of the business became more important, not less.

Large and Verified Network of Healthcare Professionals

The Company's registered base of healthcare professionals’ spans specialities and geographies and provides access to the medical community for education, surveys, studies and market intelligence purposes. The network is verified and speciality-mapped, and it is this verification, rather than raw scale alone, that underpins the credibility of the data and insights generated for clients.

Building an equivalent network requires sustained investment over an extended period and continuous engagement with the professional community. It is not a capability that can be acquired quickly, and it constitutes a practical barrier to entry in the Company's principal markets.

Established Reseller and Distributor Network

During the year the Company concluded reseller and distributor arrangements covering a majority of its current services and products. These arrangements provide access to established relationships in defined territories and market segments, expand market coverage without a corresponding increase in fixed selling cost, and allow the Company to concentrate its own resources on content, delivery, quality and margin management.

The model also improves the variability of the Company's cost structure. Partner compensation is linked to business actually transacted, whereas a direct sales organisation carries cost irrespective of outcome. In a business with the revenue volatility that the Company has experienced, this is a material improvement in operating resilience.

Traditional, Directly Billed Client Relationships

A substantial part of the Company's revenue continues to arise from directly billed engagements with pharmaceutical and healthcare clients under established commercial arrangements. These engagements are repeat in nature, are documented, and provide reasonable revenue visibility from one year to the next. The Company has consciously prioritised the protection and growth of this business. It is well understood, it is delivered by teams with long experience of the clients concerned, and it carries the lowest cost of acquisition of any revenue available to the Company.

Compliance-Led Design and Delivery

The Company's processes are designed around the compliance requirements applicable to its clients, including the Uniform Code for Pharmaceutical Marketing Practices, 2024 and the professional conduct requirements applicable to registered medical practitioners. Programme design, documentation, disclosure and record-keeping are structured so as to withstand scrutiny by the client's own compliance function and by regulators.

As the industry has restructured its engagement with healthcare professionals, this has moved from being a cost of doing business to being a basis of selection. Clients increasingly empanel a smaller number of service providers capable of meeting these standards, and the Company benefits from that consolidation.

Information Security and Quality Credentials

The Company's ISO 27001:2013 certification for its Information Security Management System, together with its "ready" status from Skill India, supports its position with clients requiring documented information security and quality standards. For multinational clients in particular, certification of this kind is frequently a condition of empanelment rather than a differentiator, and its absence would exclude the Company from consideration.

Independent Ethics Oversight for Research

The Company's Ethics Committee is registered with the Central Drugs Standard Control Organisation, enabling independent review and oversight of research protocols. This provides clients with assurance as to the independence of the research process and enables the Company to support studies that would otherwise require the involvement of a third party.

Asset-Light and Scalable Delivery Model

The Company's technology-driven infrastructure enables delivery without geographic constraint and supports incremental volumes without proportionate infrastructure investment. Content, once developed, is reusable across programmes, clients and geographies.

Following the cost rationalisation undertaken during the year, the Company's fixed cost base is materially lighter than it was. Incremental volumes can therefore be absorbed at a lower marginal cost, and the operating leverage available to the Company on a recovery in volumes is correspondingly greater.

Promoter and Management Experience

The promoters bring over 25 years of collective experience across healthcare advertising, health IT, healthcare communications and event management, and remain actively engaged in the business development and strategic aspects of the Company. The senior management team combines domain knowledge of the pharmaceutical and healthcare industry with technology and programme delivery capability.

3. MD, FOUNDER & CFO'S LETTER:

Paresh Sampat, Managing Director

Dear Respected Investors,

I am pleased to address you at this pivotal moment in Doctrack's journey, where our transformation into a comprehensive healthcare research and technology ecosystem is delivering both strategic and financial strength.

While our chairman has set out the Company's long-term vision and our CEO has established the strategic direction, our management team has remained focused on disciplined execution through stronger governance, rigorous compliance, prudent financial management, and continuous operational improvement. These efforts have strengthened the Company's ability to deliver sustainable value to shareholders while maintaining the highest standards of corporate governance.

The year marked an important evolution in the Company's operating model through the implementation of reseller and distributor partnerships, enabling broader market access while maintaining ownership of our platforms, content, and quality standards. Together with a renewed focus on profitable client engagements, operational efficiency, and disciplined execution, these initiatives have strengthened the foundation for sustainable growth.

From an operational perspective, our focus remains on:

Operational Excellence – Driving disciplined execution across all business verticals through enhanced delivery standards, process optimisation, and a continued focus on client satisfaction.

Governance and Compliance – Strengthening corporate governance, regulatory compliance, data security, and quality assurance to uphold the highest standards of operational integrity.

Financial Discipline – Restoring sustainable profitability through prudent cost management, disciplined pricing, operational efficiency, and a balanced approach to growth.

People and Capability Development – Investing in our people by strengthening organisational capabilities, encouraging multi-skilling, and aligning talent with high-value delivery and client service functions.

We are particularly encouraged by the positive progress achieved through our reseller and distributor partnerships, renewed emphasis on directly billed engagements, and disciplined cost rationalisation initiatives. These measures have expanded our market reach, strengthened operational efficiency, and enhanced our ability to deliver sustainable value while maintaining a prudent and scalable operating model.

As Managing Director, I view my role as ensuring that the bold vision of our leadership is matched with robust execution, transparent governance, and measurable outcomes. Together, these elements will secure Doctrack's place as a credible, high-growth player in the global healthcare research market while delivering sustainable returns to you, our valued investors.

I extend my gratitude for your continued trust and support as we advance confidently on this exciting journey.

Paulson Paul Thazhathedath, Founder, Chairman & Whole Time Director:

Dear Shareholders,

It is my privilege to write to you at the close of a financial year in which your Company chose consolidation over expansion, and margin over headline growth. I believe this was the right decision, and I would like to set out the reasoning behind it, together with an honest account of where the business stands.

Over the preceding years, your Company invested substantially in building platforms, content and a network of healthcare professionals. Those investments were necessary and they remain the foundation of the business. What became apparent, however, was that the cost of taking those capabilities to market directly, across a widely dispersed client base and an equally dispersed community of healthcare professionals, had grown faster than the revenue it generated. The result was a business with scale but with insufficient operating profit to show for it. Correcting that has been the central task of the year under review.

The first step was distribution. During the year we concluded reseller and distributor tie-ups covering a majority of our current services and products. Our partners bring established relationships in their territories and market segments, and they carry the front-end cost of developing that market. We retain our content, our platforms, our delivery standards and our quality obligations. I want to be direct with you about what this means in the accounts. Where business is transacted through a partner, our share of the end-customer value is lower than it would be on a directly billed engagement. Reported revenue may therefore moderate. In exchange, we remove a substantial and largely fixed layer of selling and market development cost, and we reach parts of the market that we could never have addressed economically on our own. On the business we are already winning, this is a better trade, and I would rather report a smaller number that carries a margin than a larger one that does not.

The second step was to return attention to our traditional, directly billed business. This is the part of the Company that has always worked: repeat mandates from pharmaceutical and healthcare clients, delivered under documented arrangements, at prices we understand, by teams who have served those clients for years. Rather than chasing new categories of business, your management concentrated during the year on renewing and expanding what we were already securing, and on exercising pricing discipline when doing so. Where an engagement did not meet our revised margin thresholds, we did not pursue it. That discipline costs revenue. It also stops the erosion of profit, and I would ask you to read any moderation in our topline in that light.

The third step was cost. We consolidated delivery around fewer and better-utilised teams, renegotiated third-party and technology costs, and reduced discretionary overheads. None of this was comfortable, and I am grateful to our colleagues for the manner in which they absorbed it. The effect of these measures was visible in the operating margin for the first half of the year, which improved over the corresponding period of the previous year.

We have also taken a hard look at our online portal business. It has not generated returns commensurate with the resources deployed on it, and it would not be honest to describe it otherwise. We are accordingly evaluating our options, which include operating it through reseller arrangements and the monetisation or divestment of certain components of the platform. No commitment has been made as at the date of this report, and any transaction will be undertaken with the approvals that are required. I mention it here because I believe shareholders are entitled to know when a part of the business is under review, rather than to learn of it afterwards.

The regulatory environment continues to move in our favour. The Uniform Code for Pharmaceutical Marketing Practices, 2024 and the professional conduct requirements applicable to registered medical practitioners have obliged the industry to restructure the way it engages with healthcare professionals. Organisations whose documentation, disclosure and record-keeping withstand scrutiny are the ones that clients will retain; the others will not be empanelled at all. Your Company has operated to those standards for some years, at a cost, and that cost is now converting into a commercial advantage.

I do not wish to overstate the position. The Company has been through a difficult period. Our results in the recent past have not been what any of us would want, our borrowing costs remain higher than we would like, and the recovery is not complete. What I can tell you is that the business is now being run for profit rather than for volume; that our cost base is materially lighter than it was; that our distribution arrangements allow us to reach more of the market for less; and that the parts of the business which do not earn their keep are being addressed rather than carried. Those are the conditions under which profitability is restored, and restoring it is the sole measure by which your Board expects to be judged in the coming year.

On behalf of the Board, I record my appreciation for the commitment of our employees, who have carried a heavier load through a demanding year; for the confidence of our clients and our new distribution partners; and for the patience of our shareholders. We are conscious of the trust placed in us and we intend to justify it.

<u>Hans Albert Lewis, Founder, Whole Time Director & Chief Financial Officer</u>

Dear Esteemed Shareholders,

It falls to me, in my capacity as your Whole-time Director and Chief Financial Officer, to describe how the strategy set out by our chairman was executed during the year, and what it has meant in financial and operational terms. I will do so plainly, because I believe that is what the office requires and what shareholders are entitled to expect.

The financial year 2025-26 was managed to a single overriding objective: the restoration of operating profitability. Everything else was subordinated to it. We did not chase revenue, we did not add new products, and we did not enter new lines of business. Instead, we did three things — we changed how the business is distributed, we became disciplined about the business we accept, and we took cost out of the structure.

On distribution, we concluded reseller and distributor tie-ups covering a majority of our current services and products. I want to explain the financial logic, because it is easy to misread the effect on the topline. A direct sales organisation carries cost whether or not it wins business; a partner is compensated only when business is transacted. By moving the front end of the market to partners, we converted a largely fixed cost into a variable one, and we extended our reach into territories and segments we could never have served economically ourselves. The consequence, which I state without qualification, is that on partner-transacted business our share of the end-customer value is lower than on a directly billed engagement, and reported revenue may therefore moderate. I would ask you to weigh that against what we removed from the cost base, and against the quality and predictability of the margins we retain. On the business we are already winning, this is the better outcome.

On the traditional, directly billed business, we returned our attention to what has always worked for this Company: repeat mandates from pharmaceutical and healthcare clients, delivered under documented arrangements by teams who know those clients well. Rather than pursue new categories of work, we concentrated on renewing and expanding the mandates we already held, and we applied pricing discipline when doing so. We revised our engagement-level margin thresholds upward, and where a piece of business did not clear them, we let it go. That discipline costs revenue in the short term. It also stops the erosion of profit, and it is the discipline I intend to maintain.

On cost, we consolidated delivery around fewer and better-utilised teams, renegotiated our third-party, technology and infrastructure contracts, and reduced discretionary overheads. We redeployed people from front-end market development, now largely carried by our partners, into delivery and client servicing. The effect was visible in our operating margin for the first half of the year, which improved over the corresponding period of the previous year. It is my responsibility to ensure that this cost base does not quietly re-expand as volumes recover, so that the benefit of recovery reaches operating profit rather than being absorbed.

We also examined our online portal business honestly. It has not earned a return commensurate with the resources it consumes, and I will not present it otherwise. We are evaluating our options for it, including operating it through reseller arrangements and the monetisation or divestment of certain components of the platform. No commitment has been made as at the date of this report, and any transaction will carry the approvals it requires and will be disclosed as required.

As Chief Financial Officer, I would draw your attention to the balance sheet as well as to the profit and loss account. During the year we directed particular attention to the ageing of our trade receivables and the discipline of our collections, to the level and cost of our borrowings, and to the conversion of operating profit into cash. Our finance costs remain higher than I consider appropriate for a business of our scale, and their reduction is an explicit objective for the year ahead. Working capital discipline and cash generation will receive the same weight in the coming year as margin.

The regulatory environment continues to work in our favour. As the industry restructures its engagement with healthcare professionals under the Uniform Code for Pharmaceutical Marketing Practices, 2024 and the professional conduct requirements applicable to registered medical practitioners, clients are consolidating around a smaller number of service providers whose documentation, disclosure and record-keeping withstand scrutiny. We have operated to those standards for some years, at a cost, and that cost is now converting into commercial advantage. Our ISO 27001:2013 certification and the independent oversight of our registered Ethics Committee are part of the same picture.

I will not overstate our position. Our recent results have not been what we would wish, the recovery is incomplete, and our cost of borrowing remains a constraint. What I can tell you is that the business is now run for profit rather than volume; that our cost base is materially lighter; that our distribution reaches further for less; and that the parts of the business which do not earn their keep are being addressed rather than carried. Those are the conditions under which profitability returns, and returning it is the measure by which I expect to be judged.

I am grateful to my colleagues, who absorbed a demanding year with commitment; to our clients and distribution partners, for their confidence; and to you, our shareholders, for your patience. We understand the trust placed in us, and we intend to earn it.

4. STRATEGIC OUTLOOK & GROWTH INITIATIVES:

The Company's strategic outlook for the period ahead is built on consolidating its established strengths, distributing its services more efficiently, and protecting the margins on the business it secures. The principal initiatives are set out below.

Enhanced Market Position: Doctrack is positioned as a hybrid organisation that combines technology-enabled delivery with established pharmaceutical and healthcare business models. The Company's comprehensive service portfolio — spanning CME and learning, research and studies, knowledge marketing services and clinical research services — addresses the evolving needs of the industry within a single compliance framework. The Company's reseller and distributor network extends this portfolio into new territories and market segments, including selective high-value and international opportunities, without a corresponding increase in fixed cost.

Revenue Diversification: The Company's multi-segment approach across education, research and studies, knowledge marketing and clinical research services creates resilient revenue streams while reducing dependency on any single market segment. The renewed focus on the traditional, directly billed pharmaceutical and healthcare business provides access to established, comparatively higher-margin opportunities, while the reseller and distributor model broadens the Company's reach at variable rather than fixed cost. Business lines that do not generate returns commensurate with the resources deployed on them are being reviewed and rationalised.

Investment in Excellence: Continued investment in regulatory compliance, technology platforms and market development will drive sustainable competitive advantages while positioning the Company for a leading role in a consolidating market for healthcare education and research services. The Company's compliance-led approach to programme design and documentation, its ISO 27001:2013 certification for Information Security Management System, and the independent oversight of its Ethics Committee registered with the Central Drugs Standard Control Organisation are central to this positioning as clients consolidate their empanelled service providers.

Operational Discipline and Margin Protection: The Company will maintain the cost rationalisation achieved during the year, apply defined engagement-level margin thresholds, and direct attention to working capital, collections, the cost of borrowing and the conversion of operating profit into cash. The Company accepts that reported topline may moderate as its distribution model changes, and regards the restoration of sustainable operating profitability as the priority measure of progress.

With its established capabilities, strategic market positioning and commitment to operational excellence, Doctrack Solutions Limited is positioned to deliver sustainable value to its stakeholders while consolidating its position in the healthcare education and research landscape.

5. BOARD OF DIRECTORS:

The Board of Directors of the Company comprises Executive, Non-Executive and Independent Directors, whose diverse backgrounds and extensive experience have been instrumental in guiding the Company and in ensuring effective oversight of its operations. Brief particulars of the Directors are set out below:

Paresh Jaysih Sampat is the Managing Director of the Company. He has completed his FCMA from the Institute of Cost Accountants of India, is a Fellow member of the Institute of Company Secretaries of India (FCS), a Chartered Management Accountant (C.I.M.A., London, U.K.), and holds an LL.B. degree and a Bachelor of Commerce degree from Mumbai University. He has extensive experience in managing commercial operations, fund raising, public issues, capital structuring, private equity, mergers, company secretarial and corporate compliances, cost audit, MIS development and the management of corporate affairs.

Paulson Paul Thazhathedath is the Promoter, Chairman and Whole-time Director of the Company. He has over 15 years of experience in the field of mass media and advertisement and has been instrumental in shaping the strategic direction of the Company.

Hans Albert Lewis is the Promoter, Chief Financial Officer and Whole-time Director of the Company. He completed his graduation in mass media and advertising from Wilson College, Mumbai in 2004. He has over 15 years of experience in the field of mass media and advertisement and plays a key role in the Company's financial management and operations.

Monina Elizabeth Lewis is a Non-Executive Director of the Company. She completed her Bachelor of Science degree from Mumbai University in 2001 and has been on the Board of the Company since March 20, 2023. She has over 6 years of experience as an officer in coordination and training follow-up with a foreign airline company.

Sujit Nityanand Chakraborty is an Independent Non-Executive Director of the Company. He holds a Master of Computer Applications degree from Indira Gandhi National Open University (2008) and an International Executive Master of Business Administration in project management from Ulyanovsk State University. He has more than 25 years of experience in the field of information technology.

Nilay Shivnarayan Sharma is an Independent Non-Executive Director of the Company. He holds a Bachelor of Engineering degree from Shivaji University, Kolhapur, and has more than 30 years of experience in the field of information technology.

The composition of the Board of Directors as at March 31, 2026 and any changes therein during the financial year 2025-26 are to be confirmed and updated in accordance with the records of the Company.

6. CORPORATE INFORMATION:

NAME AND DESIGNATION OF DIRECTORS:

Name of the Director	DIN	Designation
Mr. Paresh Jaysih Sampat	00410185	Managing Director
Mr. Paulson Paul Thazhathedath	02301881	Chairman & Whole Time Director
Mr. Hans Albert Lewis	02301853	Whole Time Director
Mr. Sujit Nityanand Chakraborty	07275025	Independent Director
Mr. Nilay Shivnarayan Sharma	00231299	Independent Director
Ms. Monina Elizabeth Lewis	10147743	Non-Executive Director

KEY MANAGERIAL PEERSONNEL (KMP):

Name of the KMP	DIN / PAN	Designation
Mr. Paresh Jaysih Sampat	00410185	Managing Director
Mr. Hans Albert Lewis	ACOPL6883G	Chief Financial Officer
Mr. Hans Albert Lewis	02301853	Whole Time Director
Mr. Paulson Paul Thazhathedath	02301881	Whole Time Director
Ms. Juhi Tanna	BAHPT5930L	Company Secretary & Compliance Officer

AUDIT COMMITTEE, NOMINATION AND REMUNERATION COMMITTEE AND STAKEHOLDERS' RELATIONSHIP COMMITTEE:

Mr. Sujit Nityanand Chakraborty	Chairman
Mr. Nilay Shivnarayan Sharma	Member
Ms. Monina Elizabeth Lewis	Member

INTERNAL AUDITOR: M/s. C.J.K. Associates Chartered Accountant (Firm Registration Number 117467W)	**REGISTRAR AND TRANSFER AGENT:** Bigshare Services Private Limited E-3, Ansa Industrial Estate, Saki Vihar Road, Sakinaka, Mumbai – 400072, Maharashtra, India
BANKERS: ICICI Bank	**REGISTERED OFFICE:** 201, Kalpataru Plaza, Rambaug, off. Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India
STATUTORY AUDITOR: M/s. R. Sundaresan Aiyar & Co., Chartered Accountant	**LISTED ON:** National Stock Exchange (SME Emerge Platform)
SECRETARIAL AUDITORS: M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 | C. P. No.: 22293)	

7. PRODUCTS & SERVICES:

The Company's service portfolio caters to the needs of healthcare professionals, medical associations and institutions, and the pharmaceutical and healthcare industry. No new products or services were introduced during the year under review. The Company's existing service lines are described below.

7.1 CME and Learning

The Company's learning platform at https://doctrack.co.in/ is a learning environment and platform-as-a-service (PaaS) with a learning management system and collaborating content, covering continuing medical education (CME) and continuing professional development (CPD), in partnership with leading medical institutions, subject matter experts, key opinion leaders and top professional bodies from across the world. Under this line, the Company offers hybrid and blended learning programmes, such as training workshops, fellowships and observerships, along with the publication of books and journals online.

i. **Certification Programs:** The Company offers certificate and non-certificate programmes developed in association with medical associations and universities across the globe, providing healthcare professionals with recognised credentials and structured continuing education pathways.

ii. **National & International Speaker Programs:** The Company organises national and international speaker programmes, inviting key opinion leaders or subject matter experts from various specialisations to facilitate learning and networking initiatives.

iii. **Live Interactive Case-Based Programs with Polling:** The Company facilitates discussions on complicated clinical cases, in which participants share their responses through live polling with real-time results and expert analysis.

iv. **Hybrid and Blended Programs:** Training workshops, fellowships and observerships combining online and in-person components, designed to provide comprehensive professional development pathways.

v. **Publishing:** Publication of books, journals and articles online for the healthcare professional community.

vi. **Target Audience:** Doctors, physicians, surgeons and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians and paramedics.

7.2 Research and Studies:

The Company operates a network-powered survey, studies and research offering to further evidence-based practice in healthcare. It is a route through which practising and certified healthcare professionals participate in or contribute to marketing surveys, clinical studies and research.

i. **Market Research:** Services include the identification of knowledge gaps, product e-detailing, rating and feedback, competitor analysis, literature studies and behavioural research to support evidence-based decision making by clients.

ii. **Studies and Surveillance:** Services include real-world studies, post-marketing surveillance studies and structured data collection for clinical and market-facing research.

iii. **Electronic Data Capture:** Deployment of electronic data capture tools for the structured collection, validation and analysis of study data, with audit trails and defined access controls.

iv. **Evidence Generation:** Generation of authentic clinical and practice-level evidence from the Company's verified professional network, under independent ethical oversight where applicable.

v. **Target Audience:** Pharmaceutical and healthcare companies, medical associations and institutions; and doctors, physicians, surgeons and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians and paramedics.

7.3 Knowledge Marketing Services

The Company assists medico-marketing organisations through knowledge marketing services, supporting the scientific and educational components of their engagement with healthcare professionals.

i. **Scientific Promotional Literature:** Review, development and presentation of scientific promotional literature consistent with applicable marketing codes.

ii. **Medical Writing and Documentation:** Medical writing support, scientific documentation and the preparation of materials for internal and external scientific communication.

iii. **Customised Learning Initiatives:** Customisation of learning initiatives to the therapeutic areas, audiences and compliance requirements of individual clients.

iv. **CRM Solutions:** Customer relationship management solutions tailored to pharmaceutical and healthcare organisations for the management of their engagement with healthcare professionals.

v. **Target Audience:** Medico-marketing companies and medical associations and institutions.

7.4 Clinical Research Services

The Company provides clinical research support services to pharmaceutical, biotechnology and medical device organisations and to academic research institutions.

i. **Study Management:** Support across protocol development, site identification and co-ordination, participant recruitment through the Company's professional network, and study monitoring.

ii. **Post-Marketing Surveillance:** Support for ongoing safety monitoring and effectiveness assessment of products in real-world clinical settings.

iii. **Ethics Committee Oversight:** Independent ethical review and oversight of research protocols through the Company's Ethics Committee, which is registered with the Central Drugs Standard Control Organisation.

iv. **Data Management:** Electronic data capture, data validation, query management and analysis, with defined audit trails and access controls.

v. **Regulatory Documentation Support:** Preparation and compilation of documentation required in connection with regulatory submissions.

vi. **Target Audience:** Pharmaceutical companies, biotechnology firms, medical device manufacturers and academic research institutions.

7.5 Online Store:

The Company operates an online store for healthcare professionals offering books, journals, articles, event passes, memberships and other offers on clinical products. As set out elsewhere in this report, the Company is reviewing the operating model for this business, including the possibility of operating it through reseller arrangements and the monetisation or divestment of certain components of the platform.

Target Audience: Doctors, physicians, surgeons and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians and paramedics.

Through this portfolio of services, the Company addresses the requirements of healthcare professionals, industry partners and institutions across learning, research and professional engagement. The Company's focus during the year under review, and for the period ahead, is on delivering these established services more profitably rather than on extending the portfolio

8. REVIEW OF PERFORMANCE

The financial year 2025-26 was a year in which your Company prioritised the restoration of operating margins and the protection of the business it was already securing over the pursuit of headline revenue growth. The summarised financial results for the year, together with the comparative figures for the previous year, are set out below.

(Rupees in Lakhs)

Particulars	Standalone		Consolidated	
	2025-26	**2024-25**	**2025-26**	**2024-25**
Income	2,691.05	4,270.27	2,691.13	4,270.28
Expenditure	2,705.10	4,467.29	2,705.34	4,466.79
Profit / (Loss) Before Tax	(14.05)	(197.02)	(14.21)	(196.52)
Less: Tax expense	-	-	-	-
Less: Deferred tax	(0.72)	(6.80)	(0.72)	(6.80)
Less: Tax in respect of earlier years	-	12.92	-	12.92
Profit / (Loss) after tax	(13.33)	(203.14)	(13.49)	(202.64)
Less: Preference Dividend	-	-	-	-
Add: Previous Year Balance B/F	521.05	724.19	520.64	723.20
Less: Capitalization of reserves	-	-	-	-
Balance carried to Balance Sheet	507.72	521.05	507.15	520.64
Less: Equity Dividend	-	-	-	-

8.1 Overview of Results

The Company's total income and operating results for the year ended March 31, 2026 are set out in the table above and are to be completed on finalisation of the audited financial statements. The movement in revenue for the year reflects two deliberate decisions: the transition of a portion of the business to a reseller and distributor-led distribution model, under which the Company's share of the end-customer value is lower than under a directly billed engagement; and the exercise of pricing discipline on renewals, under which engagements that did not meet the Company's revised margin thresholds were not pursued. The corresponding reduction in direct selling and market development costs, together with the cost rationalisation programme implemented during the year, supported an improvement in operating margins. The Company's operating margin for the first half of the financial year improved over the corresponding period of the previous year.

8.2 Margin Protection and Cost Discipline

The principal operational objective for the year was the restoration of operating profitability. Delivery was consolidated around fewer and better-utilised teams; third-party, technology and infrastructure costs were renegotiated; discretionary overheads were reduced; and manpower was redeployed from front-end market development, now substantially undertaken by appointed partners, towards delivery and client servicing.

Pricing discipline was applied on renewals and engagement-level margin thresholds were revised upward. Management intends to hold the cost base at its rationalised level as volumes recover, so that the benefit of any improvement in volume accrues to operating profit rather than being absorbed by cost.

8.3 Reseller and Distributor-Led Distribution

The reseller and distributor tie-ups concluded during the year cover a majority of the Company's current services and products. These arrangements extend market coverage without a corresponding increase in fixed selling cost, and convert a portion of fixed selling cost into variable partner compensation linked to business actually transacted.

Where business is transacted through a partner, the Company's share of the end-customer value is lower than under a directly billed engagement, and reported topline may therefore be affected. The arrangements nonetheless improve the quality of margins, the predictability of the cost base and the Company's resilience to fluctuations in demand.

8.4 Traditional, Directly Billed Business

The Company placed renewed emphasis on the traditional business of directly billed engagements with pharmaceutical and healthcare clients. Management concentrated during the year on renewing and expanding mandates from existing clients rather than pursuing new categories of business. This business remains the core of the Company's revenue and the principal focus of its growth efforts, and it carries the lowest cost of acquisition of any revenue available to the Company.

8.5 Review of the Online Portal Business

The online portal business has not generated returns commensurate with the resources deployed on it. The Company is evaluating its options for this line, including operating it through reseller arrangements and the monetisation or divestment of certain components of the platform. No binding commitment has been entered into as at the date of this report, and any transaction will be undertaken with such approvals as may be required.

8.6 Network, Platform and Assets

The Company's registered base of healthcare professionals continued to be maintained and verified during the year and remains the foundation of the learning, survey and studies businesses. Development work previously carried as capital work-in-progress was completed and capitalised during the year, with a corresponding increase in the fixed asset base and in the depreciation charge for the year.

8.7 Operational Excellence and Compliance

The Company's ISO 27001:2013 certification for Information Security Management System, its "ready" status from Skill India, and the registration of its Ethics Committee with the Central Drugs Standard Control Organisation continue to support its position with clients requiring documented compliance and quality standards. The Company also continued to strengthen its secretarial and compliance function during the year.

8.8 Financial Position and Liquidity

Management's focus during the year extended beyond the profit and loss account to the balance sheet. Attention was directed towards the ageing of trade receivables and the discipline of collections, the level and cost of borrowings, and the conversion of operating profit into cash. The Company's borrowing costs remain higher than management considers appropriate for a business of its scale, and their reduction is an objective for the period ahead.

8.9 Outlook

The Company's focus for the coming year remains unchanged: to grow the traditional, directly billed business; to extend reach through the reseller and distributor network; to hold the cost base at its rationalised level; to address business lines that do not generate adequate returns; and to convert improved operating margins into cash. Management accepts that reported revenue may moderate as the distribution model changes, and considers this an acceptable outcome in exchange for the restoration of sustainable operating profitability

DOCTRACK SOLUTIONS LIMITED
DIRECTORS' REPORT

To,
The Members,

Your Directors take pleasure in presenting 09th (Nineth) Annual Report of your Company together with the Audited Financial Statement for the year ended 31st March, 2026.

1. Financial Performance of the Company:

(Rupees in Lakhs)

Particulars	Standalone		Consolidated	
	2025-26	2024-25	2025-26	2024-25
Income	2691.05	4270.27	2,691.13	4270.28
Expenditure	2705.10	4467.29	2,705.34	4466.79
Profit/ (Loss) Before Tax	(14.05)	(197.02)	(14.21)	(196.52)
Less: Tax expense	-	-	-	0.08
Less: Deferred tax	(0.72)	(6.80)	(0.72)	(6.80)
Less: Tax in respect of earlier years	-	12.92	-	12.92
Profit/ (Loss) after tax	(13.33)	(203.14)	(13.49)	(202.64)
Less: Preference Dividend	-	-	-	-
Add: Previous Year Balance B/F	521.05	724.19	520.64	723.20
Less: Capitalization of reserves	-	-	-	-
Balance carried to Balance Sheet	507.72	521.05	507.15	520.64
Less: Equity Dividend	-	-		-

2. Details of the Subsidiaries, Associate and Joint Ventures:

The Company does not have any Joint Venture or Associate Company as on 31st March, 2026. The statement containing salient features of the financial statements of the Company's subsidiary is given in Form AOC-1 as an ***Annexure-I*** to this Directors' Report.

The highlights of performance of subsidiaries and their contribution to the overall performance of the Company during the financial year is given under the consolidated financial statements forming part of the Annual Report.

During the year under review, none of the companies ceased to be a subsidiary of the Company.

3. State of the Company's Affairs:

The Company has earned total income of Rs. 2691.05 Lakhs [Previous Year: Rs. 4270.27 Lakhs on a standalone basis and INR 2,691.13 Lakhs [Previous Year: INR 4270.28 Lakhs] on consolidated basis. The expenses incurred during the year are INR 2,705.10 Lakhs [Previous Year: INR 4467.29 Lakhs] on standalone basis and INR 2,705.34 Lakhs [Previous Year: INR 4466.79 Lakhs] on consolidated basis. After meeting all the expenses, your Company has incurred a total loss after tax of INR 13.33 Lakhs [Previous Year: 203.14 Lakhs] on standalone basis and INR 13.49 Lakhs [Previous Year: 202.64 Lakhs] on consolidated basis.

Your directors are expecting better business opportunities in the coming year, which may lead to expansion and diversification of the business of the company.

4. Transfer to Reserve:

During the Financial Year 2025-26, the Company has not transferred any amount to the general reserve.

5. Change in the Nature of Business, if any:

During the Financial Year, the Company has not changed nature of its business activity at any point of time between the Financial Year.

6. Allotment and listing of shares:

During the financial year, the Company has not allotted any shares nor listed any shares on stock exchange.

7. Material Changes and Commitments, if any:

(i) On 30th June 2025, the Company has received a notice from the Debenture Holder, Ms. Bindi Mehta, for enforcement of 6,69,116 equity shares pledged by the both the promoters as collateral against the issue of Tranche-I and Tranche-II Non-Convertible Debentures aggregating to Rs. 1,25,00,000. Pursuant to the invocation of the pledge, and after excluding locked-in shares, 5,21,063 equity shares were enforced, comprising 3,34,558 shares held by Mr. Hans Lewis and 1,86,505 shares held by Mr. Paulson Paul Thazhathedath, together representing 16.57% of the total paid-up share capital of the Company.

(ii) On 22nd August, 2025, the company has received a notice from the Debenture Holder, Ms. Varsha Mehta, for enforcement of 88,807 equity shares pledged by the promoters as collateral against the issue of Tranche-II Non-Convertible Debentures aggregating to Rs. 25,00,000. Pursuant to the invocation of the pledge, and after excluding locked-in shares, 44,403 equity shares held by Mr. Paulson Paul Thazhathedath, representing 1.41% of the total paid-up share capital of the Company, were enforced.

8. Change in Registered Office of the Company:

During the Financial Year, the registered office of the company was shifted ***from*** 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India, ***to*** 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India within local limits of city or town.

9. Dividend:

Your directors, during the Financial Year under review have not recommended any dividend on the Equity Shares of the Company.

10. Transfer of unclaimed shares/dividend and interest thereon to IEPF:

As required under Section 124 of the Act there are no unclaimed shares /dividend and interest thereon lying with the Company for a period of seven years liable to be transferred to the Investor Education and Protection Fund (IEPF) established by the Central Government.

11. Details of Adequacy of Internal Financial Controls:

Your Company has put in place adequate Internal Financial Controls commensurate to the scale of operations.

12. Disclosure of Accounting Treatment:

These Financial statements of the Company are prepared in accordance with the Applicable Accounting Standards ("AS"), notified under section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information.

13. Details of Significant and Material Orders Passed by the Regulators or Courts or Tribunals Impacting the Going Concern Status and Company's Operations in Future, if any:

No Material Orders were passed by the Regulators or Courts or Tribunals impacting the going concern status and Company's operations in the future.

14. Significant Changes:

(i) Aquilon Capital Emerging Sectors I transferred 75 Trench -II NCDs of the Company to Mr. Nikhil Ashok Dike for a total consideration of Rs. 75,00,000, as approved by the Board on 20th April 2026.

(ii) Ms. Reshma Susan Thomas, Company Secretary of the Company, resigned from her position with effect from 30th April, 2025 and Ms. Juhi Tanna was appointed as Company Secretary and Compliance Officer of Company w.e.f 30th May, 2026.

(iii) The Company changed its name from "Docmode Health Technologies Limited" to "Doctrack Solutions Limited" vide Members' Special Resolution passed in Extra-Ordinary General Meeting dated 8th July, 2026.

(iv) During the Financial Year, the registered office of the company was shifted ***from*** 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India, ***to*** 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra w.e.f 1st January, 2026.

15. Number of Meeting of Board of Directors held during the year:

The Board of Directors duly met 9 (Nine) times, during the year on 30/05/2025, 30/06/2025, 10/07/2025, 29/08/2025, 14/11/2025, 03/12/2025, 01/01/2026, 06/03/2026 and 16/03/2026 in respect of which proper notices were given and the proceedings were properly recorded, signed and maintained in the Minutes book kept by the Company for the purpose.

16. Meetings of the Members:

The Last i.e. the 08th Annual General Meeting of the Company for the financial year 2024-2025 was held on 30/09/2025 at the Registered Office of the Company.

17. Particulars of the Extra-Ordinary General Meeting of the Company held during the year

No Extra-Ordinary General Meeting of the Members of the Company was held during the year under review.

18. Directors and Key Managerial Personnel:

Appointments / Re-appointments / Changes in designation:

Ms. Juhi Tanna was appointed as Company Secretary and Compliance Officer of Company w.e.f 30th May, 2026.

Resignations:

Ms. Reshma Susan Thomas, Company Secretary of the Company, resigned from her position with effect from 30th April, 2025.

Directors liable to retire by rotation:

During the year under review, Ms. Monina Elizabeth Lewis, Non-Executive Director of Company, is liable to retire by rotation at the ensuing Annual General Meeting of the Company pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of the Company. Being eligible, she has offered herself for re-appointment, based on the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors."

Key Managerial Personnel:

As on 31st March, 2026, the following are the Key Managerial Personnel of the Company in terms of Section 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014: Mr. Paresh Jaysih Sampat, Managing Director; Mr. Hans Albert Lewis, Chief Financial Officer and Whole-Time Director and Mr. Paulson Paul Thazhathedath, Whole-time Director of the company."

Independent Directors:

The Independent Directors of the Company hold office for a term of five (5) years and are not liable to retire by rotation in terms of the provisions of the Companies Act, 2013. The present Independent Directors of the Company are Mr. Nilay Shivnarayan Sharma and Mr. Sujit Nityanand Chakraborty.

Declaration of Independence from Independent Directors:

The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence as prescribed under the provisions of the Act, read with the schedules and rules issued thereunder.

Apart from the above-mentioned changes, during the Financial Year under review, no other changes took place in the constitution of the Board of Directors of the Company:

As on 31st March, 2026, the Board of Directors of the Company comprised the following: Mr. Paulson Paul Thazhathedath, Mr. Hans Albert Lewis, Mr. Nilay Shivnarayan Sharma, Mr. Sujit Nityanand Chakraborty, Mr. Paresh Jaysih Sampat and Ms. Monina Elizabeth Lewis.

19. Committees of the Board:

Audit Committee:

Audit Committee of the Board is duly constituted in accordance with the provisions of Section 177 (8) of the Act read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014 and Regulation 18 of the Listing Regulations. The details of its composition & meetings held during the Financial Year 2025-26 etc., is as below. All recommendations made by the Audit Committee were accepted by the Board during the Financial Year 2025-26. During the year under review, there are Seven (7) audit committee meetings held.

As on 31st March, 2026, the Audit Committee comprised of Mr. Sujit Nityanand Chakraborty as Chairman, Non-Executive Independent Director, Mr. Nilay Shivnarayan Sharma as Member, Non-Executive Independent Director and Ms. Monina Elizabeth Lewis as Member, Non-Executive Director.

Nomination and Remuneration Committee:

The Board of Directors has formulated a policy that provides a framework for the selection and appointment of Directors and Senior Management, and for determining the qualifications, positive attributes, and independence of Directors. The Board has also adopted a policy relating to the remuneration of Directors, Key Managerial Personnel, and Senior Management, which is available on the Company's website at https://doctrack.co.in/policy/. During the year under review, One (1) meetings of the Nomination and Remuneration Committee were held.

Stakeholders Relationships Committee:

The Company has formulated and adopted Stakeholders Relationships Committee in accordance with the provisions of the Companies Act, 2013 read with the Rules made thereunder and the Listing Regulations. During the year under review, Four (4) Stakeholders Relationship committee meetings was held. The details of its composition during the Financial Year 2025-26 etc., is as below.

As on 31st March, 2026, the Stakeholders Relationships Committee comprised of Mr. Sujit Nityanand Chakraborty as Chairman, Non-Executive Independent Director, Mr. Nilay Shivnarayan Sharma as Member, Non-Executive Independent Director and Ms. Monina Elizabeth Lewis as Member, Non-Executive Director.

Details of Investor Complaints

Complaints at the beginning of FY 2025-26	0
Complaints received during the year	0
Complaints resolved during the year	0
Complaints unresolved during the year	0
Complaints pending during the year	0
Complaints at the end of FY 2025-26	0

20. Independent Directors:

As on 31st March, 2026, the Board of Directors of the Company included 2 (Two) Independent Directors Mr. Sujit Nityanand Chakraborty and Mr. Nilay Shivnarayan Sharma. In Compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Regulations) Requirement, 2015; the Independent Directors' Meeting of the Company was held on 26th March, 2026.

Independent Directors of the Company have been issued formal letters of appointment setting out in detail the terms of their appointment, roles, duties and responsibilities. The Company also conducts familiarization programs from time to time to keep the Independent Directors updated on their roles, rights, responsibilities, the nature of the industry in which the Company operates, and the business model of the Company.

Web link of Website for the Familiarization Policy for Independent Directors:
https://d3030h7whein66.cloudfront.net/PDF/Doctrack+/7.+Directors+Familiarisation+Programe_Doctrack.pdf

21. Annual Evaluation of Board's and Committee Performance:

Pursuant to the provisions of the Act, the SEBI LODR Regulations and the Guidance Note issued by SEBI, the Nomination and Remuneration Committee of the Board carried out an evaluation of performance of Independent Director, Individual Executive and Non-Executive Director and Board as whole and that of its committees.

The performance evaluation of the Chairman, the Non-Independent Directors and the Board as a whole was carried out by the Independent Directors in a separate meeting held on 26th March, 2026 after considering their overall contribution and engagement in the growth of the Company, active role in monitoring the effectiveness of Company's Corporate Governance practices and adherence to the Code of Conduct etc. The exercise of performance evaluation was carried out through a structured evaluation process covering various criteria as recommended by the Nomination and Remuneration Committee.

The Board of Directors evaluated the performance of the Nomination and Remuneration Committee based on the Committee's terms of reference. Additionally, the Committee undertook a review of the Board and other Committees. The responsibility for evaluating the Nomination and Remuneration Committee itself was placed with the Board of Directors.

Overall, the performance of the Independent Director, Individual Executive and Non-Executive Director and the Board as whole and that of its committees as a whole was quite satisfactory and up to the mark during the year under review.

22. Whistle Blower Policy:

Pursuant to the provisions of Section 177(9) of the Act, the Board of Directors of the Company has framed the Vigil Mechanism/ Whistle Blower Policy for employees and/ or volunteers of the Company. The said Policy encourages to report any action or suspected action taken within the Company that is illegal, fraudulent or in violation of any adopted policy of the Company including reporting of instances of leak or suspected leak of unpublished price sensitive information. The Policy also provides access to the Chairperson of the Audit Committee under certain circumstances. The Whistle Blower Policy is posted on the website of the Company at:
https://d3030h7whein66.cloudfront.net/PDF/Doctrack+/1.+Whistle+Blower+Policy_Doctrack.pdf.

23. Directors' Responsibility Statement:

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statement in terms of the Provisions of the Section 134 (5) of the Companies Act, 2013 (the Act):

a. That in the preparation of the Annual Accounts for the year ended 31st March, 2026, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;

b. That the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2026 and of the profit of the Company for the year ended on that date;

c. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. The Annual Accounts have been prepared on a going concern basis; and

e. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

24. Management Discussion and Analysis:

The Management Discussion and Analysis report as required under Regulation 34 and Schedule V of SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015 forms and integral part of this report and provides overview of the business and operations of the Company as per ***Annexure-II***

25. Code of Conduct:

The Board of Directors has adopted the Policy on Codes of Fair Disclosure and Conduct ("Fair Disclosure Code") in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The Fair Disclosure Code of the Company lays down guidelines and procedures to be followed and disclosures to be made while dealing with shares of the Company as well as consequences of violation.

The code of practices and procedures for fair Disclosures of unpublished price sensitive information and code of conduct to regulate, monitor and report trading by Insiders is available on the website https://d3030h7whein66.cloudfront.net/PDF/Doctrack+/5.+Policy+on+Code+of+Fair+Disclosure+of+UPSI_Doctrack.pdf.

All Board members and Senior Management Personnel have affirmed compliance of the Code of Conduct. The Board has also adopted separate code of conduct with respect to duties of Independent Directors as per the provisions of the Companies Act, 2013 and is available on the website https://d3030h7whein66.cloudfront.net/PDF/Doctrack+/11.+Policy+on+code+of+conduct+for+Independent+Directors_Doctrack.pdf.

26. Auditors:

In line with the Resolution passed in the Annual General Meeting of the Company held in the Calendar Year 2023, M/s. R. Sundaresan Aiyar & Co., Chartered Accountants, Mumbai (ICAI Firm Registration Number: 110564W/ Membership No. 043946) were appointed as Statutory Auditors of the Company for a period of 5 years till the conclusion of Annual General Meeting of the Company to be held in the calendar year 2028.

M/s. R. Sundaresan Aiyar & Co. have confirmed that they are not disqualified from continuing as Statutory Auditors of the Company and satisfy the prescribed eligibility criteria.

27. Audit Report:

The Report given by the Statutory Auditors on the financial statements of the Company is part of this Integrated Annual Report. The said Report was issued by the Statutory Auditors with a qualified opinion which are:

27.1 The Company has defaulted in repayment of NCDs aggregating to ₹2.25 crore, and the pledged shares of the promoters were partly invoked towards the default. However, as at 31 March 2026, the NCDs continued to appear as outstanding in the BENPOS, and no confirmation of redemption/appropriation or discharge of the NCD obligations was made available by the Debenture Trustee/debenture holders. Consequently, interest and default interest aggregating to ₹29.84 lakh were not recognized by the Company, resulting in understatement of finance costs and financial liabilities. For detailed comment refer page number 1 of Auditors Report and point number ix of Annexure B of Auditors Report.

Comments of Directors on Audit Report:

The Company has noted the observation of the Statutory Auditors regarding the accounting of coupon interest and additional default interest on the NCDs. Pursuant to the default, certain pledged shares of the promoters were invoked by the pledgees and the management had considered the value of such shares against the outstanding NCD obligations.

However, in the absence of formal confirmation from the Debenture Trustee/debenture holders regarding appropriation of the invoked shares and discharge of the NCD obligations, the Statutory Auditors have considered the aforesaid interest as payable.

The Company is in the process of obtaining the requisite confirmation and supporting documents from the Debenture Trustee/debenture holders and shall take appropriate accounting and consequential regulatory actions based on the final confirmation and reconciliation of the NCD obligations.

28. Details of remuneration as required under Section 197(12) of the Companies Act, 2013:

The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2025-26, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2025-26 and the comparison of remuneration of each Key Managerial Personnel (KMP) are given in ***Annexure-III***.

29. Particulars Of Employees:

Particulars of the employees as required to be disclosed in terms of Section 134 of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given in ***Annexure-IV***.

30. Secretarial Auditor:

30 Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 | C. P. No.: 22293) to conduct the Secretarial Audit of the Company for financial year 2025-26. The Secretarial Audit Report is annexed to this Report as ***Annexure-V***. The said Report contains following qualifications / reservations or adverse remarks:

30.1 The Company has defaulted in repayment of NCDs aggregating to Rs. 2.25 crore, and the pledged shares of the promoters were partly invoked towards the default. However, as at 31 March, 2026, the NCDs continued to appear as outstanding in the BENPOS, and no confirmation of redemption/appropriation or discharge of the NCD obligations was made available by the Debenture Trustee/debenture holders. Consequently, interest and default interest aggregating to Rs. 29.84 lakh were not recognized by the Company, resulting in understatement of finance costs and financial liabilities

30.2 The financial results along with the Limited Review Report for the half-year ended 30th September, 2025 were approved by the Board of Directors at its meeting held on 03rd December, 2025. As per applicable regulatory requirements, the said results were required to be approved and submitted within 45 days from the end of the half-year, i.e., on or before 14th November, 2025. The completion of the audit process and finalisation of the financial statements could not be concluded within the stipulated timeline due to emergency leave of key personnel involved in the finalisation process, which impacted the completion of audit within the prescribed period. The Company had also appropriately intimated NSE regarding the circumstances leading to the delay. The outcome of the Board meeting along with the financial results and limited review report (Consolidated & Standalone) was subsequently submitted to the stock exchange on 03rd December, 2025.

30.3 As per SEBI LODR requirements, the annual audited financial results for FY 2025-26 were to be submitted by 30th May 2026. However, the submission has not been completed till date. The Company is now planning to convene a Board Meeting on 4th September 2026 to consider and approve the said financial results. The Company has also appropriately intimated NSE regarding the circumstances leading to the delay.

30.4 The registration of both the Independent Directors of the company in the Independent Directors' Databank stood lapsed due to non-compliance with the requirements relating to the online proficiency self-assessment test under Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

30.5 The Company Secretary and Compliance Officer of the Company resigned with effect from 30th April, 2025. In terms of Regulation 6 of the SEBI (LODR) Regulations, 2015, a listed entity is required to appoint a qualified Company Secretary as Compliance Officer, and such appointment is to be made within three months from the date of vacancy. Accordingly, the due date for appointment of the new Company Secretary and Compliance Officer was 31st July, 2025. However, said appointment was made w.e.f 30th May 2026 and Ms. Juhi Tanna (ACS-59864), was appointed as Whole-Time Company Secretary and Compliance Officer of the company.

30.6 During the audit period, the Company received penalty notices from NSE for non-appointment of a Company Secretary and for delays in submission of the half-yearly unaudited financial statements [30th September 2025] and the annual audited financial statements [31st March 2026]. The Company has paid a portion of the penalties, while certain amounts remain outstanding as on date.

30.7 The Company's Annual General Meeting was held on 30th September 2025. However, due to a vacancy in the office of the Company Secretary, Form MGT-15 could not be filed within the statutory timeline. Consequently, the form was filed on 20th June 2026, resulting in a delayed submission under the provisions of the Companies Act, 2013.

30.8 The Company made a delay of one (1) day in submitting the prior intimation under Regulation 29(2)/29(3) of SEBI (LODR) Regulations, 2015, in respect of the Board Meeting convened to consider the audited financial results for the half-year ended 31st May, 2025.

Comments of Directors on Secretarial Audit Report:

a. Observation 30.1: The Company has noted the observation of the Statutory Auditors regarding the accounting of coupon interest and additional default interest on the NCDs. Pursuant to the default, certain pledged shares of the promoters were invoked by the pledgees and the management had considered the value of such shares against the outstanding NCD obligations.

However, in the absence of formal confirmation from the Debenture Trustee/debenture holders regarding appropriation of the invoked shares and discharge of the NCD obligations, the Statutory Auditors have considered the aforesaid interest as payable.

The Company is in the process of obtaining the requisite confirmation and supporting documents from the Debenture Trustee/debenture holders and shall take appropriate accounting and consequential regulatory actions based on the final confirmation and reconciliation of the NCD obligations.

b. Observation 30.2 & 30.3: The Board acknowledges the delay and regrets the non-compliance. It is clarified that the delay was procedural in nature and not intentional. The Company has strengthened its internal monitoring mechanism to avoid recurrence and will ensure timely submission of financial results in the future.

c. Observation 30.4: The Board notes that the registration of both the Independent Directors in the Independent Directors' Databank has lapsed due to non-compliance with the requirements relating to the online proficiency self-assessment test under Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014. The Independent Directors have assured the Board that necessary steps are being initiated to regularize their registration and complete the prescribed proficiency test within the stipulated timelines. The Board remains committed to ensuring full compliance with the applicable provisions of the Companies Act, 2013 and related rules.

d. Observation 30.5: The delay in appointment of the Company Secretary and Compliance Officer was due to the non-availability of a suitable candidate despite continuous recruitment efforts. During the intervening period, interim arrangements were made to ensure uninterrupted regulatory compliance and communication with the National Stock Exchange of India Limited (NSE), stakeholders and other regulatory authorities. The Company subsequently appointed a qualified Company Secretary and Compliance Officer on 30th May, 2026, thereby regularising the compliance.

e. Observation 30.6: The Board notes that the Company has received penalty notices from NSE during the audit period for non-appointment of a Company Secretary and for delays in submission of the half-yearly unaudited financial statements (30th September 2025) and the annual audited financial statements (31st March 2026). The Company has already paid a portion of the penalties, while certain amounts remain outstanding as on date. The Board assures that corrective measures are being taken to strengthen compliance processes, including timely appointment of Key Managerial Personnel and adherence to prescribed timelines for financial disclosures, to avoid recurrence of such instances in future.

f. Observation 30.7: The Board notes that the Company's Annual General Meeting was duly convened on 30th September 2025. However, owing to a vacancy in the office of the Company Secretary, Form MGT-15 could not be filed within the statutory timeline. The said form was subsequently filed on 20th June 2026. The Board takes note of the observation of the Secretarial Auditor. The Board assures stakeholders that necessary steps are being taken to strengthen compliance processes, including timely appointment of Key Managerial Personnel, to ensure adherence to statutory timelines and to prevent recurrence of such delays in future.

g. Observation 30.8: The Board notes that there was a delay of one (1) day in submitting the prior intimation under Regulation 29(2)/29(3) of SEBI (LODR) Regulations, 2015, in respect of the Board Meeting convened to consider the audited financial results for the year ended 31st March 2025. The delay was inadvertent and not deliberate. The Board has taken cognizance of the lapse and assures stakeholders that necessary steps are being implemented to strengthen internal compliance monitoring so as to ensure timely submission of all future intimations and disclosures.

31. Compliance with the Secretarial Standards:

The Company has complied with all the necessary provisions of "Secretarial Standards on Meetings of the Board of Directors" and "Secretarial Standards on General Meetings" issued by the Institute of Company Secretaries of Indian, from time to time.

32. Extract of Annual Return:

As required, in accordance with the Section 92(3) of the Act, copy of Annual Return in Form MGT-7, is available on the website of the Company https://doctrack.co.in/

33. Conservation of Energy, Technology Absorption and Foreign Exchange Earnings & Outgo:

Information in accordance with the provisions of 134(3)(m) of the Act read with the Companies (Accounts) Rules, 2014, regarding conservation of energy, technology absorption, Foreign Exchange Earnings and Outgo is given in below:

a. Conservation of Energy:

i. the steps taken or impact on conservation of energy: Energy consumption is monitored and maintenance systems are improved.

ii. the steps taken by the Company for utilizing alternate sources of energy: The Company is trying to make effective/ efficient use of current sources of energy.

iii. the capital investment on energy conservation equipments: NIL

b. Technology Absorption and Research & Development: The Company's operations do not require significant import of technology. No expenditure had been incurred on research & development activities.

c. Foreign Exchange Earning and Outgo:

(Rupees in Lakhs)

No.	Particulars	2025-26	2024-25
1.	Earning in Foreign Exchange	2.72	6.89
2.	Outgo in Foreign Exchange	30.30	99.66

34. Details relating to Deposits:

The Company has not accepted any deposits from the public/members under Section 73 of the Companies Act, 2013 (hereinafter referred to as the Act) read with Companies (Acceptance of Deposits) Rules, 2014 during the year. There are no deposits which are outstanding as on 31st March, 2026. The Company has not accepted any deposits which are not in compliance with the requirements of Chapter V of the Companies Act, 2013.

35. Particulars of Loans, Guarantees or Investments (Under Section 186 of the Act):

Loans and Investments in compliance with the provisions of the Section 186 of the Companies Act, 2013 forms part of the Notes to the financial statements of the Company.

36. Risk Management Policy:

The Company has not formulated Risk Management Policy as it is not mandatory to the Company.

37. Corporate Social Responsibility Policy:

The Company is not covered under the requirements of Section 135 of the Act read with the Companies (Corporate Social Responsibility Policy) Rules 2014.

38. Related Party Transactions:

During the year under review, no transactions were entered into by the Company with its related parties as per the provisions of Section 188 of the Companies Act, 2013. Further, there were no contracts or arrangements with any related party which were material in nature, and hence the Form AOC-2 is not applicable to the Company.

The Policy on Materiality of Related Party Transactions and dealing with Related Party Transactions as approved by the Board is put up on the Company's website and can be accessed at https://doctrack.co.in/policy/.

39. Disclosure on complaints received by the Internal Complaints Committee (ICC), formed under The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has duly constituted an Internal Complaints Committee (ICC) in accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 but no complaints were received by the ICC during the year under review.

40. Disclosure relating to maintenance of cost records:

The Company is not required to conduct cost audit and maintenance of cost records is also not applicable to the company as per Section 148(1) of the Companies Act, 2013 and the rules made thereunder.

41. Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made by the Company under the Insolvency and Bankruptcy Code and accordingly the requirement of disclosing the following details is not applicable to the Company:

i. the details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year; and
ii. the details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

42. **Corporate Governance Report:**

As company is listed on SME Exchange of NSE, the compliance with the corporate governance provisions as specified in LODR under regulations 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and Para C, D and E of Schedule V are exempted to the company. Hence, requirements of corporate governance under regulation 27 and under Para C of Schedule V of LODR have not been included in this Annual Report.

43. **Details of utilization of funds & Statement of deviation(s) or variation(s):**

The proceeds have been fully utilized for the purposes as disclosed in the offer document. Accordingly, no further disclosure under Regulation 32(2) is required to be given.

44. Compliance with the Maternity Benefit Act, 1961:

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. All eligible women employees are provided with maternity benefits as prescribed under the Maternity Benefit Act, 1961. The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation.

45. Acknowledgement:

The Directors express their sincere appreciation to the valued Stakeholders including Shareholders, Bankers and Clients for their support and contribution to the Company.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCTRACK SOLUTIONS LIMITED

____

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881

Place: Mumbai
Date: 04/09/2026

Annexure to Directors' Report

1. Details of Subsidiaries in Form AOC-1 is given in **Annexure-I**
2. Management Discussion and Analysis is given in **Annexure-II**
3. Details of remuneration is given in **Annexure-III**
4. Statement containing the name and other particulars of employees is given in **Annexure-IV**
5. Secretarial Audit Report is given in **Annexure-V**

Annexure - I

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries

Part A: Subsidiaries

(Rs. in Lakhs)

S. No.	Name of the subsidiary	Date since when subsidiary was acquired	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Reporting Currency	Exchange rate as on the last date of the Financial Year (in Rs.)	Share Capital	Reserves and Surplus	Total Assets	Total Liabilities	Investments	Turnover	Profit before taxation	Provision for taxation/ deferred tax	Profit after taxation	Proposed Dividend	Extent of shareholding (%)
1	CCME World Services Private Limited*^	13/05/2020	N.A.	INR	N.A.	0.10	-0.65	0.2	0.2	-	0	-0.16	0	-0.16		95%#

*Subsidiary is yet to commence operations

^Subsidiary pursuant to Section 2(87)(ii) of the Companies Act, 2013

#Share Capital of the Subsidiary is held directly (94.8%) by the Holding Company and indirectly (0.02%) through its Nominees - Directors of the Company

There is no subsidiary which has been liquidated or sold during the year

Part B: Associates and Joint Ventures - Not Applicable, as there are no Joint Ventures or Associate Company

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCTRACK SOLUTIONS LIMITED

PAULSON PAUL THAZHATHEDATH	**HANS ALBERT LEWIS**
WHOLETIME DIRECTOR	**WHOLETIME DIRECTOR**
DIN: 02301881	**DIN: 02301853**

Place: Mumbai
Date: 04/09/2026

Annexure-II

MANAGEMENT DISCUSSION AND ANALYSIS

1. COMPANY OVERVIEW:

Originally incorporated as "Docmode Health Technologies Private Limited" in Mumbai, Maharashtra in 2017, the company was subsequently converted to a Public Limited company in December 2022 and its name was changed to "Docmode Health Technologies Limited." Thereafter, the name of the Company was further changed from "Docmode Health Technologies Limited" to "Doctrack Solutions Limited" pursuant to the approval granted by the Registrar of Companies (ROC) vide approval letter dated 28th July, 2026. Under the experienced leadership of our founders with over 25 years of collective expertise in healthcare advertising, health IT, healthcare communications, and event management, Doctrack has evolved into a multi-faceted organization serving diverse stakeholders across the global healthcare ecosystem

Doctrack is engaged in the business of offering integrated learning solutions through online and offline learning models to healthcare professionals and learners across the world, spanning the education value chain. The Company's offline learning model includes conferences and workshops, while the online courses are developed and presented by the in-house content development team, medical institutions, associations, subject matter experts, and key opinion leaders.

Doctrack's primary focus is on providing tech-driven online learning solutions that allow healthcare professionals and learners to engage in self-paced, inclusive, and individualized learning experiences. The Company's online learning model comprises notes, recorded videos, live conferences, and workshops. Additionally, Doctrack provides a platform for inter-professional, cross-industrial learning via panel discussions and courses, as well as leverages its performance assessment tools to enhance the clinical acumen of its users.

Beyond learning, the Company operates a network-powered surveys, studies and research offering that enables practising and certified healthcare professionals to participate in and contribute to marketing surveys, clinical studies and research; a knowledge marketing services line that supports medico-marketing organisations with scientific promotional literature, medical writing and customised learning initiatives; clinical research support services delivered under the oversight of an Ethics Committee registered with the Central Drugs Standard Control Organisation; and an online store for healthcare professionals offering books, journals, articles, event passes and memberships.

The Company is led by its experienced promoters, who have a collective experience of over 25 years in the fields of healthcare advertising, health IT, healthcare communications, and event management. Doctrack's promoters founded the Company with the vision of "Transforming Learning & Practice" in the medical fraternity, and they actively oversee the business development and strategic aspects of the Company.

The Company is supported by a team of qualified and experienced professionals who have demonstrated their ability to manage and grow the Company's operations, adapt and diversify its offerings, and leverage market opportunities. The Company is registered as ISO 27001:2013 for Information Security Management System and has also received a "ready" status from Skill India.

Contributors: Doctrack collaborates with international medical associations, key opinion leaders, and subject matter experts to develop certified courses for its users.

We offer the following services to Health Care Professionals:

OUR SERVICES:

a. CME and Learning:

- The Company's learning platform at https://doctrack.co.in/ is a learning environment and platform-as-a-service (PaaS) with a learning management system and collaborating content (CPD and CME) in partnership with leading medical institutions, subject matter experts, key opinion leaders, and top professional bodies from across the world.
- Under this program, the Company offers hybrid and blended learning programmes, such as training workshops, fellowships, and observerships, along with publishing books and journals online.

- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians, and paramedics.

i. **Certification Programs:** As of March 31, 2026, the Company has continued to maintain and develop its certificate and non-certificate programme portfolio, having associated with leading medical associations and universities across the globe.

ii. **National & International Speaker Programs:** The Company organises national and international speaker programmes, inviting key opinion leaders or subject matter experts from various specialisations to facilitate learning and networking initiatives.

iii. **Live Interactive Case-Based Programs with Polling:** The Company facilitates discussions on complicated clinical cases, in which participants share their responses through live polling with real-time results.

b. Research and Studies:

- The Company's research offering is a network-powered survey, studies, and research platform to further evidence-based practice in healthcare.
- It is a route for practising and certified healthcare professionals to participate in or contribute to marketing surveys, clinical studies, and research, including real-world studies and post-marketing surveillance studies supported by electronic data capture.
- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians, and paramedics.

c. Knowledge Marketing Services:

- The Company assists medico-marketing organisations through knowledge marketing services, including the review and presentation of scientific promotional literature, medical writing support and the customisation of learning initiatives, along with CRM solutions.
- **Target Audience:** Medico-Marketing Companies and Medical Associations/Institutions.

d. Clinical Research Services:

- The Company provides clinical research support services, including study management, post-marketing surveillance, site co-ordination, data management through electronic data capture systems, and regulatory documentation support.
- The Company's Ethics Committee is registered with the Central Drugs Standard Control Organisation (CDSCO), enabling independent review and oversight of research protocols.
- **Target Audience:** Pharmaceutical companies, biotechnology firms, medical device manufacturers, and academic research institutions.

e. Online Store (previously called STORE):

- The Company's online store for healthcare professionals offers books, journals, articles, event passes, memberships, and other offers on clinical products.
- The operating model for this business is under review, as described elsewhere in this report.
- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dieticians, physiotherapists, nurses, technicians, and paramedics.

2. ENVIRONMENT AND STATE OF THE INDUSTRY:

Global-Economy:

The global healthcare industry continues to demonstrate remarkable resilience and growth momentum in 2025-2026, driven by several key factors including the rising prevalence of chronic diseases, aging demographics, breakthrough advancements in medical technology, and substantial government and private sector investments. According to recent global economic assessments, while overall economic growth patterns remain cautiously optimistic, the healthcare sector continues to outperform traditional economic indicators.

The healthcare industry has consistently shown its ability to weather economic uncertainties while maintaining steady growth trajectories. The sustained demand for quality healthcare services, innovative medical devices, and pharmaceutical products continues to drive market expansion, particularly in emerging and developing economies (EMDEs) where expanding middle-class populations, increased disposable incomes, and rapidly improving healthcare infrastructure are creating robust market opportunities.

The healthcare sector's resilience can be attributed to fundamental demographic shifts, including the growing prevalence of lifestyle-related diseases, an aging global population, and an increased focus on preventive healthcare and wellness solutions. Additionally, the accelerated adoption of digital health technologies, artificial intelligence in healthcare, telemedicine platforms, and the expansion of healthcare insurance coverage have further strengthened the industry's growth prospects.

Key growth drivers for 2025-2026 include:

- Accelerated digital transformation in healthcare delivery and in professional education;
- Continued investment in clinical research, real-world evidence generation and drug development;
- Growing emphasis on evidence-based medicine and on documented clinical and market studies;
- Rising demand for regulatory compliance, documentation and quality assurance in the industry's engagement with healthcare professionals;
- Consolidation of empanelled service providers by pharmaceutical companies in response to tighter marketing codes

At the same time, the pharmaceutical industry globally has been operating under increasing pressure on marketing and promotional expenditure, with greater scrutiny of the manner in which manufacturers engage with healthcare professionals. This has driven a shift away from unstructured promotional spending towards documented, auditable and evidence-led engagement, and a corresponding preference for external partners capable of delivering to those standards.

Indian Economic Review:

India has continued to record among the strongest growth rates of the major economies, supported by resilient domestic consumption, sustained public capital expenditure and continued development of both physical and digital infrastructure. The healthcare sector remains a significant contributor to this growth.
India's healthcare sector benefits from several structural advantages, including a large and growing population, increasing healthcare awareness, rising disposable incomes, and a substantial base of skilled healthcare professionals. Government focus on healthcare infrastructure development, digital health initiatives and medical education reform continues to provide a supportive environment for organisations operating in this space.

Key factors supporting the growth of India's healthcare sector in 2025-26 include:

- Strong domestic demand for healthcare services, professional education and clinical research;
- Government initiatives promoting pharmaceutical research and development;
- Expanding healthcare infrastructure across urban and rural areas;
- Increased focus on regulatory compliance and quality standards in the engagement between industry and healthcare professionals;
- Growing international recognition of Indian clinical research and data management capability;
- A favourable investment climate for pharmaceutical and biotechnology companies.

Regulatory Landscape:

The Uniform Code for Pharmaceutical Marketing Practices, 2024 and the professional conduct requirements applicable to registered medical practitioners have continued to reshape the manner in which the pharmaceutical and healthcare industry engages with healthcare professionals. Expenditure that was previously unstructured is now required to be documented, justified and, in defined cases, disclosed. Manufacturers are correspondingly required to satisfy themselves as to the processes of the service providers they engage.

These developments increase compliance obligations for manufacturers and correspondingly increase the value of partners whose documentation, disclosure and record-keeping practices are capable of withstanding scrutiny. The practical effect observable in the market is a consolidation of empanelled service providers: clients are working with fewer partners, and selecting those partners on the basis of process rather than price alone.

The Company believes that these regulatory developments are, over the medium term, favourable to its business. The Company has for several years designed and delivered its educational and research programmes to internationally accepted standards of independence and documentation, and this has become a basis on which clients select and retain service providers rather than merely a cost of compliance.

Implications for the Company:

Three consequences follow for the Company. First, the shift of industry expenditure from unstructured promotion towards documented education and evidence generation is directionally favourable to the Company's principal service lines. Second, the consolidation of empanelled providers favours organisations able to offer several services within a single compliance framework, which the Company is able to do. Third, competition within the empanelled group is on price and delivery quality, which places a premium on a low and largely variable cost base of the kind the Company has moved towards during the year under review.

3. COMPANY’S PERFORMANCE:

The Company's consolidated Operating Revenue for the year ended March 31, 2026 was Rs. 2,551.59 Lakhs as against Rs. 4,177.29 Lakhs in FY 2024-25, a change of 38.91%. The Other Income was Rs. 139.54 Lakhs for the year ended March 31, 2026 as against Rs. 92.98 Lakhs in FY 2024-25. Operating Expenses were Rs. 2,705.34 Lakhs for FY 2025-26 as against Rs. 4,466.79 Lakhs in FY 2024-25. Profit Before Tax was Rs. (14.21) Lakhs for FY 2025-26 as against Rs. (196.52) Lakhs in FY 2024-25, while Profit After Tax was Rs. (13.49) Lakhs for FY 2025-26 as against Rs. (202.64) Lakhs in FY 2024-25. The overall tax expense was Rs. (0.72) Lakhs for FY 2025-26 as against Rs. 6.12 Lakhs in FY 2024-25. The basic and diluted EPS for the year was Rs. (0.43) as against Rs. (6.45) in FY 2024-25. The Cash and Cash Equivalents amounted to Rs. 17.77 Lakhs as at March 31, 2026, against Rs. 183.50 Lakhs as at March 31, 2025.

The movement in revenue for the year reflects the transition of a portion of the Company's business to a reseller and distributor-led distribution model, under which the Company's share of the end-customer value is lower than under a directly billed engagement, together with the exercise of pricing discipline on renewals under which engagements not meeting the Company's revised margin thresholds were not pursued.

The corresponding reduction in direct selling and market development costs, and the structured cost rationalisation programme implemented during the year, supported an improvement in operating margins. The Company's operating margin for the first half of the financial year improved over the corresponding period of the previous year. Depreciation for the year increased following the completion and capitalisation of platform development work previously carried as capital work-in-progress. Finance costs remained significant in relation to the scale of the business, and their reduction is an objective for the period ahead.

Changes in Key Financial Ratios:

Ratios	FY 2025-26	FY 2024-25	% Change	Explanation (for > 25% variance)
Liquidity Ratio				
Current Ratio (times)	___0.73___	1.30	-44.08	Higher current liabilities
Solvency Ratio				
Debt Equity Ratio (times)	0.45	0.82	-44.50	Increase in Debt Repayment
Debt Service coverage ratio (times)	0.22	(0.02)	-1017.45	Decrease in Debt Repayment
Profitability Ratio				
Net profit ratio (%)	(0.52)	(4.86)	89.25	Reduction in operating expenses and improvement in revenue, resulting in lower net losses.
Return on Equity Ratio (%)	(1.61)	(21.68)	92.58	Improvement in profitability leading to better returns for shareholders.
Return on Capital employed (%)	7.20	(2.28)	310.51	Improved operating profit and more efficient utilization of capital employed.
Return on Investment (%)	1.75	(1.14)	253.48	Improved returns due to higher profitability from investments.

Ratios	FY 2025-26	FY 2024-25	% Change	Explanation (for > 25% variance)
Utilisation Ratio				
Inventory Turnover Ratio (times)	2.10	(2.00)	60.14	Improved inventory management and higher sales/consumption of inventory.
Trade Receivables turnover ratio (times)	3.06	4.03	24.14	
Trade payables turnover ratio (times)	4.50	2.14	49.60	Faster payment to suppliers resulting in higher trade payables turnover.
Net capital turnover ratio (times)	(3.99)	(9.68)	142.62	

Explanations in respect of ratios recording a variance in excess of 25% are to be inserted on finalisation of the audited financial statements for the year ended March 31, 2026. The Company's ratios for the year are expected to reflect the change in the distribution model, the reduction in the fixed cost base, the capitalisation of platform development work and the movement in borrowings during the year.

4. Future Outlook:

The Company's approach for the coming year is one of consolidation. The objective is to secure and grow the business that the Company is already winning, to extend reach through appointed partners rather than through fixed selling cost, to hold the cost base at its rationalised level, and to convert improved operating margins into cash. The Company does not propose to add new business lines or new products during the coming year.

Strategic Focus Areas:

Reseller and Distributor Network: The Company has concluded reseller and distributor arrangements covering a majority of its current services and products. Appointed partners undertake front-end market development and client engagement in defined territories and market segments, while the Company retains responsibility for content, platforms, delivery and quality. This model expands market coverage without a corresponding increase in fixed selling cost, converts a portion of fixed selling cost into variable partner compensation, and allows the Company's own resources to be concentrated on delivery and margin management. The Company recognises that, where business is transacted through a partner, its share of the end-customer value is lower than under a directly billed engagement, and that reported topline may be affected as a result. The Company will continue to expand partner coverage into territories and segments not presently addressed.

Growth of the Traditional, Directly Billed Business: The Company will continue to place emphasis on its traditional business of directly billed engagements with pharmaceutical and healthcare clients. These engagements are repeat in nature, are supported by documented service arrangements, and provide reasonable revenue visibility. Management's focus is on renewing and expanding mandates from existing clients, on improving realisations, and on exercising pricing discipline rather than pursuing volume for its own sake.

Margin Protection: The Company will maintain the cost rationalisation measures implemented during the year, covering manpower deployment, delivery costs, technology and infrastructure spends and discretionary overheads. Engagement-level margin thresholds will continue to be applied, and engagements that do not meet those thresholds will not be pursued. Management intends that the benefit of any recovery in volume should accrue to operating profit rather than be absorbed by a re-expansion of cost.

Review of the Online Portal Business: The Company is evaluating its options for the online portal business, which has not generated returns commensurate with the resources deployed on it. The options under consideration include operating the business through reseller arrangements and the monetisation or divestment of certain components of the platform. No binding commitment has been entered into as at the date of this report, and any transaction will be undertaken in accordance with applicable law and with such approvals as may be required.

Regulatory Compliance as a Differentiator: The Uniform Code for Pharmaceutical Marketing Practices, 2024 and the professional conduct requirements applicable to registered medical practitioners continue to reshape the manner in which the industry engages with healthcare professionals. The Company's compliance-led approach to programme design, documentation and disclosure is expected to support the retention and expansion of client relationships as clients restructure their engagement models and consolidate their empanelled providers.

Balance Sheet and Cash: Management will continue to direct attention to the ageing of trade receivables and the discipline of collections, to the level and cost of borrowings, and to the conversion of operating profit into cash. The reduction of finance costs is an explicit objective for the period ahead.

Key Highlights:

a. **Existing Client Relationships:** Repeat mandates from long-standing pharmaceutical and healthcare clients remain the principal source of revenue and the most cost-efficient source of growth available to the Company.

b. **Distribution Reach:** The reseller and distributor network extends coverage into territories and client segments that were not economically addressable through a direct sales force, and does so at variable rather than fixed cost.

c. **CME and Learning:** The Company's continuing medical education and professional development platform continues to be supported by institutional and association tie-ups and by tech-led delivery, and is increasingly taken to market through appointed partners.

d. **Research and Studies:** The shift in industry spend from traditional promotion towards data-driven and documented engagement continues to support this line, assisting clients in addressing communication gaps, understanding practice behaviour and improving the return on their expenditure.

e. **Operating Leverage:** Following the cost rationalisation undertaken during the year, incremental volumes can be absorbed at a materially lower marginal cost, supporting margin recovery as volumes are restored.

f. **Regulatory Tailwinds:** Increased compliance obligations on manufacturers favour service providers with documented, auditable and independent processes, and the Company has operated to such standards for several years.

Financial Performance Outlook:

The Company's financial objective for the coming period is the restoration of sustainable operating profitability rather than the maximisation of reported revenue. Management accepts that the transition to a reseller and distributor-led distribution model, together with the exercise of pricing discipline on renewals, may moderate reported topline. In exchange, the Company expects a materially lighter and more variable cost base, improved and more predictable operating margins, and better conversion of operating profit into cash.

The Company's approach to sustainable performance emphasises:

- Growth of the traditional, directly billed business with existing clients;
- Extension of market coverage through the reseller and distributor network at variable cost;
- Maintenance of the rationalised cost base and of engagement-level margin discipline;
- Rationalisation of business lines that do not generate returns commensurate with the resources deployed on them;
- Improved working capital management, collection discipline and reduction in the cost of borrowing;
- Strategic allocation of capital to the service lines generating the highest returns.

Market Position:

The Company's combination of an established client base, a large verified network of healthcare professionals, a breadth of service lines delivered within a single compliance framework, and a distribution network operating at variable cost provides a basis on which the business can be grown without a return to the fixed cost structure that constrained profitability in earlier periods. Your Directors consider that the measures implemented during the year under review have established the conditions necessary for that growth to be profitable.

5. ACCOUNTING POLICIES:

The Company has selected the accounting policies described in the Notes to Accounts, which have been consistently applied, and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on March 31, 2026, and of the Profit or Loss of the Company for the year. The financial statements have been prepared in accordance with the applicable Accounting Standards notified under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. The significant accounting policies and practices followed by the Group are disclosed in the Notes to the Consolidated Financial Statements for the year.

6. RELATED PARTY TRANSACTIONS:

Related Party transactions are defined as transactions of sale / purchase of goods / services made by the Company with Promoters, Directors, Key Managerial Personnel, Subsidiaries, Associates, or other parties in which Promoters or Directors are having significant interest / control directly or indirectly, which may have potential conflict of interest with the Company. There were no material transactions during the year under review that were prejudicial to the interests of the Company.

All transactions covered under related party transactions were regularly ratified and/or approved by the Board, the guiding principles being arm's length, fairness, and transparency. Please refer to Note No. 35 of the standalone financial statements and Note No. 36 of the consolidated financial statements for details of related party transactions during the year.

7. HUMAN RESOURCES:

The Company's Human Resource (HR) department is committed to developing and maintaining a high-performing workforce that is aligned with the Company's strategic goals. With this objective, it has implemented a number of innovative practices and invested in best-in-class processes to create an enabling environment for its employees.

During the year under review, the Company consolidated delivery around fewer and better-utilised teams as part of its cost rationalisation programme. The reallocation of front-end market development to appointed resellers and distributors permitted a corresponding redeployment of the Company's own manpower towards delivery, client servicing and quality assurance. Emphasis was accordingly placed on multi-skilling, internal mobility and cross-functional deployment, so that consolidated teams were able to support a broader range of programmes without a loss of delivery quality.

Learning and development for employees continued to be delivered largely through the Company's own platforms, at negligible incremental cost. The Company remains committed to providing opportunities for growth and career advancement within the organisation and to enabling its employees to work effectively in an evolving digital environment.

8. REWARDS AND RECOGNITION:

The Company continued to invest in its people, its association relationships and the scientific standing of its work during the year. Initiatives in the areas of reward and recognition, health and wellness, and learning and development were sustained through a demanding operating period, and the Company records its appreciation of the manner in which its colleagues absorbed the organisational changes described in this report.

The Company's engagement with medical associations and professional bodies was maintained and extended during the year, including with the Endocrine Society of India, the Heart Failure Association of India and the Research Society for the Study of Diabetes in India. Globally recognised key opinion leaders continued to be engaged across therapeutic areas for the design and delivery of the Company's programmes, and work undertaken with the Company's involvement continued to result in publication in Indian and international peer-reviewed journals.

Particulars of awards, recognitions, association tie-ups, publications and key opinion leader engagements for the financial year 2025-26 are to be confirmed and updated in accordance with the records of the Company.

9. RISKS, CHALLENGES AND CONCERNS:

The Company operates in a complex and evolving environment and faces several risks that could affect its business. The Company recognises these potential pitfalls and has put in place necessary safeguards and mitigation measures. Awareness of these risks and their proactive management are central to sustaining performance and protecting stakeholder interests.

a. **Channel Risks:** As the Company provides integrated learning solutions through online and offline learning models to healthcare professionals and learners engaged in the medical fraternity, the Company relies heavily on the engagement of good learners and healthcare professionals. Serving this community demands continuous enhancement of content quality, technology and mentoring capability. Effective channel management, including direct marketing, referrals and digital optimisation, is essential to maintain engagement and retention.

b. **Reseller and Distributor Risk:** With a majority of the Company's current services now taken to market through appointed resellers and distributors, the Company's revenue is to that extent dependent on the performance, conduct and continuity of its partners. Partner underperformance, partner attrition or conduct inconsistent with the Company's compliance standards could affect revenue and reputation.

c. **Margin and Pricing Risk:** Competitive pressure within a consolidating group of empanelled service providers, and the transition to a partner-led distribution model, may affect realisations. A failure to hold the rationalised cost base would compound this effect.

d. **Obsolescence Risk:** Evolution in technologies and disruptive business models can drastically alter the nature and volume of skills in demand. Educational content, technology and methodologies can quickly become outdated, necessitating agile curriculum development and continuous content updates.

e. **Regulatory Risk:** The Company's clients operate in a regulated environment, and changes in the codes and rules governing engagement with healthcare professionals may affect the manner and the volume of business placed with the Company.

f. **Execution Risk:** Despite well-defined and thoughtfully designed processes, there is a possibility of failure during the delivery of services because of external factors, mishaps or human error. Failures in the form of time delays, quality issues or cost overruns may lead to financial loss, penalties, loss of reputation and customer exits.

g. **Credit and Collection Risk:** A significant portion of the Company's revenue is billed on credit terms. Delay or default in collection would affect working capital and increase the Company's reliance on borrowings.

h. **Financing and Interest Rate Risk:** The Company's finance costs remain significant in relation to the scale of its operations. Adverse movements in the cost or availability of finance could constrain operations.

i. **Information Security and Data Privacy Risk:** The Company holds professional and study-related data, and any compromise of that data would carry regulatory, contractual and reputational consequences.

The Company's mitigation approaches are varied and effectively address the above risks. Some of the standard risk mitigation approaches employed by the Company include:

- Continuous research, agile curriculum development and strategic partnerships to mitigate obsolescence risk;
- A broad network of business partners and other channel partners, thus preventing over-reliance on a single partner or a small group, with partners selected after a detailed assessment of their financial viability, operational capability, adherence to quality and focus on customer service;
- Written arrangements with resellers and distributors defining territory, scope, performance expectations, quality and compliance obligations and termination rights, supported by periodic performance review;
- Retention by the Company of ownership of content, platforms and delivery standards, notwithstanding the appointment of partners;
- Defined engagement-level margin thresholds, with engagements below those thresholds not being pursued;

– Investment in technology across the value chain to manage operations efficiently, obtain real-time visibility and deliver a consistent experience for customers;
– Client-wise credit assessment, monitoring of receivable ageing and structured collection follow-up;
– Design of processes to the stricter of the applicable regulatory standards, so that changes in codes do not require the reconstruction of delivery models;
– Maintenance of the Information Security Management System certified to ISO 27001:2013, with defined access controls and audit trails;
– Promotion of a culture of quality and process orientation to minimise execution issues.

The Company has a Risk Management Policy covering the above mitigation approaches to manage all probable and possible risks to the Company.

10. INTERNAL CONTROLS AND THEIR ADEQUACIES:

The Company has a comprehensive internal control framework that is designed to achieve the objectives of operational efficiency and quality, process and regulatory compliance, safety of assets, accuracy of reporting, and management of risk. The key components of the internal control framework include:

- A clear organisational hierarchy with well-defined roles and responsibilities;
- Documented and published policies and procedures;
- A well-defined authority matrix;
- Regular reviews by management, including monitoring of performance against budgets;
- Engagement-level margin review and approval prior to acceptance of business;
- Defined processes for the appointment, review and, where necessary, termination of resellers and distributors;
- Internal and statutory audits to ensure compliance;
- A well-defined system of recording and maintaining audit trails;
- Oversight by the Board of Directors and by the Audit Committee.

The internal control framework is reviewed and updated on a regular basis to ensure that it remains effective in meeting the needs of the business. The Company has put in place adequate internal financial controls commensurate with the scale of its operations.

11. CAUTIONARY STATEMENT:

Statements in this management discussion and analysis describing the Company's views about the industry, objectives, estimates, and expectations may be "forward-looking statements" within the meaning of applicable laws and regulations. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results, performances, or achievements could differ materially from those expressed or implied in such statements. Readers are cautioned not to place undue reliance on the same.

Annexure-III

Details pertaining to remuneration as required under Section 197(12) of the Companies Act, 2013 read with Rules 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

(i) The percentage increase/decrease in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2025-26, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2025-26 and the comparison of remuneration of each Key Managerial Personnel (KMP) against the performance are as under:

No	Name of Director / KMP and designation	Remuneration for the FY 2025-26 ('In Lakhs)	% decrease in Remuneration in the FY 2024-25	Ratio of remuneration to median employees' remuneration	Comparison of remuneration of the KMP against the performance of the Company
1	Paulson Paul Thazhathedath, Whole Time Director	12	30.76	2.28	NA
2	Hans Albert Lewis, Whole Time Director	12	30.76	2.28	NA
3.	Reshma Susan Thomas	0.2	7.01	0.4	NA

Consolidated Net Loss before exceptional item and tax for the year ended 31st March, 2026 has decreased by 92.76%.

(ii) The median remuneration of employees of the Company during financial year was Rs. 5,25,300/-
(iii) In the financial year there was increase in percentage of the median remuneration of employees.
(iv) There were 39 permanent employees on the rolls as on 31st March, 2026.
(v) Average percentage increase made in the salaries of employees other than the managerial personnel (i.e. Managing Director & CFO and Whole Time Director) in the FY 2025-26: (61.80%) from FY 2024-25.
(vi) The percentage increase in the managerial remuneration in the FY 2025-26: NIL
(vii) It is affirmed that the remuneration paid is as per the Remuneration Policy.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCTRACK SOLUTIONS LIMITED

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881

Place: Mumbai
Date: 04/09/2026

Annexure-IV

Statement containing the name and other particulars of employees

[Pursuant to Section 197 (12) of the Companies Act, 2013 read with rule 5 (2) and Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

(a) Name of the top ten employees in terms of the remuneration drawn, including name of employees employed throughout the financial year 2025-26 who were in receipt of remuneration equal or greater than Rs. 1,02,00,000/- per annum: **Nil**

(b) Name of Employees, employed for part of the financial year 2025-26 who were in receipt of remuneration equal or greater than Rs. 8,50,000/- per month: **Nil**

(c) No employee was in receipt of remuneration for the year under review in the aggregate or at a rate which in the aggregate, was in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCTRACK SOLUTIONS LIMITED

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881

Place: Mumbai
Date: 04/09/2026

Annexure-V

SECRETARIAL AUDIT REPORT
FORM NO. MR-3
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Doctrack Solutions Limited
(Previously known as Docmode Health Technologies Limited)
201, Kalpataru Plaza, Rambaug,
Off. Chincholi Bunder Road, Malad West,
Mumbai - 400064, Maharashtra, India

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Doctrack Solutions Limited** (Previously Known as Docmode Health Technologies Limited) having CIN: L74999MH2017PLC297413 (Hereinafter called 'the Company'). Secretarial Audit was conducted for the financial year 2025-26, in a manner that provided a reasonable basis for evaluating the corporate conducts/statutory compliances of the Company and for expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, the explanations and clarifications given to me and representations made by the Management, during the audit period covering the financial year ended on 31st March, 2026 ("Audit Period"), the Company has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and legal compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2026 and I report that the Company has complied with the provisions of the following list of laws and regulations, including amendments thereof:

(i) The Companies Act, 2013 (the Act) and the rules made there under;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **[Not applicable during the Audit Period]**.

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

a) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;
b) SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018;
c) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
d) SEBI (Buyback of Securities) Regulations, 2018; **[Not applicable during the Audit Period]**.
e) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021; **[Not applicable during the Audit Period]**.
f) SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **[Not applicable during the Audit Period]**.
g) SEBI (Prohibition of Insider Trading) Regulations, 2015;
h) SEBI (Depositories and Participants) Regulations, 2018;
i) SEBI (Registrars to an Issue and Share Transfer Agents) Regulations, 1993
j) SEBI (Delisting of Equity Shares) Regulations, 2021 **[Not applicable during the Audit Period]**

(vi) We have relied on the representations made by the Company and its officers for systems and mechanism formed by the Company for compliances of other specific applicable Acts, Laws and Regulations to the Company. As informed by the management, apart from the Information Technology Act, 2000, there are no other laws specifically applicable to the Company.

2. We have not examined compliance by the company with respect to:

(i) Applicable financial laws, like direct and indirect tax laws, maintenance of financial records, etc., since the same have been subject to review by statutory (financial) auditors, tax auditors and other designated professionals.

(ii) As informed by the company the Industry specific laws/general laws as applicable to the company has been complied with. The management has also represented and confirmed that all the laws, rules, regulations, orders, standards and guidelines as are specifically applicable to the Company relating to Industry/Labour etc., have been complied with.

3. I have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards with regard to Meeting of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (effective from 01st July, 2015); under the provisions of Companies Act, 2013;

(ii) SME Listing Agreement entered into by the Company with NSE (SME Platform)

4. On the basis of our examination and representation made by the Company, we report that during the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines etc. mentioned above and there are no material non-compliances that have come to our knowledge subject to the following observations:

(i) The Company has defaulted in repayment of NCDs aggregating to Rs. 2.25 crore, and the pledged shares of the promoters were partly invoked towards the default. However, as at 31 March, 2026, the NCDs continued to appear as outstanding in the BENPOS, and no confirmation of redemption/appropriation or discharge of the NCD obligations was made available by the Debenture Trustee/debenture holders. Consequently, interest and default interest aggregating to Rs. 29.84 lakh were not recognized by the Company, resulting in understatement of finance costs and financial liabilities.

(ii) The financial results along with the Limited Review Report for the half-year ended 30th September, 2025 were approved by the Board of Directors at its meeting held on 03rd December, 2025. As per applicable regulatory requirements, the said results were required to be approved and submitted within 45 days from the end of the half-year, i.e., on or before 14th November, 2025. The completion of the audit process and finalisation of the financial statements could not be concluded within the stipulated timeline due to emergency leave of key personnel involved in the finalisation process, which impacted the completion of audit within the prescribed period. The Company had also appropriately intimated NSE regarding the circumstances leading to the delay. The outcome of the Board meeting along with the financial results and limited review report (Consolidated & Standalone) was subsequently submitted to the stock exchange on 03rd December, 2025.

(iii) As per SEBI LODR requirements, the annual audited financial results for FY 2025-26 were to be submitted by 30th May 2026. However, the submission has not been completed till date. The Company is now planning to convene a Board Meeting on 4th September 2026 to consider and approve the said financial results. The Company has also appropriately intimated NSE regarding the circumstances leading to the delay.

(iv) The registration of both the Independent Directors of the company in the Independent Directors' Databank stood lapsed due to non-compliance with the requirements relating to the online proficiency self-assessment test under Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

(v) The Company Secretary and Compliance Officer of the Company resigned with effect from 30th April, 2025. In terms of Regulation 6 of the SEBI (LODR) Regulations, 2015, a listed entity is required to appoint a qualified Company Secretary as Compliance Officer, and such appointment is to be made within three months from the date of vacancy. Accordingly, the due date for appointment of the new Company Secretary and Compliance Officer was 31st July, 2025. However, said appointment was made w.e.f 30th May 2026 and Ms. Juhi Tanna (ACS-59864), was appointed as Whole-Time Company Secretary and Compliance Officer of the company.

(vi) During the audit period, the Company received penalty notices from NSE for non-appointment of a Company Secretary and for delays in submission of the half-yearly unaudited financial statements [30th September 2025] and the annual audited financial statements [31st March 2026]. The Company has paid a portion of the penalties, while certain amounts remain outstanding as on date.

(vii) The Company's Annual General Meeting was held on 30th September 2025. However, due to a vacancy in the office of the Company Secretary, Form MGT-15 could not be filed within the statutory timeline. Consequently, the form was filed on 20th June 2026, resulting in a delayed submission under the provisions of the Companies Act, 2013.

(viii) The Company made a delay of one (1) day in submitting the prior intimation under Regulation 29(2)/29(3) of SEBI (LODR) Regulations, 2015, in respect of the Board Meeting convened to consider the audited financial results for the year ended 31st March, 2025.

5. I further report that during the audit period the following events/actions had a significant bearing and changes on the Company's affairs in pursuance of the above-mentioned Acts, Rules, Regulations, Guidelines and Standards:

(i) Aquilon Capital Emerging Sectors I transferred 75 Trench -II NCDs of the Company to Mr. Nikhil Ashok Dike for a total consideration of Rs. 75,00,000, as approved by the Board on 20th April 2026.

(ii) Ms. Reshma Susan Thomas, Company Secretary of the Company, resigned from her position with effect from 30th April, 2025 and Ms. Juhi Tanna was appointed as Company Secretary and Compliance Officer of Company w.e.f 30th May, 2026.

(iii) On 30th June 2025, the Company has received a notice from the Debenture Holder, Ms. Bindi Mehta, for enforcement of 6,69,116 equity shares pledged by the both the promoters as collateral against the issue of Tranche-I and Tranche-II Non-Convertible Debentures aggregating to Rs. 1,25,00,000. Pursuant to the invocation of the pledge, and after excluding locked-in shares, 5,21,063 equity shares were enforced, comprising 3,34,558 shares held by Mr. Hans Lewis and 1,86,505 shares held by Mr. Paulson Paul Thazhathedath, together representing 16.57% of the total paid-up share capital of the Company.

(iv) On 22nd August, 2025, the company has received a notice from the Debenture Holder, Ms. Varsha Mehta, for enforcement of 88,807 equity shares pledged by the promoters as collateral against the issue of Tranche-II Non-Convertible Debentures aggregating to Rs. 25,00,000. Pursuant to the invocation of the pledge, and after excluding locked-in shares, 44,403 equity shares held by Mr. Paulson Paul Thazhathedath, representing 1.41% of the total paid-up share capital of the Company, were enforced.

(v) The Company changed its name from "Docmode Health Technologies Limited" to "Doctrack Solutions Limited" vide Special Resolution passed in Extra-Ordinary General Meeting dated 8th July, 2026.

(vi) During the Financial Year, the registered office of the company was shifted ***from*** 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India, ***to*** 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra w.e.f 1st January, 2026.

6. I further report that:

(i) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

(ii) That the company has filed all forms in time with/without any additional fees to the Registrar of Companies/ Regional Director or Central Government under various sections of The Companies Act, 2013.

(iii) Adequate notice is given to all directors to schedule the committee and Board Meetings, agenda and detailed notes on agenda are sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meetings.

(iv) All the decisions at the Board Meetings and the Committee Meetings were carried out unanimously as recorded in the minutes of the Board of Directors and minutes of the Committee Meetings as the case may be.

7. I further report that:

(i) There are adequate systems and processes in the Company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

FOR M/s. VIDHI JOBANPUTRA & CO.
PRACTICING COMPANY SECRETARY

VIDHI JOBANPUTRA
PROPRIETOR
FCS NO.: 11160 | C. P. No.: 22293
UDIN: F011160H001333613

Date: 02/09/2026
Place: Mumbai

*This report is to be read with my letter of even date which is annexed as 'Enclosure-I' and forms an integral part of this report.

Enclosure-I

To,
The Members,
Doctrack Solutions Limited
(Previously known as Docmode Health Technologies Limited)
201, Kalpataru Plaza, Rambaug,
Off. Chincholi Bunder Road, Malad West,
Mumbai - 400064, Maharashtra, India.

My Secretarial Audit Report for the financial Year ended March 31, 2026 of even date is to be read along with this letter.

1. Maintenance of Secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these Secretarial records based on my audit.

2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the processes and practices | followed provide a reasonable basis for my opinion.

3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required, I have obtained Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations and standards is the responsibility of the management. My examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

FOR M/s. VIDHI JOBANPUTRA & CO.
PRACTICING COMPANY SECRETARY

VIDHI JOBANPUTRA
PROPRIETOR
FCS NO.: 11160 | C. P. No.: 22293
UDIN: F011160H001333613

Date: 02/09/2026
Place: Mumbai

Independent Auditor's Report

To the Members of
Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)

Report on the Audit of the Standalone Financial Statements

Qualified Opinion

We have audited the accompanying standalone financial statements of **Doctrack Solutions Limited** (Formerly known as **DocMode Health Technologies Limited** (**"the Company"**), which comprise the standalone Balance Sheet as at 31st March 2026, and standalone Statement of Profit and Loss and standalone Statement of Cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, **except for the effects of the matter described in the Basis for Qualified Opinion section of our report,** the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, its Loss and its Cash Flows for the year ended on that date.

Basis for Qualified Opinion

We draw attention to Note 9 to the financial statements regarding Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures ("NCDs") aggregating to Rs.2,25,00,000/- issued by the Company in two tranches.

The NCDs aggregating to Rs.1,00,00,000/- issued under Tranche I carry coupon interest at 18.00% per annum and the NCDs aggregating to Rs.1,25,00,000/- issued under Tranche II carry coupon interest at 18.50% per annum. The NCDs also carry additional default interest at 2.00% per annum over and above the applicable coupon rate upon occurrence of default, subject to the terms of the NCD documents.

The Company defaulted in repayment of the principal amounts and payment of interest in accordance with the terms of the NCDs. The entire principal amount of Rs.2,25,00,000/- had become contractually due for repayment by November 24, 2025 and remains recognized as outstanding by the Company as at 31 March 2026.

Consequent upon the defaults, out of 9,11,934 equity shares pledged by the promoters as security for the NCDs, the pledgees invoked 3,34,558 shares on August 22, 2025, 1,86,505 shares on August 25, 2025 and 44,403 shares on November 24, 2025, aggregating to 5,65,466 shares.

Management has represented that the aggregate quoted market value of the shares on the respective dates of invocation exceeded the outstanding dues towards principal, coupon interest and additional default interest and, on this basis, the Company has not recognized coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/-, aggregating to Rs.29,83,744/- for the year ended March 31, 2026.

However, neither the Company nor we have received any confirmation or statement of appropriation/realization from the Debenture Trustee/debenture holders confirming that the invoked shares have been appropriated towards discharge of the NCD obligations or confirming cessation of the Company's contractual obligation to pay interest.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the Beneficial Position (BENPOS) statement issued by the Registrar and Transfer Agent as at March 31, 2026.

Based on the terms of the NCD documents and in the absence of evidence establishing discharge of the Company's contractual obligations, in our opinion, the Company ought to have recognized coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/-, aggregating to Rs.29,83,744/- for the year ended March 31, 2026.

Consequently, finance costs and loss before tax for the year ended March 31, 2026 are understated by Rs.29,83,744/- and financial liabilities as at March 31,2026 are understated by Rs.29,83,744/-, with consequential impact, if any, on taxation and other related balances.
Our opinion is qualified in respect of the above matter.

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion on standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Except for the matters described in the Basis for Qualified Opinion section of our report, we have determined that there are no other key audit matters to communicate in our report

Information other than the standalone financial statements and auditors’ report thereon

The Company’s board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board’s Report including Annexures to Board’s Report but does not include the financial statements and our auditor’s report thereon. The company’s annual report is expected to be made available to us after the date of this auditor’s report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.

• Conclude on the appropriateness of management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143 (3) of the Act, we report that:

    a) We have sought and except for the matters described in the Basis for Qualified Opinion paragraph obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

    b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters described in the Basis for Qualified Opinion paragraph.

    c) The standalone Balance Sheet, the standalone Statement of Profit and Loss and the standalone Cash Flow Statement dealt with by this Report are in agreement with the books of account.

    d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

    e) On the basis of the written representations received from the Directors as on 31st March, 2026 taken on record by the Board of Directors, none of the Directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

    f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure A'. Our report express an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to the financial statements.

    g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 read with Schedule V to the Act.

    h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

        i. The Company does not have any pending litigations which would impact its financial position.

        ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share Premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:

- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or
- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:

- directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or
- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

vi. Based on our examination which included test checks the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except that audit trail was not enabled at the database level to log any direct changes for the accounting software used for maintaining the books of account. For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit.

2. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure B', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946MYSNBA3337

Doctrack Solutions Limited (Formerly known as **DocMode Health Technologies Limited)**

Annexure - A to the Independent Auditor's Report for the year ended March 31, 2026

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in Paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements section of our report of even date)

Opinion

We have audited the internal financial controls with reference to the financial statements of **Doctrack Solutions Limited** (Formerly known as **DocMode Health Technologies Limited** (**"The Company"**) as of March 31, 2026, in conjunction with our audit of the standalone financial statements of the Company as at and for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting, and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India". These responsibilities include the design, implementation, and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***for* R. Sundaresan Aiyar & Co**
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946MYSNBA3337

Doctrack Solutions Limited (Formerly known as **DocMode Health Technologies Limited**

Annexure-B to Independent Auditors' Report on the Standalone Financial Statements for the year ended March 31, 2026

(Referred to in paragraph 2 under "Report on Other Legal and Regulatory Requirements' section of our report of even date)

i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and the situation of Property, plant, and equipment on the basis of available information .

(B) The Company has maintained proper records showing full particulars of intangible assets on the basis of available information.

(b) According to the information and explanation given to us and on the basis of our examination of the records of the Company, Property, plant and equipment have been physically verified by the management at reasonable intervals. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, plant and equipment (including Right-of-use assets) or Intangible assets or both during the year

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

ii) (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits in excess of Rs.5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.

iii) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not made any investments in, provided guarantee or security, granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties during the year. Consequently, the provisions of clauses iii (a), (b) and (c) of the order are not applicable to the Company.

iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 and the Company has not provided any guarantee or security as specified under Section 186 of the Companies Act, 2013.

v) In our opinion and according to the information and explanation given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

vi) As per information & explanation given to us, the Central Government has not prescribed the maintenance of cost records under section 148 (1) of the Companies Act, 2013 for the products manufactured and/or services rendered by the Company. Accordingly, clause 3(vi) of the Order is not applicable.

vii) (a) The Company does not have any liability in respect of Sales tax, Service Tax, Duty of Excise and Value Added Tax during the year since effective July 1, 2017, these statutory dues have been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues, including Goods and Service Tax (GST), Provident Fund, Income-tax, Duty of Customs, Cess and other material statutory have generally been deposited with the appropriate authorities, though there have been delay in few cases of provident fund.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of GST, Provident fund, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2026 for a period of more than six months from the date they became payable except the payment of Tax Deducted at Source of Rs.21.72 Lacs & Provident Fund of Rs.1.98 Lac.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no dues of GST, Provident Fund, Income-tax, Sales Tax, Service Tax, Duty of Customs or other statutory dues which have not been deposited on account of any disputes.

viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.

ix) (a) According to the information and explanations given to us and based of our examination of the books of accounts of the Company, NCD documents and other records of the Company, the Company has defaulted in repayment of borrowings and payment of any interest thereon. The details of defaults are as under;

Nature of borrowing including debt securities	Amount not paid on due date (Rs.)	Principal or interest	Due date / period	Remarks
Tranche I – Secured Redeemable NCDs	25,00,000	Principal	30/11/2024	Continuing default as at 31 March 2026
Tranche I – Secured Redeemable NCDs	25,00,000	Principal	28/02/2025	Continuing default as at 31 March 2026
Tranche I – Secured Redeemable NCDs	50,00,000	Principal	09/05/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	30/06/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	31/07/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	31/08/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	30/09/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	31/10/2025	Continuing default as at 31 March 2026
Tranche II – Secured Redeemable NCDs	20,83,333.33	Principal	24/11/2025	Continuing default as at 31 March 2026
Secured Redeemable NCDs	27,50,000	Coupon Interest	FY 2025-26 / respective contractual due dates	Unpaid and not provided in the books
Secured Redeemable NCDs	2,33,744	Additional Default Interest	FY 2025-26 / as contractually applicable	Unpaid and not provided in the books

As more fully explained in Note 9 to the financial statements, the aforesaid NCDs are secured, inter alia, by pledge of 9,11,934 equity shares held by the promoters of the Company.

During the year, the pledgees invoked 3,34,558 shares on 22 August 2025, 1,86,505 shares on 25 August 2025 and 44,403 shares on 24 November 2025, aggregating to 5,65,466 shares. The balance 3,46,468 pledged shares could not be invoked on account of applicable lock-in restrictions.

Management has represented that the aggregate quoted market value of the shares on the respective dates of invocation exceeded the outstanding principal, coupon interest and additional default interest under the NCDs.

However, neither the Company nor we have received confirmation or a statement of appropriation/realisation from the Debenture Trustee/debenture holders confirming adjustment of the invoked shares against the outstanding dues or discharge, either wholly or partly, of the Company's obligations.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the BENPOS statement issued by the Registrar and Transfer Agent as at 31 March 2026.

Accordingly, for the purpose of reporting under this clause, we have considered the aforesaid principal and interest amounts as continuing defaults as at 31 March 2026.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Companies Act, 2013.Accordingly, clause 3(ix)(e) of the Order is not applicable.

(f)According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(f) of the Order is not applicable.

x) (a) The company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x) (b) of the Order is not applicable.

xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

(c) According to the information and explanations given to us, no whistle-blower complaints were received during the year by the Company.

xii) According to the information and explanations given to us, the company is not a Nidhi Company. Accordingly, clause (xii) of the order is not applicable to the company.

xiii) According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards.

xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

xv) According to the information and explanations given to us, in our opinion during the year the company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the company.

xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company has not conducted any Non-Banking Financial or Housing Finance activities during the year and hence, the company is not required to obtain certificate of registration from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.Accordingly, reporting under clause 3(xvi)(b) of the order is not applicable.

(c)The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

xvii) The company has not incurred cash loss during the financial year. The company has incurred cash loss of Rs.167 Lacs in the immediately preceding financial year.

xviii) No auditor has resigned from the post of the statutory auditors during the period under review.

xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

xx) In our opinion and according to the information and explanations given to us, the Company is not covered under the provisions of section 135 (5) of the Companies Act, 2013. Accordingly, clause (xx) of the order is not applicable.

xxi) The requirement of clause 3(xxi) is not applicable in respect of Standalone Financial Statements.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946MYSNBA3337

<u>Statement on Impact of Audit Qualification (For Audit Report with Modified Opinion) submitted along with Annual Standalone & Consolidated Audited Financial results.</u>

Statement on Impact of Audit Qualification for the financial year ended 31st March, 2026 (Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

A. Details of Audit Qualification:

Following are the qualifications given by the Auditors in Audit Report on Standalone & Consolidated Financials Statement of Company.

The Company has defaulted in repayment of NCDs aggregating to Rs. 2.25 crore, and the pledged shares of the promoters were partly invoked towards the default. However, as at 31 March 2026, the NCDs continued to appear as outstanding in the BENPOS, and no confirmation of redemption/appropriation or discharge of the NCD obligations was made available by the Debenture Trustee/debenture holders. Consequently, interest and default interest aggregating to Rs.29.84 lakh were not recognized by the Company, resulting in understatement of finance costs and financial liabilities. For detailed comment refer page number 1 of Auditors Report and Annexure B of auditors report (Standalone & Consolidated)

B. Type of Audit Qualification: Qualified Opinion

C. Frequency of Qualification: First Time

D. For Audit Qualification(s) where the impact is quantified by the Auditor:

i. Management's Views:

The Company has noted the observation of the Statutory Auditors regarding the accounting of coupon interest and additional default interest on the NCDs. Pursuant to the default, certain pledged shares of the promoters were invoked by the pledgees and the management had considered the value of such shares against the outstanding NCD obligations.

However, in the absence of formal confirmation from the Debenture Trustee/debenture holders regarding appropriation of the invoked shares and discharge of the NCD obligations, the Statutory Auditors have considered the aforesaid interest as payable.

The Company is in the process of obtaining the requisite confirmation and supporting documents from the Debenture Trustee/debenture holders and shall take appropriate accounting and consequential regulatory actions based on the final confirmation and reconciliation of the NCD obligations.

E. For Audit Qualification(s) where the impact is not quantified by the Auditor:

i. Management's estimation on the impact of audit qualification: NA

ii. If management is unable to estimate the impact, reasons for the same: NA

F: Signatories Details:

PARESH JAYSIH SAMPAT **MANAGING DIRECTOR** **DIN: 00410185**	**CA R SUNDARESAN AIYAR** **STATUTORY AUDITOR** **MEMBERSHIP NO: 043946**

HANS ALBERT LEWIS
CFO
PAN: ACOPL6883G

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Balance Sheet As At March 31,2026

Indian Rupee in Lacs

		Particulars	Note	March 31,2026	March 31,2025
I.	**EQUITY AND LIABILITIES**				
1	**Shareholder's funds**				
	(a)	Share capital	3	314.28	314.28
	(b)	Reserves and surplus	4	507.72	521.05
	(c)	Money received against share warrants		-	-
2	**Share application money pending allotment**			-	-
3	**Non-current liabilities**				
	(a)	Long Term Borrowings	5	108.92	112.45
	(b)	Deferred Tax Liabilities (Net)		-	-
	(c)	Other Long Term Liabilities		-	-
	(d)	Long Term Provisions	6	61.13	69.71
4	**Current liabilities**				
	(a)	Short Term Borrowings	7	263.68	569.91
	(b)	Trade Payables	8	350.99	533.54
	(c)	Other Current Liabilities	9	1,531.55	1,451.63
	(d)	Short Term Provisions	10	211.38	358.55
		TOTAL		**3,349.64**	**3,931.11**
II.	**ASSETS**				
1	**Non-current assets**				
	(a)	Property, Plant and Equipment and Intangible Assets	11		
		(i) Property, Plant and Equipment		97.68	120.74
		(ii) Intangible Assets		0.44	0.84
		(iii) Capital Work-In-Progress		-	-
		(iv) Intangible Assets under Development		1,347.94	1,159.76
	(b)	Non Current Investments	12	121.32	120.61
	(c)	Deferred Tax Assets (net)	13	26.23	25.51
	(d)	Long-term Loans and Advances	14	27.77	8.70
	(e)	Other Non Current Assets	15	10.71	12.91
2	**Current assets**				
	(a)	Current Investments	16	9.25	8.69
	(b)	Inventories	17	774.59	1,116.93
	(c)	Trade Receivables	18	743.60	923.94
	(d)	Cash and Cash Equivalents	19	17.65	178.81
	(e)	Short Term Loans and Advances	20	150.23	228.75
	(f)	Other Current Assets	21	22.21	24.91
		TOTAL		**3,349.64**	**3,931.11**
	Significant Accounting Policies		2		
	The notes are integral parts of the financial statements				

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946MYSNBA3337

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN : BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited

(Formerly known as DocMode Health Technologies Limited)

CIN : L74999MH2017PLC297413

Standalone Statement of Profit & Loss for the year ended March 31, 2026

Indian Rupee in Lacs

	Particulars	**Note No**	**March 31,2026**	**March 31,2025**
I.	Revenue from Operations	22	2,551.59	4,177.29
II.	Other Income	23	139.47	92.97
III.	**Total Income (I + II)**		2,691.05	4,270.27
IV.	**Expenses:**			
	Cost of Materials Consumed		-	-
	Purchases / Consumption of Goods & Services	24	1,648.03	4,478.42
	Changes in inventories	25	342.34	(865.55)
	Employee benefits Expense	26	272.04	376.30
	Finance Costs	27	96.50	191.21
	Depreciation and Amortization Expense	28	23.46	29.92
	Other Expenses	29	322.74	256.99
	Total expenses		2,705.10	4,467.29
V	**Profit before exceptional and extraordinary items and tax (III- IV)**		(14.05)	(197.02)
VI	Exceptional Items		-	-
VII	**Profit before extraordinary items and tax (V - VI)**		(14.05)	(197.02)
VIII	Extraordinary items		-	-
IX	**Profit before tax (VII- VIII)**		(14.05)	(197.02)
X	**Tax expense:**			
	(1) Current tax		-	-
	Less : MAT Credit Entitlement		-	-
			-	-
	(2) Deferred tax Liability/(Asset)		(0.72)	(6.80)
	(3) Tax in respect of earlier years		-	12.92
	(4) Profit / (Loss) of Prior Period Depreciation		-	-
			(0.72)	6.12
XI	**Profit (Loss) for the period from continuing operations (IX-X)**		(13.33)	(203.14)
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	**Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)**		-	-
XV	**Profit (Loss) for the period (XI + XIV)**		**(13.33)**	**(203.14)**
XVI	**Earnings per equity share of Rs. 10 each**			
	Basic		(0.42)	(6.46)
	Diluted		(0.42)	(6.46)
	Significant Accounting Policies			
	The notes are integral parts of the financial statements			

As per our report of even date

for R Sundaresan Aiyar & Co

Chartered Accountants

Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946MYSNBA3337

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN : BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited

(Formerly known as DocMode Health Technologies Limited)

CIN : L74999MH2017PLC297413

Statement of Cash Flows for the year ended March 31, 2026

Indian Rupee in Lacs

		March 31,2026	March 31,2025
(A)	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit before Tax and Extraordinary Items	(14.05)	(197.02)
	Adjusted for		
	Depreciation	23.46	29.92
	Profit on Sale of Fixed Assets	-	-
	Provision for Gratuity	(8.58)	3.43
	Interest Expenses	96.50	191.21
	Operating Profit before Working Capital changes	97.33	27.54
	Adjutments for changes in working capital		
	(Increase)/Decrease in Inventories	342.34	(865.55)
	(Increase)/Decrease in Trade and Other Receivables	180.34	222.95
	(Increase)/Decrease in Short Loans & Advances	78.52	(30.58)
	(Increase)/Decrease in Long term Loans & Advances	(19.07)	(1.13)
	(Increase)/Decrease in Other Current Assets	2.69	(24.91)
	(Increase)/Decrease in Other Non Current Assets	2.20	-
	Increase/(Decrease) in Trade Payables	(182.55)	257.94
	Increase/(Decrease) in Other Non Current liabilities	-	-
	Increase/(Decrease) in Current liabilities	79.92	1,095.64
	Increase/(Decrease) in Short Term Provisions	(147.17)	(4.81)
	Cash generated from operations	434.55	677.11
	Direct Taxes Paid	-	(12.92)
	NET CASH FLOW FROM OPERATING ACTIVITIES	434.55	664.19
(B)	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Sale/ (Purchase) of Fixed Assets	(188.18)	(364.53)
	Sale/ (Purchase) of Investments	(1.27)	(2.96)
	Rent Deposit paid to landlord for office premises	-	0.22
	NET CASH USED IN INVESING ACTIVITIES	(189.45)	(367.27)
(C)	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Proceeds/(Repayment) from long term borrowings	(3.53)	(325.75)
	Proceeds from Short Term Borrowings	(306.22)	90.08
	Proceeds from issue of Shares	-	-
	Interest paid	(96.50)	(191.21)
	NET CASH FROM FINANCING ACTIVITIES	(406.26)	(426.88)
	NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(161.16)	(129.96)
	OPENING BALANCE OF CASH AND CASH EQUIVALANTS	178.81	308.76
	CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	17.65	178.81

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881

Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN : BAHPT5930L
Place : Mumbai
Date : September 04, 2026

AUDITORS' REPORT ON CASH FLOW STATEMENT

We have examined the above Cash Flow Statement of Doctrack Solutions Ltd derived from audited financial statements and the books and records maintained by the company for the period ended March 31, 2026 and found the same in agreement therewith.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946

Place : Mumbai
Date : September 04, 2026
UDIN : 26043946MYSNBA3337

1.Background of the Company

Docmode Health Technologies Limited ("the Company")was incorporated on July 17,2017. The registered office of the Company is located at 201, Kalpataru Plaza, Rambaug, Off. Chincholi Bunder Road, Malad (West), Mumbai 400064. The Company is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry for the healthcare stakeholders. The Company also conducts offline/ online events/ sessions/ seminars for knowledge enhancement and sharing for the healthcare stakeholders.

Subsequent to the financial year ended 31 March 2026, the name of the Company was changed from Docmode Health Technologies Limited to Doctrack Solutions Limited pursuant to the approval of the members and the approval of the Registrar of Companies / Central Government, as applicable.

The Registrar of Companies issued a fresh Certificate of Incorporation consequent upon change of name dated 28th July,2026 and accordingly the change of name became effective from July 28,2026.

The change in name does not result in any change in the legal status, constitution, rights or obligations of the Company and does not have any financial impact on the financial statements for the year ended 31 March 2026.

Accordingly, these financial statements, which relate to the financial year ended 31 March 2026, have been issued in the name of Doctrack Solutions Limited (formerly known as Docmode Health Technologies Limited).

2. Significant accounting policies

2.1 Basis of preparation & presentation

The financial statements have been prepared to comply in all material respects with the Accounting Standards issued as per the provisions of Section 133 of the Companies Act, 2013 read with rule 7 of Companies (Accounts) Rules 2014.The financial statements are prepared on going concern basis under the historical cost convention on the accrual basis except in case of assets for which provision for impairment is made and revaluation is carried out. The accounting policies have been consistently applied by the Company .

2.2 Functional and Presentation Currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are mentioned in lakhs and rounded off to 2 decimals unless, otherwise stated.

2.3 Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires judgements, estimates and assumptions to be made that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognized in the year in which the results are known / materialized.

2.4 Property, Plant & Equipment

Tangible assets

Tangible assets are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to assets.

Subsequent expenditures related to an item of Tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Projects under which assets are not ready for its intended use are disclosed under capital work in progress.

Intangible assets

Intangible assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization / depletion and impairment loss, if any. The cost comprises purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to intangible assets.

2.5 Leases

Leases of assets, where the company assumes substantially all the risk and benefits of ownership are classified as finance leases. Finance leases are capitalized at the lower of fair value of the leased assets at inception and the present value of minimum lease payments. Lease payments are apportioned between the finance charge and the outstanding liability. The finance charge is allocated periods during the lease term at a constant periodic rate of interest on the remaining balance of the liability.

Leases where the lessor effectively retains substantially all the risk and benefits of ownershipare classified, as operating leases. Lease rentals in respect of assets taken under operating leases are charged to statement of profit & loss on a straight line basis over the lease term.

2.6 Depreciation

Depreciation is provided on a pro-rata basis under the Written Down Value method over the useful life of the assets as prescribed under part C of Schedule II of the Companies Act,2013.

Fixed assets individually costing Rupees Five Thousand or less are depreciated at 100% over a period of one year.

Assets under finance lease are amortized over their estimated useful life or the lease term whichever is lower.

2.7 Impairment

As asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit & Loss Statement in the year in which as asset is treated as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

2.8 Foreign Currency Transactions

i. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction or that approximates the actual rate at the date of transaction.

ii. Monetary items denominated in foreign currencies at the year- end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year- end rate and the rate on the date of contract is recognized as exchange difference and the premium paid on forward contracts is recognized over the life of contract.

iii. Non-monetary foreign currency assets are carried at cost.

iv. Any income or expense on account of exchange differences either on settlement or on translation is recognized in the Profit & Loss Statement, except in the case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

2.9 Investments

Current investments are carried at lower of cost and quoted / fair value, computed category-wise. Non- current investments are stated at cost. Provision for diminution in the value of Non-Current Investments is made only if such a decline is other than temporary.

2.10 Cash and Cash equivalents

Cash and cash equivalents comprise cash and cash on deposit with banks. The company considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalents.

2.11 Revenue recognition

i. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

ii.Revenue from sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer. Revenue from sale of goods is net of sales tax, trade discounts, rebates etc.

iii. Revenue from services is recognized as and when the services are rendered in accordance with the terms of the specific contracts, net of all contractual deductions. Revenue from Services is recognized net of all taxes and levies..

iv. Income from interest on deposits is recognized on a time proportion basis.

v. Dividend income is recognized when the right to receive payment is established.

2.12 Employee benefits

(i) Short term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by the employees are recognized as expense during the period when the employee render the services. These benefits include performance incentive and compensated absences.

(ii) Post-employment benefits

a) Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Company pays specified contributions to a separate entity. The Company makes specified monthly contribution towards Provident Fund and pension scheme. The Company's contribution is recognized as an expense in the Profit and Loss Statement during the period in which the employee renders the related service.

b) Defined benefit plans

Gratuity

Benefits payable to eligible employees of the Company with respect to gratuity, a defined benefit plan is accounted for on the basis of an actuarial valuation as at the balance sheet date. In accordance with the Payment of Gratuity Act, 1972, the plan provides for lump sum payments to vested employees upon retirement, death while in service or upon termination of employment in an amount equivalent to 15 days salary for each completed year of service. Vesting occurs upon completion of five years of service. The company contributes premium towards gratuity liability arrived by actuarial valuation performed by an independent actuary.

Acturial Valuation

The actuarial valuation method used for measuring the liability either Gratuity or Compensated absence is the Projected Unit Credit method. The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. The expected rate of return on plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Actuarial gain/losses are recognized in the Statement of Profit and Loss in the year they are determined.

2.13 Borrowing costs

Borrowing costs include exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are attributable to the acquisition or construction of a qualifying asset are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred. Capitalisation of borrowing costs is suspended during the extended period in which active development is interrupted. Capitalisation of borrowing costs is ceased when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Other borrowing costs are charged to statement of profit and loss as and when incurred.

2.14 Provisions, contingent liabilities and contingent assets

Provision is recognized in the accounts when there is present obligation as a result of a past event(s) and it is probable that an outflow of resources will be required and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date.

Contingent liabilities are disclosed unless the possibility of outflow of resources is remote.

Contingent assets are neither recognized nor disclosed in the financial statements.

2.15 Income Taxes

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates.

Deferred income tax reflect the current period timing difference between taxable income and accounting income for the year and reversal of timing difference of earlier years/period. Deferred tax assets are recognized only to the extent there is reasonable certainty that the sufficient future income will be available except that deferred tax assets, in case there are unabsorbed depreciation or losses, are recognized only if there is virtual certainty that sufficient future taxable income will be available to realize the same.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date.

2.16 Earnings per share

Basic earnings per share are computed by dividing the net profit for the year attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity and dilutive equity equivalent shares outstanding during the year, except where the results would be anti-dilutive.

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)
Note 3
Share Capital

Particulars	March 31,2026	March 31,2025
Authorised Share Capital		
40,00,000 (P.Y 40,00,000) Equity Shares of Rs. 10 each	400.00	400.00
50,000(P.Y 50,000) Preference Shares of Rs 10 each	5.00	5.00
Total	**405.00**	**405.00**
Issued, Subscribed & Paid up		
31,42,800 (P.Y 31,42,800) Equity Shares of Rs. 10 each fully paid	314.28	314.28
Total	**314.28**	**314.28**

The Company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. In the event of liquidation, the equity shareholders are eligilble to receive the remaining assets of the Company, after distribution of all preferential amounts, In proportion of their shareholding.

Reconciliation of no. of shares outstanding at the beginning and at the end of the year

Particulars	March 31,2026 Equity Shares		March 31,2025 Equity Shares	
	Number	**Amount**	**Number**	**Amount**
Shares outstanding at the beginning of the year	31,42,800	3,14,28,000	31,42,800	3,14,28,000
Shares Issued during the year	-	-		
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	31,42,800	3,14,28,000	31,42,800	3,14,28,000

Details of Shares held by shareholders holding more than 5% in the Company:

Name of Shareholder	March 31,2026		March 31,2025	
	No. of Shares held	**% of Holding**	**No. of Shares held**	**% of Holding**
Paulson Paul Thazhathedath	5,14,382	16.37%	7,45,290	23.71%
Hans Albert Lewis	4,10,732	13.07%	7,45,290	23.71%
Anil Khanna	4,01,310	12.77%	4,01,310	12.77%
Aalok Pathak	4,00,164	12.73%	4,00,164	12.73%
Bindi Mehta	5,21,063	16.58%	-	0.00%
Ramesh Kumar Jain	1,60,000	5.09%	92,800	2.95%
	24,07,651	**76.61%**	**23,84,854**	**75.88%**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)
Details of Shares held by Promoters at the end of the year

Name of Promoter	March 31,2026		March 31,2025		% Change During the year
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	
Paulson Paul Thazhathedath	5,14,382	16.37%	7,45,290	23.71%	-7.35%
Kenneth Paul Lewis	1,982	0.06%	382	0.01%	0.05%
Hans Albert Lewis	4,10,732	13.07%	7,45,290	23.71%	-10.65%
	9,27,096	**29.50%**	**14,90,962**	**47.44%**	**-17.94%**

Pledge of Promoters' Shares
Promotors shares pledged to secure Non Convertible Debentures of the company.

Consolidated Reconciliation

Particulars	No of Shares held by		Total no. of Shares
	Paulson Paul Thazhathedath	Hans Albert Lewis	
Opening Shares as on 01.04.2025	7,45,290	7,45,290	14,90,580
Less : Shares Invoked	(2,30,908)	(3,34,558)	(5,65,466)
Closing Shares as on 31.03.2026	5,14,382	4,10,732	9,25,114

Out of closing shares:

Shares pledged but not invoked	2,25,059	1,21,409	3,46,468
Free / unpledged shares	1,19,976	84,838	2,04,814
Lock-in shares	1,69,347	2,04,485	3,73,832
Total Closing Shares	5,14,382	4,10,732	9,25,114

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

Note 4
Reserves and Surplus

Particulars	March 31,2026	March 31,2025
Surplus/Deficit in the Statement of Profit and Loss		
Opening Balance	521.05	724
(-) Capitalisation of reserves	-	-
(+) Securities Premium	-	-
(+) Net Profit/(Net Loss) For the current year	(13.33)	(203.14)
Total	**507.72**	**521.05**

Note 5
Long Term Borrowings

Particulars	March 31,2026	March 31,2025
Unsecured Loans		
a) Bonds / Debentures	-	-
b) Term Loans	-	-
A) From Banks	21.13	3.49
B) From Other Parties	87.79	108.96
Total	**108.92**	**112.45**

Note 6
Long Term Provisions

Particulars	March 31,2026	March 31,2025
a) Provision for Employee Benefits	61.13	69.71
Total	**61.13**	**69.71**

Note 7
Short Term Borrowings

Particulars	March 31,2026	March 31,2025
Secured Loans		
a) Bonds / Debentures	-	175.00
b) Bank Overdraft Account	109.93	111.12
Unsecured Loans		
Current Maturities of Long Term Borrowings	153.75	283.78
Total	**263.68**	**569.91**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

Note 8
Trade Payables

Particulars	March 31,2026	March 31,2025
Total outstanding dues of Creditors of Micro & Small Enterprises	71.59	184.02
Total outstanding dues of Creditors other than Micro & Small Enterprises	279.39	349.52
Total	**350.99**	**533.54**

Trade Payables Ageing Schedule as at March 31,2026

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	68.35	3.24	-	-	71.59
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	151.08	108.99	18.15	1.18	279.39
Total					**350.99**

Trade Payables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	172.68	11.34	-	-	184.02
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	333.99	11.38	-	4.14	349.52
Total					**533.54**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)
Note 9
Other Current Liabilities

	Particulars	March 31,2026	March 31,2025
	Interest Accrued and due on Debentures	1.03	1.54
	Income Received in Advance	1,303.04	1,381.33
*	Unpaid matured debentures and interest accrued thereon	225.00	55.45
	Other Payables	2.48	13.32
	Total	**1,531.55**	**1,451.63**

*** Secured Redeemable Non-Convertible Debentures, Default, Invocation of Pledged Shares and Non-Provision of Interest**

During May 2024, the Company raised Rs.2,25,00,000 by issue of 225 Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures ("NCDs") of face value ₹1,00,000 each in two tranches, as under:

Particulars	Tranche - I	Tranche - II
Date of issue	08-May-2024	24-May-2024
Number of NCDs	100	125
Face Value per NCD	1,00,000	1,00,000
Aggregate principal	Rs. 10000000	Rs. 12500000
Coupon Rate	18% p.a	18.5% p.a
Additional Default Interest	2.00% p.a	2.00% p.a

The NCDs were contractually redeemable as follows:

Particulars	Due Date	Redeemption Amount in Rs.
Tranche - I	30-Nov-2024	25,00,000
	28-Feb-2025	25,00,000
	09-May-2025	50,00,000
Total		**1,00,00,000**
Tranche - II	30-June-2025	20,83,333
	31-July-2025	20,83,333
	31-Aug-2025	20,83,333
	30-Sept-2025	20,83,333
	31-Oct-2025	20,83,333
	24-Nov-2025	20,83,333
Total		**1,25,00,000**

The Company defaulted in repayment of the principal amounts and payment of interest in accordance with the terms of the NCDs.

Security and invocation thereof

The NCDs were secured, inter alia, by pledge of 9,11,934 equity shares held by the promoters of the Company.
Consequent upon the defaults, the pledgees invoked the pledged shares as follows:

Date of invocation	Number of shares invoked
22-Aug-25	3,34,558
25-Aug-25	1,86,505
24-Nov-25	44,403
Total shares invoked	**5,65,466**

The aforesaid shares were debited from the respective demat accounts of the promoters and credited to the demat accounts of the pledgees.
The balance 3,46,468 pledged equity shares could not be invoked on account of applicable lock-in restrictions, which, as represented to the Company, are expected to cease in February 2027

(Currency: Indian rupee in Lacs)

Based on the quoted market prices of the equity shares on the respective dates of invocation, the aggregate market value of the 5,65,466 shares invoked was higher than the outstanding dues towards principal, coupon interest and default interest under the NCDs.

However, up to the date of approval of these financial statements, neither the Company nor its Statutory Auditors have received any confirmation, statement of appropriation/realisation or other communication from the Debenture Trustee/debenture holders confirming:

(a) whether the invoked shares have been sold, realised, appropriated or otherwise adjusted against the outstanding NCD dues;
(b) the value at which such shares have been realised or appropriated, if at all;
(c) the amounts, if any, adjusted against principal, coupon interest, additional default interest and other charges;
(d) whether the obligations of the Company under the NCDs have been discharged, either wholly or partly;
(e) whether the obligation to pay coupon interest and/or additional default interest ceased consequent upon invocation of the pledged shares; and
(f) the balance amount, if any, remaining payable by the Company.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the Beneficial Position (BENPOS) statement issued by the Registrar and Transfer Agent as at March 31, 2026

Accordingly, in the absence of documentary evidence establishing extinguishment of the Company's obligations, the Company has continued to recognise the principal amount of Rs.2,25,00,000 in respect of the NCDs as outstanding as at March 31, 2026.

Non-provision of coupon and default interest

During the financial year ended March 31, 2026, the Company has not recognised/provided coupon interest aggregating to Rs.27,50,000 and additional default interest aggregating to Rs.2,33,744 payable in respect of the aforesaid NCDs in accordance with the applicable terms thereof.

Management considers that, having regard to the invocation of 5,65,466 pledged equity shares during the year and the aggregate quoted market value thereof on the respective dates of invocation being higher than the outstanding dues towards principal, coupon interest and default interest, no further provision towards coupon interest and default interest is required.

However, the aforesaid position of management has not been confirmed by the Debenture Trustee/debenture holders and no statement of appropriation/realisation or confirmation of discharge has been received by the Company.

Accordingly, coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/- aggregating to Rs.29,83,744/- have not been recognised in these financial statements.

Had the aforesaid coupon interest and additional default interest been recognised, finance costs and loss before tax for the year ended 31 March 2026 would have been higher by Rs.29,83,744/- and financial liabilities as at March 31,2026 would have been higher by the corresponding amount, with consequential impact, if any, on taxation and other related balances.

The ultimate adjustment of the outstanding NCD principal, coupon interest, additional default interest and other charges, if any, remains subject to confirmation/reconciliation with the Debenture Trustee/debenture holders and determination of the effect of realisation/appropriation of the invoked pledged shares

Note 10
Short Term Provisions

Particulars	March 31,2026	March 31,2025
Provision for Employee Benefits	116.34	139.98
GST Payable	30.15	21.29
TDS Payable	58.89	191.27
Provision for Audit Fees	6.00	6.00
Total	**211.38**	**358.55**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
Note 11 - Property, Plant and Equipment
(Currency: Indian rupee in Lacs)

Particulars/Assets	Tangible Assets				Intangible			Gross Total
	Computers	Machinery	Office Equipments	Total	Software	Assets Under Development	Total	
Gross Block								
At 1st April 2024	18.84	86.99	1.55	107.38	5.41	849.92	855.33	962.71
Additions	0.09	54.60		54.69	-	309.84	**309.84**	364.53
Deductions/Adjustments	-	-	-	-	-		-	-
At 1st April 2025	18.93	141.59	1.55	162.07	5.41	1,159.76	1,165.17	1,327.24
Additions				-	-	188.18	**188.18**	188.18
Deductions/Adjustments	-	-	-	-	-		-	-
At 31st March 2026	**18.93**	**141.59**	**1.55**	**162.07**	**5.41**	**1,347.94**	**1,353.35**	**1,515.42**
Depreciation								
At 1st April 2024	10.73	0.21	1.23	12.17	3.80	-	3.80	15.97
Additions	4.85	24.18	0.13	29.16	0.76	-	0.76	29.92
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2025	15.57	24.39	1.36	41.32	4.57	-	4.57	45.89
Additions	1.77	21.23	0.07	23.06	0.40	-	0.40	23.46
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2026	**17.34**	**45.62**	**1.43**	**64.38**	**4.97**	**-**	**4.97**	**69.35**
Net Block								
At 31st March 2025	**3.36**	**117.19**	**0.19**	**120.74**	**0.84**	**1,159.76**	**1,160.60**	**1,281.35**
At 31st March 2026	**1.59**	**95.97**	**0.13**	**97.68**	**0.44**	**1,347.94**	**1,348.39**	**1,446.07**

If Assets Purchase During the Year the Dep formula = Life used in Purchasing Year x Depreciable Amount over whole Life x Rate of Depreciation
If Opening Assets Depreciation Formula = IF(AND(Remaining Life<1,Remaining Life>0),(Opening WDV-Salvage Value),(Opening WDV*Rate of Depreciation))

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

Note 12
Non Current Investments

Particulars	**March 31,2026**	**March 31,2025**
Investment in Equity Instruments	0.10	0.10
Investment in Fixed Deposits	121.22	120.52
Total	**121.32**	**120.61**

NOTE 13
Deferred Tax Assets (Net)

Particulars	**March 31,2026**	**March 31,2025**
Deferred Tax Assets	26.23	25.51
Total	**26.23**	**25.51**

Note 14
Long Term Loans and Advances

Particulars	**March 31,2026**	**March 31,2025**
a) Capital Advances	-	-
Secured, Considered good	-	-
Unsecured, Considered good	-	-
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
b) Loans and Advances to related Parties		
Secured, Considered good		
Unsecured, Considered good	0.12	6.05
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
c) Other Loans and Advances		
MAT Credit Entitlement	-	-
Unsecured, Considered good	27.65	2.65
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
	-	-
Total	**27.77**	**8.70**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

NOTE 15
Other Non Current Assets

Particulars	March 31,2026	March 31,2025
i) Security Deposits		
Central Depository Services	0.10	0.10
Rent Security Deposits	3.90	6.10
National Stock Exchange	6.71	6.71
Total	**10.71**	**12.91**

Note16
Current Investments

Particulars	March 31,2026	March 31,2025
Investment in Fixed Deposit	9.25	8.69
	9.25	**8.69**

Note 17
Inventories

Particulars	March 31,2026	March 31,2025
Inventory of Digital Course Content	-	248.46
Service Work in Progress	772.99	866.77
Inventory of Books	1.60	1.70
	774.59	**1,116.93**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)
Note 18
Trade Receivables

Particulars	March 31,2026	March 31,2025
Trade Receivable		
Secured, considered good	-	-
Unsecured, considered good	743.60	923.94
Unsecured, considered doubtful	-	-
Less: Provision for doubtful debts	-	-
Total	**743.60**	**923.94**

Trade Receivables Ageing Schedule as at March 31,2026

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables-Considered Good	69.52	0.29	2.11	669.91	1.78	**743.60**
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Total	**69.52**	**0.29**	**2.11**	**669.91**	**1.78**	**743.60**

Trade Receivables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables-Considered Good	150.05	29.62	77.95	666.32	-	**923.94**
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Total	**150.05**	**29.62**	**77.95**	**666.32**	**-**	**923.94**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

Note19
Cash and Cash Equivalents

Particulars	March 31,2026	March 31,2025
Cash & Cash Equivalents		
a) Balance with Bank	15.83	176.12
b) Cheques, Drafts on Hand	-	-
c) Cash on Hand	1.82	2.68
Total	**17.65**	**178.81**

Note 20
Short Term Loans and Advances

Particulars	March 31,2026	March 31,2025
Loans & Advances to related Parties		
Others		
Loan to Staff	-	-
Balances with revenue authorities	3.98	25.37
Advance Tax & TDS (Net of Provision for Tax)	108.94	160.89
Other Loans & Advances	37.32	42.49
Total	**150.23**	**228.75**

NOTE 21
Other Current Assets

Particulars	March 31,2026	March 31,2025
Excess Interest Paid Recoverable	-	6.81
TDS Revcoverable from NBFC	22.21	18.10
Total	**22.21**	**24.91**

Notes To The Financial Statements
(Currency: Indian rupee in Lacs)

Note 22
Revenue from Operations

Particulars	March 31,2026	March 31,2025
Sale of products		
Sale of Goods	316.79	682.39
Sale of Services		
Sale of Services	2,234.79	3,494.90
Other Operating Revenue	-	
Total	**2,551.59**	**4,177.29**

Note 23
Other Income

Particulars	March 31,2026	March 31,2025
Interest Income	15.38	13.02
Miscellaneous Income	0.02	2.27
Discount Received	-	0.04
Sundry Balances written off	124.07	77.64
Total	**139.47**	**92.97**

Note 24
Purchases / Consumption of Goods & Services

Particulars	March 31,2026	March 31,2025
CME Course Content	7.80	22.40
Purchase of Books	1.62	14.83
Purchases	102.17	293.17
Printed Literature	137.82	200.63
Travelling Expenses	152.29	208.31
Event Consumables	360.59	683.34
Professional Fees	811.97	2,607.41
Contractee Fees	21.71	415.74
Webinar Expenses	4.38	15.03
Transcription Charges	1.70	4.93
Service Charges	6.61	2.52
Content Expenses	20.07	10.11
Other Direct Expenses	19.29	-
Total	**1,648.03**	**4,478.42**

Note 25
Changes in inventories

Particulars	March 31,2026	March 31,2025
Opening Stock		
Service Work in Progress	866.77	-
CME Course Content	250.16	251.39
Total (A)	**1,116.93**	**251.39**
Closing Stock		
CME Course Content	-	248.46
Service Work in Progress	772.99	866.77
Others	1.60	1.70
Total (B)	**774.59**	**1,116.93**
Total (A-B)	**342.34**	**(865.55)**

Note 26
Employee Benefits Expenses

Particulars	March 31,2026	March 31,2025
Salaries & Wages	252.81	337.55
Contribution to Providend Fund and Other Fund	22.21	26.74
Contribution to Recognised Gratuity Fund	-7.53	5.61
Staff Welfare	4.55	6.40
Total	**272.04**	**376.30**

Note 27
Finance Costs

Particulars	March 31,2026	March 31,2025
Interest Expenses		
On Borrowings	77.65	157.47
On Deferred/Delayed Payment of Taxes	2.71	29.54
Other Borrowing Cost	9.62	1.26
Applicable net gain/loss on foreign currency transactions and	6.52	2.93
Total	**96.50**	**191.21**

Note 28
Depreciation and Amortization Expense

Particulars	March 31,2026	March 31,2025
Depreciation on Tangible Assets	23.06	29.16
Depreciation on Intangible Assets	0.40	0.76
Total	**23.46**	**29.92**

Note 29
Other Expenses

Particulars	March 31,2026	March 31,2025
Event Expenses	-	0.52
Advertising & Marketing Expenses	10.56	8.27
Cloud Services	56.68	4.16
Service Charges	14.58	11.18
Software Charges	11.09	7.20
Webinar Expenses	0.59	3.72
Electricity Expenses	1.39	1.63
Rent	34.76	41.61
Recruitment Charges	-	3.49
Commission & Brokerage	-	0.56
Telephone Expenses	0.55	0.56
Insurance Charges	2.28	0.64
Repairs & Maintenance	1.18	0.79
Sponsorship Service	12.10	-
Office Expenses	5.83	4.96
Professional Fees	109.43	115.68
IT Consultancy & Support Service	-	1.73
Profession Tax	0.21	0.08
Travelling Expenses	6.89	9.51
GST Expensed out	12.16	5.61
Printing, Postage & Courier	0.55	2.03
Rates & Taxes	-	1.84
Other Expenses	32.15	20.91
Business Promotion	0.14	-
Prior Period Expenses	3.61	4.31
Payment to Auditors	-	-
Audit Fees	6.00	6.00
Total	**322.74**	**256.99**

(Currency: Indian rupee in Lacs)

Note 30 - Contingent liabilities & Commitments in respect

Particulars	March 31,2026	March 31,2025
A. Contingent Liabilities		
a Claims against the company not acknowledge as debts	Nil	Nil
b. Guarantees	Nil	Nil
c.Other money for which the company is contingently liable.	Nil	Nil
Total	-	-

B. Commitments

There are no commitments as at 31st March, 2026

Note 31 - Deferred Tax Asset (Liability)

Particulars	March 31,2026	March 31,2025
Permanent Difference		
Items disallowed under Income Tax Act, 1961	-	-
Timing Difference		
Difference in Gratuity Provision	(61.13)	(71.57)
Difference in Fixed Assets	(7.63)	(4.40)
Creditors Disallowance u/s 43B(h)	(32.12)	(22.15)
Total	(100.87)	(98.11)
Deferred Tax Asset on Timing Difference	**(26.23)**	**(25.51)**

Note 32 - Auditor's Remuneration

Particulars	March 31,2026	March 31,2025
Statutory Audit Fees	6.00	6.00
Total	**6.00**	**6.00**

Note 33 - Expenditure / Income in foreign currency (on accrual basis):

Particulars	March 31,2026	March 31,2025
Import	30.30	99.66
Export	2.72	6.89
Total	**33.02**	**106.55**

Note 34 - Earning Per Share

Particulars	March 31,2026	March 31,2025
Net Profit after tax	(13.33)	(203.14)
Weighted Average number of equity shares	31.43	31.43
EPS (Basic) (Rs.)	(0.42)	(6.46)
EPS (Diluted) (Rs.)	(0.42)	(6.46)
Face Value per equity share (Rs.)	10.00	10.00

Note 35 - Related Party Transactions

(a) Names of Related Parties & Nature of Relationship	
Paulson Paul Thazhathedath	Director
Hans Albert Lewis	Director
Paresh Sampat	Director
Monina Elizabeth Lewis	Director
Docmode Endeavors LLP	Director having substantial Interest
Augmentors Healthcare Limited	Director having substantial Interest
Aumen Healthcare Pvt Ltd	Director having substantial Interest
Kenneth Paul Lewis	Relative of Director
Docmode Endeavors LLP	Director having substantial Interest
CCME World Services Pvt Ltd	Subsidiary Company

(c) Loan given to Related Party	March 31,2026	March 31,2025
Paulson Paul Thazhathedath	-	-
Hans Albert Lewis	-	-
CCME World Services Pvt Ltd	0.05	6.00
Total	**0.05**	**6.00**

(d) Income Received in Advance from Related Party	March 31,2026	March 31,2025
Augmentors Healthcare Limited	-	17.93
	-	-
Total	**-**	**17.93**

(e) Capital Expenditure	March 31,2026	March 31,2025
Augmentors Healthcare Limited	-	143.06
Aumen Healthcare Pvt Ltd	-	214.08
Total	**-**	**357.14**

Note 36 - Leases

Particulars	March 31,2026	March 31,2025
Operating Lease		
Lease rentals charged to revenue for lease agreements for the right to use the following		
Office Equipments	15.19	20.37
Office Premises	19.57	21.25
Total	**34.76**	**41.61**

The Lease agreements are executed for a reasonable period with a renewal clause and also provide for termination at will by either party by giving prior notice.

Note 37 - Disclosure pursuant to Accounting Standard 15 (Employee benefits)

a)Defined Contribution Plans to Provident fund (defined contribution)

The Company makes contributions to Provident Fund which is defined contribution plans for qualifying employees. Under the scheme, the Company is required to contribute a specified percentage of the payroll cost to fund the benefits. The Company recognized Rs. 10.94 Lacs (March,2025: 13.18 Lacs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to the plan by the Company are at the rates specified in the rules of the scheme.

a) Gratuity (defined benefit)

Every employee is entitled to the benefit equivalent to 15 days of total gross salary last drawn for each completed year of service. Gratuity is payable to all eligible employees of the Company on retirement or separation or death or permanent disablement in terms of the provisions of the Payment of Gratuity Act. The Company recognized Rs.-7.52 Lacs (March, 2025: Rs.5.61 Lacs) in the Statement of Profit and Loss.

	March 31,2026	March 31,2025
Method	Projected Unit Credit Method	Projected Unit Credit Method
Assumptions		
Discount Rate	7.40%	6.83%
Expected Return on Plan Assets	NA	NA
Funding Status	Unfunded	Unfunded
Mortality Table	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban
Future Salary increases	10%	10%
Disability	Nil	Nil
Attrition	5%	5%
Retirement	60 years	60,65 & 70 years

Note 38 - Funding Arrangement

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”) with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Note 39 - Segment Information

The Company is engaged in the business of providing vocational training. DocMode is a platform that provides authoritative, comprehensive and interactive learning programs for Health Professionals - Doctors, Nurses, Allied and Medical Students - across the world. The company is comeup with new segments during the year namely publishing of Medical books, trading of medical books and journals, conducting customised and inhouse events. The company operates in 13 geographical segments within India namely Maharashtra, Karnataka, Himachal Pradesh, Uttarakhand, West Bengal, Kerala, Tamilnadu, Telangana, Andhra Pradesh, Uttar Pradesh, Goa, Delhi, Haryana.

Note 40 - Other Additional Information

Information with regard to the other additional information and other disclosures to be disclosed by way of notes to statement of profit and loss as specified in the Schedule III of the Companies Act, 2013 is either ‘nil’ or ‘not applicable’ to the Company for the year.

Note 41 - Others

Previous year figures have been regrouped / reclassified wherever necessary to correspond with the current year classification / disclosure.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

for Doctrack Solutions Limited

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946MYSNBA3337

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN : BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413

Notes To The Financial Statements
(Currency: Indian rupee in Lacs)
Additional Regulatory Information

I) Title deeds of Immovable Property not held in name of the Company

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company**
PPE	There is no immovable property whose title deeds are not held in the name of the company therefore not applicable.				-
Investment property					-
Non-current asset held for sale					-
Others					-

II) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year

III) No Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties either severally or jointly with

IV) Intangible Assets under Development
CWIP aging schedule

Intangible Assets under development ageing schedule
a) For Intangible Assets under development

Intangible assets under development	Amount in CWIP for a period of				Rupees in Lacs
	Less than 1 Year	**1-2 Years**	**2-3 Years**	**More than 3 Years**	**Total**
Projects in progress	**188.18**	**309.84**	**647.12**	**202.80**	**1,347.94**
Projects temporarily suspended					

V) Details of Benami property:
No proceedings have been initiated or are pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.

VI) Wilful Defaulter
The Company has not been declared as a wilful defaulter by any bank or financial institution or government or any government authority

VII) The company has no borrowings from banks or financial institutions on the basis of security of current assets.

VIII) Relationship with Struck off Companies
Details of relationship with Companies struck off under Section 248 of Companies Act, 2013 or Section 560 of the Companies Act, 1956

Name of struck off Company	Nature of transactions with struck-off Company	Balance outstanding	Relationship with the Struck off company, if any, to be disclosed
There is no transaction with struck off company.			

IX) Compliance with number of layers of companies
The Company has complied with the number of layers prescribed under the Companies Act, 2013.

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413

Notes To The Financial Statements
Additional Regulatory Information (Continued)

X) RATIO ANALYSIS

Sr.No	Ratios	Numerator	Denominator	March 31,2026	March 31,2025
Liquidity Ratio					
1	Current Ratio (times)	Current Assets	Current Liabilities	0.73	1.30
Solvency Ratio					
2	Debt Equity Ratio (times)	Total Debt	Shareholder's Equity (Total Equity)	0.45	0.82
3	Debt Service coverage ratio (times)	Earnings Available for Debt Service	Debt Service (Interest + Principal)	0.22	(0.02)
Profitability Ratio					
4	Net profit ratio (%)	Profit or (Loss) For the Year	Revenue From Operations	(0.52)	(4.86)
5	Return on Equity Ratio (%)	Net Profit After Tax	Average Shareholder's Equity	(1.61)	(21.68)
6	Return on Capital employed (%)	Earnings Before Interest & Tax	Capital Employed (Average Total Equity + Long Term Debt)	7.20	(3.42)
7	Return on Investment (%)	Earnings Before Interest and Tax	Average Total Assets	1.75	(1.14)
Utilisation Ratio					
8	Inventory Turnover Ratio (times)	Cost of Goods Sold	Average Inventory	2.10	5.28
9	Trade Receivables turnover ratio (times)	Revenue From Operations	Average Trade Receivables	3.06	4.03
10	Trade payables turnover ratio (times)	Cost of Goods Sold	Average Trade Payables	4.50	8.93
11	Net capital turnover ratio (times)	Revenue From Operations	Working Capital	(3.99)	9.35

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

Doctrack Solutions Limited

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946MYSNBA3337

Paulson Paul Thazhathedath
Wholetime Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN : BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Independent Auditor's Report

To the Members of
Doctrack Solutions Limited
(**Formerly known as DocMode Health Technologies Limited**)

Report on the Audit of the Consolidated Financial Statements

Qualified Opinion

We have audited the consolidated financial statements of **Doctrack Solutions Limited** (Formerly known as **DocMode Health Technologies Limited** (**"the Parent Company"**) and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), which comprise the Consolidated Balance Sheet as at 31st March 2026, and Consolidated Statement of Profit and Loss and Consolidated Statement of Cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as the "consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, **except for the effects of the matter described in the Basis for Qualified Opinion section of our report,** the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March, 2026, its consolidated Loss and its consolidated Cash Flows for the year ended on that date.

Basis for Qualified Opinion

We draw attention to Note 10 to the financial statements regarding Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures ("NCDs") aggregating to Rs.2,25,00,000/- issued by the Company in two tranches.

The NCDs aggregating to Rs.1,00,00,000/- issued under Tranche I carry coupon interest at 18.00% per annum and the NCDs aggregating to Rs.1,25,00,000/- issued under Tranche II carry coupon interest at 18.50% per annum. The NCDs also carry additional default interest at 2.00% per annum over and above the applicable coupon rate upon occurrence of default, subject to the terms of the NCD documents.

The Parent defaulted in repayment of the principal amounts and payment of interest in accordance with the terms of the NCDs. The entire principal amount of Rs.2,25,00,000/- had become contractually due for repayment by November 24, 2025 and remains recognized as outstanding by the Company as at 31 March 2026.

Consequent upon the defaults, out of 9,11,934 equity shares pledged by the promoters as security for the NCDs, the pledgees invoked 3,34,558 shares on August 22, 2025, 1,86,505 shares on August 25, 2025 and 44,403 shares on November 24, 2025, aggregating to 5,65,466 shares.

Management has represented that the aggregate quoted market value of the shares on the respective dates of invocation exceeded the outstanding dues towards principal, coupon interest and additional default interest and, on this basis, the Company has not recognized coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/-, aggregating to Rs.29,83,744/- for the year ended March 31, 2026.

However, neither the Company nor we have received any confirmation or statement of appropriation/realization from the Debenture Trustee/debenture holders confirming that the invoked shares have been appropriated towards discharge of the NCD obligations or confirming cessation of the Company's contractual obligation to pay interest.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the Beneficial Position (BENPOS) statement issued by the Registrar and Transfer Agent as at March 31, 2026.

Based on the terms of the NCD documents and in the absence of evidence establishing discharge of the Company's contractual obligations, in our opinion, the Company ought to have recognized coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/-, aggregating to Rs.29,83,744/- for the year ended March 31, 2026.

Consequently, finance costs and loss before tax for the year ended March 31, 2026 are understated by Rs.29,83,744/- and financial liabilities as at March 31,2026 are understated by Rs.29,83,744/-, with consequential impact, if any, on taxation and other related balances.
Our opinion is qualified in respect of the above matter.

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion on consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Except for the matters described in the Basis for Qualified Opinion section of our report, we have determined that there are no other key audit matters to communicate in our report.

Information other than the consolidated financial statements and auditors' report thereon

The Parent Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the consolidated financial statements and our auditor's report thereon. The company's annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Parent Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the respective Board of Directors of the Companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Parent Company and its subsidiary company have adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.

• Conclude on the appropriateness of management and Board of Directors use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Gropu's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Gropu to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements.

We communicate with those charged with governance of the Parent Company and such other entities included in the consolidated financial statements of which we are the independent auditors, where applicable, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

<u>Report on Other Legal and Regulatory Requirements</u>

1. As required by Section 143 (3) of the Act, we report that:

   a) We have sought and except for the matters described in the Basis for Qualified Opinion section above obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

   b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept by the Company so far as it appears from our examination of those books except for the matters described in the Basis for Qualified Opinion paragraph.

   c) The consolidated Balance Sheet, the consolidated Statement of Profit and Loss and the consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

   d) Except for the effects of the matter described in Basis for Qualified Opinion section above, in our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

   e) On the basis of the written representations received from the Directors of the Parent Company as on 31st March, 2026 and taken on record by the Board of Directors and the report of statutory auditor of its subsidiary company, none of the Directors of the Group companies, is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Parent Company and its subsidiary company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure A'. Our report express an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to the financial statements.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Parent Company and the its Subsidiary Company to its directors during the year is in accordance with the provisions of section 197 read with Schedule V to the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Group does not have any pending litigations which would impact its financial position.

ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Group.

iv. (a) The Board of Directors of the Parent Company and the Subsidiary Company have represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share Premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:

- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or
- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Board of Directors of the Parent Company and the Subsidiary Company, have represented, that, to the best of its knowledge and belief, no funds have been received by the Group from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Group shall:

- directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or

- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. The Group has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

vi. Based on our examination which included test checks the Parent Company and its Subsidiary have used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except that audit trail was not enabled at the database level to log any direct changes for the accounting software used for maintaining the books of account. For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit.

2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, based on the CARO reports issued by us to the Parent Company and the Subsidiary Company, we give in the 'Annexure B', a statement on on the qualifications and/or adverse remarks, if any, contained in such CARO reports.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946KCWJVG4004

Doctrack Solutions Limited (Formerly known as **DocMode Health Technologies Limited**

Annexure A to the Independent Auditor's Report of Consolidated Financial Statements for the year ended March 31, 2026

Report on the Internal Financial Controls over financial reporting with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in Paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements section of our report of even date)

Opinion

We have audited the internal financial controls with reference to the consolidated financial statements of **Doctrack Solutions Limited** (Formerly known as **DocMode Health Technologies Limited** ("the Parent Company") and its subsidiaries (the Parent Company and its subsidiaries together referred to as "the Group") as of March 31, 2026, in conjunction with our audit of the consolidated financial statements of the Parent Company as at and for the year ended on that date.

In our opinion, the Parent Company and its subsidiary have, in all material respects, an adequate internal financial controls system over financial reporting with reference to consolidated financial statements, and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting with reference to consolidated financial statements criteria established by the Parent Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

Management's Responsibility for Internal Financial Controls

The respective Company's Management and Board of Directors of the Parent Company and its subsidiaries, which are companies incorporated in India are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to consolidated financial statements criteria established by the respective company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and Completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Parent Company and its subsidiaries, which are companies incorporated in India, internal financial controls over financial reporting with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting with reference to the consolidated financial statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to the consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on internal financial controls over financial reporting with reference to consolidated financial statements.

Meaning of Internal Financial Controls Over Financial Reporting with reference to the consolidated financial statements

A Parent company's internal financial control over financial reporting with reference to the consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Parent company's internal financial control over financial reporting with reference to the consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Parent company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Parent company are being made only in accordance with authorisations of management and directors of the Parent company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Parent company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting with reference to the consolidated financial statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to the consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these consolidated financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

for **R. Sundaresan Aiyar & Co**
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946KCWJVG4004

Doctrack Solutions Limited (Formerly known as **DocMode Health Technologies Limited**

Annexure- B to Independent Auditors' Report on the Consolidated Financial Statements for the year ended March 31, 2026

(Referred to in paragraph 1 under "Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the management and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, and based on the consideration of the CARO reports issued by us and/or the respective auditors of the companies included in the consolidated financial statements to which reporting under the Companies (Auditor's Report) Order, 2020 ("CARO") is applicable, we report that the following qualification/adverse remark has been reported in the CARO report of the Parent Company:

Sr. No.	Name of the Company	CIN	Holding Company / Subsidiary	Clause number of CARO report containing qualification/adverse remark
1.	**Doctrack Solutions Limited** (Formerly known as **DocMode Health Technologies Limited**	L74999MH2017PLC297413	Parent Company	Clause 3(ix)(a)

The Parent Company had issued 225 Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures ("NCDs") of face value Rs.1,00,000/- each aggregating to Rs.2,25,00,000/- in two tranches during May 2024.

The Parent Company defaulted in repayment of the principal amounts and payment of interest in accordance with the terms of the NCDs. The entire principal amount of Rs.2,25,00,000 had become contractually due for repayment by November 24, 2025 and remained unpaid/unredeemed as at March 31, 2026.

The Parent Company has also not paid/provided coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/- aggregating to Rs.29,83,744/- pertaining to the financial year ended March 31, 2026.

As more fully explained in Note 9 to the consolidated financial statements, the NCDs were secured, inter alia, by pledge of 9,11,934 equity shares held by the promoters of the Parent Company.

Consequent upon the defaults, the pledgees invoked 3,34,558 shares on August 22, 2025, 1,86,505 shares on August 25, 2025 and 44,403 shares on November 24, 2025, aggregating to 5,65,466 shares. The balance 3,46,468 pledged shares could not be invoked on account of applicable lock-in restrictions.

Management has represented that the aggregate quoted market value of the shares on the respective dates of invocation exceeded the outstanding dues towards principal, coupon interest and additional default interest under the NCDs.

However, neither the Parent Company nor its Statutory Auditors have received any confirmation or statement of appropriation/realisation from the Debenture Trustee/debenture holders confirming adjustment of the invoked shares against the outstanding NCD dues or discharge, either wholly or partly, of the Parent Company's obligations.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the Beneficial Position (“BENPOS”) statement issued by the Registrar and Transfer Agent as at March 31, 2026.

Accordingly, the Parent Company's standalone auditor's report under clause 3(ix)(a) of CARO 2020 reports the aforesaid defaults in repayment of NCD principal and payment of interest thereon.

Except for the matter stated above, there are no qualifications or adverse remarks in the CARO reports of the companies included in the consolidated financial statements to which CARO 2020 is applicable.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: September 04, 2026
UDIN: 26043946KCWJVG4004

<u>Statement on Impact of Audit Qualification (For Audit Report with Modified Opinion) submitted along with Annual Standalone & Consolidated Audited Financial results.</u>

Statement on Impact of Audit Qualification for the financial year ended 31st March, 2026 (Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

A. Details of Audit Qualification:

Following are the qualifications given by the Auditors in Audit Report on Standalone & Consolidated Financials Statement of Company.

The Company has defaulted in repayment of NCDs aggregating to Rs. 2.25 crore, and the pledged shares of the promoters were partly invoked towards the default. However, as at 31 March 2026, the NCDs continued to appear as outstanding in the BENPOS, and no confirmation of redemption/appropriation or discharge of the NCD obligations was made available by the Debenture Trustee/debenture holders. Consequently, interest and default interest aggregating to Rs.29.84 lakh were not recognized by the Company, resulting in understatement of finance costs and financial liabilities. For detailed comment refer page number 1 of Auditors Report and Annexure B of auditors report (Standalone & Consolidated)

B. Type of Audit Qualification: Qualified Opinion

C. Frequency of Qualification: First Time

D. For Audit Qualification(s) where the impact is quantified by the Auditor:

i. Management's Views:

The Company has noted the observation of the Statutory Auditors regarding the accounting of coupon interest and additional default interest on the NCDs. Pursuant to the default, certain pledged shares of the promoters were invoked by the pledgees and the management had considered the value of such shares against the outstanding NCD obligations.

However, in the absence of formal confirmation from the Debenture Trustee/debenture holders regarding appropriation of the invoked shares and discharge of the NCD obligations, the Statutory Auditors have considered the aforesaid interest as payable.

The Company is in the process of obtaining the requisite confirmation and supporting documents from the Debenture Trustee/debenture holders and shall take appropriate accounting and consequential regulatory actions based on the final confirmation and reconciliation of the NCD obligations.

E. For Audit Qualification(s) where the impact is not quantified by the Auditor:

i. Management's estimation on the impact of audit qualification: NA

ii. If management is unable to estimate the impact, reasons for the same: NA

F: Signatories Details:

PARESH JAYSIH SAMPAT
MANAGING DIRECTOR
DIN: 00410185

CA R SUNDARESAN AIYAR
STATUTORY AUDITOR
MEMBERSHIP NO: 043946

HANS ALBERT LEWIS
CFO
PAN: ACOPL6883G

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Consolidated Balance Sheet As At March 31,2026

Indian Rupee In Lacs

	Particulars		Note	March 31,2026	March 31,2025
I.	**EQUITY AND LIABILITIES**				
1	**Shareholder's funds**				
	(a)	Share capital	3	314.28	314.28
	(b)	Reserves and surplus	4	507.15	520.64
	(c)	Money received against share warrants		-	-
	Minority Interest		5	(0.08)	(0.07)
2	**Share application money pending allotment**			-	-
3	**Non-current liabilities**				
	(a)	Long Term Borrowings	6	108.92	112.45
	(b)	Deferred Tax Liabilities (Net)		-	-
	(c)	Other Long Term Liabilities		-	-
	(d)	Long Term Provisions	7	61.13	69.71
4	**Current liabilities**				
	(a)	Short Term Borrowings	8	263.68	569.91
	(b)	Trade Payables	9	351.69	534.06
	(c)	Other Current Liabilities	10	1,531.55	1,451.63
	(d)	Short Term Provisions	11	211.38	358.55
		TOTAL		**3,349.70**	**3,931.14**
II.	**ASSETS**				
1	**Non-current assets**				
	(a)	Property, Plant and Equipment and Intangible Assets	12		
		(i) Property, Plant and Equipment		97.68	120.74
		(ii) Intangible Assets		0.44	0.84
		(iii) Capital Work-In-Progress		-	-
		(iv) Intangible Assets under Development		1,347.94	1,159.76
	(b)	Non Current Investments	13	121.22	120.52
	(c)	Deferred Tax Assets (net)	14	26.23	25.51
	(d)	Long-term Loans and Advances	15	27.80	2.78
	(e)	Other Non Current Assets	16	10.71	12.91
2	**Current assets**				
	(a)	Current Investments	17	9.25	8.69
	(b)	Inventories	18	774.59	1,116.93
	(c)	Trade Receivables	19	743.60	923.94
	(d)	Cash and Cash Equivalents	20	17.77	183.50
	(e)	Short Term Loans and Advances	21	150.23	230.10
	(f)	Other Current Assets	22	22.21	24.91
		TOTAL		**3,349.70**	**3,931.14**
	Significant Accounting Policies		2		
	The notes are integral parts of the financial statements				

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946KCWJVG4004

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN: BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited

(Formerly known as DocMode Health Technologies Limited)

CIN : L74999MH2017PLC297413

Consolidated Statement of Profit & Loss for the year ended March 31, 2026

Indian Rupee In Lacs

	Particulars	**Note No**	**March 31,2026**	**March 31,2025**
I.	Revenue from Operations	23	2,551.59	4,177.29
II.	Other Income	24	139.54	92.98
III.	**Total Income (I + II)**		2,691.13	4,270.28
IV.	**Expenses:**			
	Cost of Materials Consumed		-	-
	Purchases / Consumption of Goods & Services	25	1,648.03	4,476.94
	Changes in inventories	26	342.34	(865.55)
	Employee benefits Expense	27	272.04	376.30
	Finance Costs	28	96.50	191.89
	Depreciation and Amortization Expense	29	23.46	29.92
	Other Expenses	30	322.97	257.29
	Total expenses		2,705.34	4,466.79
V	**Profit before exceptional and extraordinary items and tax (III- IV)**		(14.21)	(196.52)
VI	Exceptional Items		-	-
VII	**Profit before extraordinary items and tax (V - VI)**		(14.21)	(196.52)
VIII	Extraordinary items		-	-
IX	**Profit before tax (VII- VIII)**		(14.21)	(196.52)
X	**Tax expense:**			
	(1) Current tax		-	0.08
	Less : MAT Credit Entitlement		-	0.08
			-	-
	(2) Deferred tax Liability/(Asset)		(0.72)	(6.80)
	(3) Tax in respect of earlier years		-	12.92
	(4) Profit / (Loss) of Prior Period Depreciation		-	-
			(0.72)	6.12
XI	**Profit (Loss) for the period from continuing operations (IX-X)**		(13.49)	(202.64)
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	**Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)**		-	-
XV	**Profit (Loss) for the period (XI + XIV)**		**(13.49)**	**(202.64)**
XVI	**Earnings per equity share of Rs. 10 each**			
	Basic		(0.43)	(6.45)
	Diluted		(0.43)	(6.45)
	Significant Accounting Policies			
	The notes are integral parts of the financial statements			

As per our report of even date

for R Sundaresan Aiyar & Co

Chartered Accountants

Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946KCWJVG4004

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN: BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Consolidated Statement of Cash Flows for the year ended March 31, 2026

Indian Rupee In Lacs

		March 31,2026	March 31,2025
(A)	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit before Tax and Extraordinary Items	(14.21)	(196.52)
	Adjusted for		
	Depreciation	23.46	29.92
	Profit on Sale of Fixed Assets	-	-
	Provision for Gratuity	(8.58)	3.43
	Interest Expenses	96.50	191.89
	Operating Profit before Working Capital changes	97.17	28.72
	Adjutments for changes in working capital		
	(Increase)/Decrease in Inventories	342.34	(865.55)
	(Increase)/Decrease in Trade and Other Receivables	180.34	222.95
	(Increase)/Decrease in Short Loans & Advances	79.87	(29.17)
	(Increase)/Decrease in Long term Loans & Advances	(25.03)	(2.75)
	(Increase)/Decrease in Other Current Assets	2.69	(24.91)
	(Increase)/Decrease in Other Non Current Assets	2.20	-
	Increase/(Decrease) in Trade Payables	(182.36)	260.75
	Increase/(Decrease) in Other Non Current liabilities	-	-
	Increase/(Decrease) in Current liabilities	79.92	1,095.64
	Increase/(Decrease) in Short Term Provisions	(147.17)	(4.81)
	Cash generated from operations	429.97	680.89
	Direct Taxes Paid	-	(12.84)
	NET CASH FLOW FROM OPERATING ACTIVITIES	429.97	668.05
(B)	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Sale/ (Purchase) of Fixed Assets	(188.18)	(364.53)
	Sale/ (Purchase) of Investments	(1.27)	(2.96)
	Rent Deposit paid to landlord for office premises	-	0.22
	NET CASH USED IN INVESING ACTIVITIES	(189.45)	(367.27)
(C)	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Proceeds/(Repayment) from long term borrowings	(3.53)	(325.75)
	Proceeds from Short Term Borrowings	(306.22)	90.08
	Proceeds from issue of Shares	-	-
	Interest paid	(96.50)	(191.89)
	NET CASH FROM FINANCING ACTIVITIES	(406.26)	(427.56)
	NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(165.73)	(126.78)
	OPENING BALANCE OF CASH AND CASH EQUIVALANTS	183.50	310.28
	CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	17.77	183.50

for Doctrack Solutions Limited

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881

Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN: BAHPT5930L
Place : Mumbai
Date : September 04, 2026

AUDITORS' REPORT ON CASH FLOW STATEMENT

We have examined the above Cash Flow Statement of Doctrack solutions Ltd. derived from audited financial statements and the books and records maintained by the company for the period ended March 31, 2026 and found the same in agreement therewith.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sunderesan Aiyar
Partner
M. No.:043946

Place : Mumbai
Date : September 04, 2026
UDIN : 26043946KCWJVG4004

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes to the financial statements
for the year ended March 31, 2026
(Currency: Indian Rupee In Lacs)

1.Background of the Company

Docmode Health Technologies Limited ("the Company")was incorporated on July 17,2017. The registered office of the Company is located at 201, Kalpataru Plaza, Rambaug, Off. Chincholi Bunder Road, Malad (West), Mumbai 400064. The Company is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry for the healthcare stakeholders. The Company also conducts offline/ online events/ sessions/ seminars for knowledge enhancement and sharing for the healthcare stakeholders.

Subsequent to the financial year ended 31 March 2026, the name of the Company was changed from Docmode Health Technologies Limited to Doctrack Solutions Limited pursuant to the approval of the members and the approval of the Registrar of Companies / Central Government, as applicable.
The Registrar of Companies issued a fresh Certificate of Incorporation consequent upon change of name dated 28th July,2026 and accordingly the change of name became effective from July 28,2026.

The change in name does not result in any change in the legal status, constitution, rights or obligations of the Company and does not have any financial impact on the financial statements for the year ended 31 March 2026.

Accordingly, these financial statements, which relate to the financial year ended 31 March 2026, have been issued in the name of Doctrack Solutions Limited (formerly known as Docmode Health Technologies Limited).

2. Significant accounting policies

2.1 Basis of preparation & presentation

The financial statements have been prepared to comply in all material respects with the Accounting Standards issued as per the provisions of Section 133 of the Companies Act, 2013 read with rule 7 of Companies (Accounts) Rules 2014.The financial statements are prepared on going concern basis under the historical cost convention on the accrual basis except in case of assets for which provision for impairment is made and revaluation is carried out. The accounting policies have been consistently applied by the Company .

2.2 Functional and Presentation Currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are mentioned in lakhs and rounded off to 2 decimals unless, otherwise stated.

2.3 Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires judgements, estimates and assumptions to be made that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognized in the year in which the results are known / materialized.

2.4 Property, Plant & Equipment

Tangible assets

Tangible assets are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to assets.

Subsequent expenditures related to an item of Tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Projects under which assets are not ready for its intended use are disclosed under capital work in progress.

Intangible assets

Intangible assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization / depletion and impairment loss, if any. The cost comprises purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to intangible assets.

2.5 Leases

Leases of assets, where the company assumes substantially all the risk and benefits of ownership are classified as finance leases. Finance leases are capitalized at the lower of fair value of the leased assets at inception and the present value of minimum lease payments. Lease payments are apportioned between the finance charge and the outstanding liability. The finance charge is allocated periods during the lease term at a constant periodic rate of interest on the remaining balance of the liability.

Leases where the lessor effectively retains substantially all the risk and benefits of ownershipare classified, as operating leases. Lease rentals in respect of assets taken under operating leases are charged to statement of profit & loss on a straight line basis over the lease term.

2.6 Depreciation

Depreciation is provided on a pro-rata basis under the Written Down Value method over the useful life of the assets as prescribed under part C of Schedule II of the Companies Act,2013.

Fixed assets individually costing Rupees Five Thousand or less are depreciated at 100% over a period of one year.

Assets under finance lease are amortized over their estimated useful life or the lease term whichever is lower.

2.7 Impairment

As asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit & Loss Statement in the year in which as asset is treated as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

2.8 Foreign Currency Transactions

i. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction or that approximates the actual rate at the date of transaction.

ii. Monetary items denominated in foreign currencies at the year- end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year- end rate and the rate on the date of contract is recognized as exchange difference and the premium paid on forward contracts is recognized over the life of contract.

iii. Non-monetary foreign currency assets are carried at cost.

iv. Any income or expense on account of exchange differences either on settlement or on translation is recognized in the Profit & Loss Statement, except in the case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

2.9 Investments

Current investments are carried at lower of cost and quoted / fair value, computed category-wise. Non- current investments are stated at cost. Provision for diminution in the value of Non-Current Investments is made only if such a decline is other than temporary.

2.10 Cash and Cash equivalents

Cash and cash equivalents comprise cash and cash on deposit with banks. The company considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalents.

2.11 Revenue recognition

i. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

ii.Revenue from sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer. Revenue from sale of goods is net of sales tax, trade discounts, rebates etc.

iii. Revenue from services is recognized as and when the services are rendered in accordance with the terms of the specific contracts, net of all contractual deductions. Revenue from Services is recognized net of all taxes and levies..

iv. Income from interest on deposits is recognized on a time proportion basis.

v. Dividend income is recognized when the right to receive payment is established.

2.12 Employee benefits

(i) Short term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by the employees are recognized as expense during the period when the employee render the services. These benefits include performance incentive and compensated absences.

(ii) Post-employment benefits

a) Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Company pays specified contributions to a separate entity. The Company makes specified monthly contribution towards Provident Fund and pension scheme. The Company's contribution is recognized as an expense in the Profit and Loss Statement during the period in which the employee renders the related service.

b) Defined benefit plans

Gratuity

Benefits payable to eligible employees of the Company with respect to gratuity, a defined benefit plan is accounted for on the basis of an actuarial valuation as at the balance sheet date. In accordance with the Payment of Gratuity Act, 1972, the plan provides for lump sum payments to vested employees upon retirement, death while in service or upon termination of employment in an amount equivalent to 15 days salary for each completed year of service. Vesting occurs upon completion of five years of service. The company contributes premium towards gratuity liability arrived by actuarial valuation performed by an independent actuary.

Acturial Valuation

The actuarial valuation method used for measuring the liability either Gratuity or Compensated absence is the Projected Unit Credit method. The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. The expected rate of return on plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Actuarial gain/losses are recognized in the Statement of Profit and Loss in the year they are determined.

2.13 Borrowing costs

Borrowing costs include exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are attributable to the acquisition or construction of a qualifying asset are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred. Capitalisation of borrowing costs is suspended during the extended period in which active development is interrupted. Capitalisation of borrowing costs is ceased when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Other borrowing costs are charged to statement of profit and loss as and when incurred.

2.14 Provisions, contingent liabilities and contingent assets

Provision is recognized in the accounts when there is present obligation as a result of a past event(s) and it is probable that an outflow of resources will be required and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date.

Contingent liabilities are disclosed unless the possibility of outflow of resources is remote.

Contingent assets are neither recognized nor disclosed in the financial statements.

2.15 Income Taxes

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates.

Deferred income tax reflect the current period timing difference between taxable income and accounting income for the year and reversal of timing difference of earlier years/period. Deferred tax assets are recognized only to the extent there is reasonable certainty that the sufficient future income will be available except that deferred tax assets, in case there are unabsorbed depreciation or losses, are recognized only if there is virtual certainty that sufficient future taxable income will be available to realize the same.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date.

2.16 Earnings per share

Basic earnings per share are computed by dividing the net profit for the year attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity and dilutive equity equivalent shares outstanding during the year, except where the results would be anti-dilutive.

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Note 3
Share Capital

Particulars	March 31,2026	March 31,2025
Authorised Share Capital		
40,00,000 (P.Y 40,00,000) Equity Shares of Rs. 10/- each	400.00	400.00
50,000(P.Y 50,000) Preference Shares of Rs 10 each	5.00	5.00
Total	**405.00**	**405.00**
Issued, Subscribed & Paid up		
31,42,800 (P.Y 31,42,800) Equity Shares of Rs. 10 each fully paid	314.28	314.28
Total	**314.28**	**314.28**

The Company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. In the event of liquidation, the equity shareholders are eligilble to receive the remaining assets of the Company, after distribution of all preferential amounts, In proportion of their shareholding.

Reconciliation of no. of shares outstanding at the beginning and at the end of the year

Particulars	March 31,2026 Equity Shares		March 31,2025 Equity Shares	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,142,800	31,428,000	2,293,200	22,932,000
Shares Issued during the year	-	-	849,600	8,496,000
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	3,142,800	31,428,000	3,142,800	31,428,000

Details of Shares held by shareholders holding more than 5% in the Company:

Name of Shareholder	March 31,2026		March 31,2025	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Paulson Paul Thazhathedath	514,382	16.37%	745,290	23.71%
Hans Albert Lewis	410,732	13.07%	745,290	23.71%
Anil Khanna	401,310	12.77%	401,310	12.77%
Aalok Pathak	400,164	12.73%	400,164	12.73%
Bindi Mehta	521,063	16.58%	-	0.00%
Ramesh Kumar Jain	160,000	5.09%	92,800	2.95%
	2,407,651	76.61%	2,384,854	75.88%

Details of Shares held by Promoters at the end of the year

Name of Promoter	March 31,2026		March 31,2025		% Change During the year
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	
Paulson Paul Thazhathedath	514,382	16.37%	745,290	23.71%	-7.35%
Kenneth Paul Lewis	1,982	0.06%	382	0.01%	0.05%
Hans Albert Lewis	410,732	13.07%	745,290	23.71%	-10.65%
	927,096	29.50%	1,490,962	47.44%	-17.94%

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

Note :

Pledge of Promoters' Shares

Promotors shares pledged to secure Non Convertible Debentures of the company.

Consolidated Reconciliation

Particulars	No of Shares held by		Total no. of Shares
	Paulson Paul Thazhathedath	Hans Albert Lewis	
Opening Shares as on 01.04.2025	745,290.00	745,290.00	1,490,580.00
Less : Shares Invoked	(230,908.00)	(334,558.00)	(565,466.00)
Closing Shares as on 31.03.2026	514,382.00	410,732.00	925,114.00

Out of closing shares:

Shares pledged but not invoked	225,059.00	121,409.00	346,468.00
Free / unpledged shares	119,976.00	84,838.00	204,814.00
Lock-in shares	169,347.00	204,485.00	373,832.00
Total Closing Shares	514,382.00	410,732.00	925,114.00

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

Note 4
Reserves and Surplus

Particulars	March 31,2026	March 31,2025
Surplus/Deficit in the Statement of Profit and Loss	-	-
Opening Balance	520.64	723.25
(-) Capitalisation of reserves	-	-
(+) Securities Premium	-	-
(+) Net Profit/(Net Loss) For the current year	(13.49)	(202.61)
Total	**507.15**	**520.64**

Note 5
Minority Interest

Particulars	March 31,2026	March 31,2025
Minority Share Capital	0.01	0.01
Minority Reserves	(0.08)	(0.07)
	(0.08)	**(0.07)**

Note 6
Long Term Borrowings

Particulars	March 31,2026	March 31,2025
Unsecured Loans		
a) Bonds / Debentures	-	-
b) Term Loans	-	-
A) From Banks	21.13	3.49
B) From Other Parties	87.79	108.96
Total	**108.92**	**112.45**

Note 7
Long Term Provisions

Particulars	March 31,2026	March 31,2025
a) Provision for Employee Benefits	61.13	69.71
Total	**61.13**	**69.71**

Note 8
Short Term Borrowings

Particulars	March 31,2026	March 31,2025
Secured Loans		
a) Bonds / Debentures	-	175.00
b) Bank Overdraft Account	109.93	111.12
Unsecured Loans		
Current Maturities of Long Term Borrowings	153.75	283.78
Total	**263.68**	**569.91**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

Note 9
Trade Payables

Particulars	March 31,2026	March 31,2025
Total outstanding dues of Creditors of Micro & Small Enterprises	71.59	184.02
Total outstanding dues of Creditors other than Micro & Small Enterprises	280.10	350.04
Total	**351.69**	**534.06**

Trade Payables Ageing Schedule as at March 31,2026

	Particulars	Outstanding for following periods from due date of payment				Total
		Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
	MSME	68.35	3.24	-	-	71.59
	Dispute dues-MSME	-	-	-	-	-
	Dispute dues	-	-	-	-	-
	Others	151.78	108.99	18.15	1.18	280.10
	Total	**220.14**	**112.23**	**18.15**	**1.18**	**351.69**

Trade Payables Ageing Schedule as at March 31,2025

	Particulars	Outstanding for following periods from due date of payment				Total
		Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
	MSME	172.68	11.34	-	-	184.02
	Dispute dues-MSME	333.99	11.38	-	4.14	349.52
	Dispute dues	-	-	-	-	-
	Others	-	0.52	-	-	0.52
	Total	**506.67**	**23.24**	**-**	**4.14**	**534.06**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Note 10
Other Current Liabilities

	Particulars	March 31,2026	March 31,2025
	Interest Accrued and due on Debentures	1.03	1.54
	Income Received in Advance	1,303.04	1,381.33
*	Unpaid matured debentures and interest accrued thereon	225.00	55.45
	Other Payables	2.48	13.32
	Total	**1,531.55**	**1,451.63**

*** Secured Redeemable Non-Convertible Debentures, Default, Invocation of Pledged Shares and Non-Provision of Interest**

During May 2024, the Company raised Rs.2,25,00,000/- by issue of 225 Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures ("NCDs") of face value Rs.1,00,000/- each in two tranches, as under:

Particulars	Tranche - I	Tranche - II
Date of issue	08-May-2024	24-May-2024
Number of NCDs	100	125
Face Value per NCD	100,000	100,000
Aggregate principal	Rs. 10000000	Rs. 12500000
Coupon Rate	18% p.a	18.5% p.a
Additional Default Interest	2.00% p.a	2.00% p.a

The NCDs were contractually redeemable as follows:

Particulars	Due Date	Redeemption Amount in Rs.
Tranche - I	30-Nov-2024	2,500,000
	28-Feb-2025	2,500,000
	09-May-2025	5,000,000
Total		**10,000,000**
Tranche - II	30-June-2025	2,083,333
	31-July-2025	2,083,333
	31-Aug-2025	2,083,333
	30-Sept-2025	2,083,333
	31-Oct-2025	2,083,333
	24-Nov-2025	2,083,333
Total		**12,500,000**

The Company defaulted in repayment of the principal amounts and payment of interest in accordance with the terms of the NCDs.

Security and invocation thereof

The NCDs were secured, inter alia, by pledge of 9,11,934 equity shares held by the promoters of the Company.
Consequent upon the defaults, the pledgees invoked the pledged shares as follows:

Date of invocation	Number of shares invoked
22-Aug-25	334,558
25-Aug-25	186,505
24-Nov-25	44,403
Total shares invoked	**565,466**

(Currency: Indian Rupee In Lacs)

The aforesaid shares were debited from the respective demat accounts of the promoters and credited to the demat accounts of the pledgees.
The balance 3,46,468 pledged equity shares could not be invoked on account of applicable lock-in restrictions, which, as represented to the Company, are expected to cease in February 2027

Based on the quoted market prices of the equity shares on the respective dates of invocation, the aggregate market value of the 5,65,466 shares invoked was higher than the outstanding dues towards principal, coupon interest and default interest under the NCDs.

However, up to the date of approval of these financial statements, neither the Company nor its Statutory Auditors have received any confirmation, statement of appropriation/realisation or other communication from the Debenture Trustee/debenture holders confirming:
(a) whether the invoked shares have been sold, realised, appropriated or otherwise adjusted against the outstanding NCD dues;
(b) the value at which such shares have been realised or appropriated, if at all;
(c) the amounts, if any, adjusted against principal, coupon interest, additional default interest and other charges;
(d) whether the obligations of the Company under the NCDs have been discharged, either wholly or partly;
(e) whether the obligation to pay coupon interest and/or additional default interest ceased consequent upon invocation of the pledged shares; and
(f) the balance amount, if any, remaining payable by the Company.

Further, the NCDs have neither been redeemed nor cancelled/extinguished and continue to appear as outstanding in the Beneficial Position (BENPOS) statement issued by the Registrar and Transfer Agent as at March 31, 2026

Accordingly, in the absence of documentary evidence establishing extinguishment of the Company's obligations, the Company has continued to recognise the principal amount of Rs.2,25,00,000/- in respect of the NCDs as outstanding as at March 31, 2026.

Non-provision of coupon and default interest
During the financial year ended March 31, 2026, the Company has not recognised/provided coupon interest aggregating to Rs.27,50,000/- and additional default interest aggregating to Rs.2,33,744/- payable in respect of the aforesaid NCDs in accordance with the applicable terms thereof.
Management considers that, having regard to the invocation of 5,65,466 pledged equity shares during the year and the aggregate quoted market value thereof on the respective dates of invocation being higher than the outstanding dues towards principal, coupon interest and default interest, no further provision towards coupon interest and default interest is required.

However, the aforesaid position of management has not been confirmed by the Debenture Trustee/debenture holders and no statement of appropriation/realisation or confirmation of discharge has been received by the Company.

Accordingly, coupon interest of Rs.27,50,000/- and additional default interest of Rs.2,33,744/- aggregating to Rs.29,83,744/- have not been recognised in these financial statements.

Had the aforesaid coupon interest and additional default interest been recognised, finance costs and loss before tax for the year ended March 31, 2026 would have been higher by Rs.29,83,744/- and financial liabilities as at March 31, 2026 would have been higher by the corresponding amount, with consequential impact, if any, on taxation and other related balances.

The ultimate adjustment of the outstanding NCD principal, coupon interest, additional default interest and other charges, if any, remains subject to confirmation/reconciliation with the Debenture Trustee/debenture holders and determination of the effect of realisation/appropriation of the invoked pledged shares

Note 11
Short Term Provisions

Particulars	March 31,2026	March 31,2025
Provision for Employee Benefits	116.34	139.98
GST Payable	30.15	21.29
TDS Payable	58.89	191.27
Provision for Audit Fees	6.00	6.00
Total	**211.38**	**358.55**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
Note 12 - Property, Plant and Equipment
(Currency: Indian Rupee In Lacs)

Particulars/Assets	Tangible Assets				Intangible			Gross Total
	Computers	Machinery	Office Equipments	Total	Software	Assets Under Development	Total	
Gross Block								
At 1st April 2024	**18.84**	**86.99**	**1.55**	107.38	**5.41**	**849.92**	855.33	962.71
Additions	**0.09**	**54.60**		**54.69**	-	**309.84**	**309.84**	364.53
Deductions/Adjustments	-	-	-	-	-		-	-
At 1st April 2025	18.93	141.59	1.55	162.07	5.41	1,159.76	1,165.17	1,327.24
Additions				-	-	**188.18**	**188.18**	188.18
Deductions/Adjustments	-	-	-	-	-		-	-
At 31st March 2026	**18.93**	**141.59**	**1.55**	**162.07**	**5.41**	**1,347.94**	**1,353.35**	**1,515.42**
Depreciation								
At 1st April 2024	10.73	0.21	1.23	12.17	**3.80**	-	3.80	15.97
Additions	**4.85**	**24.18**	**0.13**	29.16	**0.76**	-	0.76	29.92
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2025	15.57	24.39	1.36	41.32	4.57	-	4.57	45.89
Additions	**1.77**	**21.23**	**0.07**	23.06	**0.40**	-	0.40	23.46
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2026	**17.34**	**45.62**	**1.43**	**64.38**	**4.97**	**-**	**4.97**	**69.35**
Net Block								
At 31st March 2025	**3.36**	**117.19**	**0.19**	**120.74**	**0.84**	**1,159.76**	**1,160.60**	**1,281.35**
At 31st March 2026	**1.59**	**95.97**	**0.13**	**97.68**	**0.44**	**1,347.94**	**1,348.39**	**1,446.07**

If Assets Purchase During the Year the Dep formula = Life used in Purchasing Year x Depreciable Amount over whole Life x Rate of Depreciation
If Opening Assets Depreciation Formula = IF(AND(Remaining Life<1,Remaining Life>0),(Opening WDV-Salvage Value),(Opening WDV*Rate of Depreciation))

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Note 13
Non Current Investments

Particulars	March 31,2026	March 31,2025
Investment in Fixed Deposits	121.22	120.52
Total	**121.22**	**120.52**

NOTE 14
Deferred Tax Assets (Net)

Particulars	March 31,2026	March 31,2025
Deferred Tax Assets	26.23	25.51
Total	**26.23**	**25.51**

Note 15
Long Term Loans and Advances

Particulars	March 31,2026	March 31,2025
a) Capital Advances	-	-
Secured, Considered good	-	-
Unsecured, Considered good	-	-
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
b) Loans and Advances to related Parties		
Secured, Considered good		
Unsecured, Considered good	0.08	0.05
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
c) Other Loans and Advances		
MAT Credit Entitlement	0.08	0.08
Unsecured, Considered good	27.65	2.65
Unsecured, considered doubtful	-	-
Less: Provision for doubtful advances	-	-
Total	**27.80**	**2.78**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

NOTE 16
Other Non Current Assets

Particulars	March 31,2026	March 31,2025
i) Security Deposits		
Central Depository Services	0.10	0.10
Rent Security Deposits	3.90	6.10
National Stock Exchange	6.71	6.71
Total	**10.71**	**12.91**

Note17
Current Investments

Particulars	March 31,2026	March 31,2025
Investment in Fixed Deposit	9.25	8.69
	9.25	**8.69**

Note 18
Inventories

Particulars	March 31,2026	March 31,2025
Inventory of Digital Course Content	-	250.16
Service Work in Progress	772.99	865.07
Inventory of Books	1.60	1.70
	774.59	**1,116.93**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Note 19
Trade Receivables

Particulars	March 31,2026	March 31,2025
Trade Receivable		
Secured, considered good	-	-
Unsecured, considered good	743.60	923.94
Unsecured, considered doubtful	-	-
Less: Provision for doubtful debts	-	-
Total	**743.60**	**923.94**

Trade Receivables Ageing Schedule as at March 31,2026

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables-Considered Good	69.52	0.29	2.11	669.91	1.78	**743.60**
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	**69.52**	**0.29**	**2.11**	**669.91**	**1.78**	**743.60**

Trade Receivables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables-Considered Good	150.05	29.62	77.95	666.32	-	**923.94**
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	150.05	29.62	77.95	666.32	-	923.94

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

Note20
Cash and Cash Equivalents

Particulars	March 31,2026	March 31,2025
Cash & Cash Equivalents		
a) Balance with Bank	15.95	180.82
b) Cheques, Drafts on Hand	-	-
c) Cash on Hand	1.82	2.68
Total	**17.77**	**183.50**

Note 21
Short Term Loans and Advances

Particulars	March 31,2026	March 31,2025
Loans & Advances to related Parties		
Others		
Balances with revenue authorities	3.98	25.37
Advance Tax & TDS (Net of Provision for Tax)	108.94	162.24
Other Loans & Advances	37.32	42.49
Total	**150.23**	**230.10**

NOTE 22
Other Current Assets

Particulars	March 31,2026	March 31,2025
Excess Interest Paid Recoverable	**-**	6.81
TDS Revcoverable from NBFC	**22.21**	18.10
Total	**22.21**	**24.91**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Note 23
Revenue from Operations

Particulars	March 31,2026	March 31,2025
Sale of products		
Sale of Goods	316.79	682.39
Sale of Services		
Sale of Services	2,234.79	3,494.90
Total	**2,551.59**	**4,177.29**

Note 24
Other Income

Particulars	March 31,2026	March 31,2025
Interest Income	15.46	13.02
Miscellaneous Income	0.02	2.27
Discount Received	-	0.04
Sundry Balances written off	124.07	77.64
Total	**139.54**	**92.98**

Note 25
Purchases / Consumption of Goods & Services

Particulars	March 31,2026	March 31,2025
CME Course Content	7.80	22.40
Purchase of Books	1.62	14.83
Purchases	102.17	293.17
Printed Literature	137.82	200.63
Travelling Expenses	152.29	208.31
Event Consumables	360.59	683.34
Professional Fees	811.97	2,620.24
Contractee Fees	21.71	415.74
Webinar Expenses	4.38	0.72
Transcription Charges	1.70	4.93
Service Charges	6.61	2.52
Content Expenses	20.07	10.11
Other Direct Expenses	19.29	-
Total	**1,648.03**	**4,476.94**

Note 26
Changes in inventories

Particulars	March 31,2026	March 31,2025
Opening Stock		
Finished Goods	-	-
Service Work in Progress	866.77	-
CME Course Content	250.16	251.39
Total (A)	**1,116.93**	**251.39**
Closing Stock		
CME Course Content	-	248.46
Service Work in Progress	772.99	866.77
Others	1.60	1.70
Total (B)	**774.59**	**1,116.93**
Total (A-B)	**342.34**	**(865.55)**

(Currency: Indian Rupee In Lacs)

Note 27

Employee Benefits Expenses

Particulars	March 31,2026	March 31,2025
Salaries & Wages	252.81	337.55
Contribution to Providend Fund and Other Fund	22.21	26.74
Contribution to Recognised Gratuity Fund	-7.53	5.61
Staff Welfare	4.55	6.40
Total	**272.04**	**376.30**

Note 28

Finance Costs

Particulars	March 31,2026	March 31,2025
Interest Expenses		
On Borrowings	77.65	157.47
On Deferred/Delayed Payment of Taxes	2.71	29.54
Other Borrowing Cost	9.62	2.00
Applicable net gain/loss on foreign currency transactions and	6.52	2.87
Total	**96.50**	**191.89**

Note 29

Depreciation and Amortization Expense

Particulars	March 31,2026	March 31,2025
Depreciation on Tangible Assets	23.06	29.16
Depreciation on Intangible Assets	0.40	0.76
Total	**23.46**	**29.92**

Note 30

Other Expenses

Particulars	March 31,2026	March 31,2025
Event Expenses	-	0.52
Advertising & Marketing Expenses	10.56	8.27
Cloud Services	56.68	4.16
Service Charges	14.58	11.18
Software Charges	11.09	7.20
Webinar Expenses	0.59	3.72
Electricity Expenses	1.39	1.63
Rent	34.76	41.61
Recruitment Charges	-	3.49
Commission & Brokerage	-	0.56
Telephone Expenses	0.55	0.56
Insurance Charges	2.28	0.64
Repairs & Maintenance	1.18	0.79
Sponsorship Service	12.10	-
Office Expenses	5.83	4.97
Professional Fees	109.43	115.68
IT Consultancy & Support Service	-	1.73
Profession Tax	0.24	0.10
Travelling Expenses	6.89	9.51
GST Expensed out	12.16	5.61
Printing, Postage & Courier	0.55	2.03
Rates & Taxes	-	1.84
ROC Fees	0.06	0.02
Other Expenses	32.15	20.91
Business Promotion	0.14	-
Prior Period Expenses	3.61	4.31
Payment to Auditors	6.15	6.25
Total	**322.97**	**257.29**

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)

Note 31 - Contingent liabilities & Commitments in respect

Particulars	March 31,2026	March 31,2025
A. Contingent Liabilities		
a Claims against the company not acknowledge as debts	Nil	Nil
b. Guarantees	Nil	Nil
c.Other money for which the company is contingently liable.	Nil	Nil
Total	**-**	**-**

B. Commitments

There are no commitments as at 31st March, 2026

Note 32 - Deferred Tax Asset (Liability)

Particulars	March 31,2026	March 31,2025
Permanent Difference		
Items disallowed under Income Tax Act, 1961	-	-
Timing Difference		
Difference in Gratuity Provision	(61.13)	(71.57)
Difference in Fixed Assets	(7.63)	(4.40)
Creditors Disallowance u/s 43B(h)	(32.12)	-
Total	(100.87)	(75.97)
Deferred Tax Asset on Timing Difference	**(26.23)**	**(21.13)**

Note 33 - Auditor's Remuneration

Particulars	March 31,2026	March 31,2025
Statutory Audit Fees	6.00	6.00
Total	**6.00**	**6.00**

Note 34 - Expenditure / Income in foreign currency (on accrual basis):

Particulars	March 31,2026	March 31,2025
Import	30.30	99.66
Export	2.72	6.89
Total	**33.02**	**106.55**

Note 35 - Earning Per Share

Particulars	March 31,2026	March 31,2025
Net Profit after tax	(13.49)	(202.64)
Weighted Average number of equity shares	31,42,800.00	31,42,800.00
EPS (Basic) (Rs.)	(0.00)	(0.00)
EPS (Diluted) (Rs.)	(0.00)	(0.00)
Face Value per equity share (Rs.)	10.00	10.00

Note 36 - Related Party Transactions

(a) Names of Related Parties & Nature of Relationship	
Paulson Paul Thazhathedath	Director
Hans Albert Lewis	Director
Paresh Sampat	Director
Monina Elizabeth Lewis	Director
Docmode Endeavors LLP	Director having substantial Interest
Augmentors Healthcare Limited	Director having substantial Interest
Aumen Healthcare Pvt Ltd	Director having substantial Interest
Kenneth Paul Lewis	Relative of Director
Docmode Endeavors LLP	Director having substantial Interest
CCME World Services Pvt Ltd	Subsidiary Company

(b) Director Remuneration	March 31,2026	March 31,2025
Paulson Paul Thazhathedath	12.00	39.00
Hans Albert Lewis	12.00	39.00
Total	**24.00**	**78.00**

(c) Loan given to Related Party	March 31,2026	March 31,2025
CCME World Services Pvt Ltd	0.05	6.00
Total	**0.05**	**6.00**

(d) Income Received in Advance from Related Party	March 31,2026	March 31,2025
Augmentors Healthcare Limited	-	17.93
Total	**-**	**17.93**

(e) Capital Expenditure	March 31,2026	March 31,2025
Augmentors Healthcare Limited	-	143.06
Aumen Healthcare Pvt Ltd	-	214.08
	-	**357.14**

(Currency: Indian Rupee In Lacs)

Note 37 - Leases

.	March 31,2026	March 31,2025
Operating Lease		
Lease rentals charged to revenue for lease agreements for the right to use the following	-	-
Office Equipments	15.19	20.37
Office Premises	19.57	21.25
Total	**34.76**	**41.61**

The Lease agreements are executed for a reasonable period with a renewal clause and also provide for termination at will by either party by giving prior notice.

Note 38 - Disclosure pursuant to Accounting Standard 15 (Employee benefits)

a)Defined Contribution Plans to Provident fund (defined contribution)

The Company makes contributions to Provident Fund which is defined contribution plans for qualifying employees. Under the scheme, the Company is required to contribute a specified percentage of the payroll cost to fund the benefits. The Company recognized Rs. 10.94 Lacs (March,2025: 13.18 Lacs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to the plan by the Company are at the rates specified in the rules of the scheme.

a) Gratuity (defined benefit)

Every employee is entitled to the benefit equivalent to 15 days of total gross salary last drawn for each completed year of service. Gratuity is payable to all eligible employees of the Company on retirement or separation or death or permanent disablement in terms of the provisions of the Payment of Gratuity Act. The Company recognized Rs.-7.52 Lacs (March, 2025: Rs.5.61 Lacs) in the Statement of Profit and Loss.

	March 31,2026	March 31,2025
Method	Projected Unit Credit Method	Projected Unit Credit Method
Assumptions		
Discount Rate	7.40%	6.83%
Expected Return on Plan Assets	NA	NA
Funding Status	Unfunded	Unfunded
Mortality Table	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban
Future Salary increases	10%	10%
Disability	Nil	Nil
Attrition	5%	5%
Retirement	60 years	60,65 & 70 years

Note 39 - Funding Arrangement

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”) with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Note 40 - Segment Information

The Company is engaged in the business of providing vocational training. DocMode is a platform that provides authoritative, comprehensive and interactive learning programs for Health Professionals - Doctors, Nurses, Allied and Medical Students - across the world. The company is comeup with new segments during the year namely publishing of Medical books, trading of medical books and journals, conducting customised and inhouse events. The company operates in 13 geographical segments within India namely Maharashtra, Karnataka, Himachal Pradesh, Uttarakhand, West Bengal, Kerala, Tamilnadu, Telangana, Andhra Pradesh, Uttar Pradesh, Goa, Delhi, Haryana.

Note 41 - Other Additional Information

Information with regard to the other additional information and other disclosures to be disclosed by way of notes to statement of profit and loss as specified in the Schedule III of the Companies Act, 2013 is either ‘nil’ or ‘not applicable’ to the Company for the year.

Note 42 - Others

Previous year figures have been regrouped / reclassified wherever necessary to correspond with the current year classification / disclosure.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

for Doctrack Solutions Limited

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946KCWJVG4004

Paulson Paul Thazhathedath
Whole Time Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN: BAHPT5930L
Place : Mumbai
Date : September 04, 2026

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Additional Regulatory Information

I) Title deeds of Immovable Property not held in name of the Company

Relevant line item in the Balance sheet	**Description of item of property**	Gross carrying value	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	**Property held since which date**	**Reason for not being held in the name of the company****
PPE	There is no immovable property whose title deeds are not held in the name of the company therefore not applicable.				-
Investment property					-
Non-current asset held for sale					-
Others					-

II) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year

III) No Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties either severally or jointly

IV) Intangible Assets under Development
CWIP aging schedule

Intangible Assets under development ageing schedule
a) For Intangible Assets under development

Intangible assets under development	**Amount in CWIP for a period of**				**Rupees in Lacs**
	Less than 1 Year	**1-2 Years**	**2-3 Years**	**More than 3 Years**	**Total**
Projects in progress	**188.18**	**309.84**	**647.12**	**202.80**	**1,347.94**
Projects temporarily suspended					

V) Details of Benami property:
No proceedings have been initiated or are pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.

VI) Wilful Defaulter
The Company has not been declared as a wilful defaulter by any bank or financial institution or government or any government authority

VII) The company has no borrowings from banks or financial institutions on the basis of security of current assets.

VIII) Relationship with Struck off Companies
Details of relationship with Companies struck off under Section 248 of Companies Act, 2013 or Section 560 of the Companies Act, 1956

Name of struck off Company	Nature of transactions with struck-off Company	Balance outstanding	Relationship with the Struck off company, if any, to be disclosed
There is no transaction with struck off company.			

IX) Compliance with number of layers of companies
The Company has complied with the number of layers prescribed under the Companies Act, 2013.

Doctrack Solutions Limited
(Formerly known as DocMode Health Technologies Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
(Currency: Indian Rupee In Lacs)
Additional Regulatory Information (Continued)

X) RATIO ANALYSIS

Sr.No	Ratios	Numerator	Denominator	March 31,2026	March 31,2025
Liquidity Ratio					
1	Current Ratio (times)	Current Assets	Current Liabilities	0.73	1.31
Solvency Ratio					
2	Debt Equity Ratio (times)	Total Debt	Shareholder's Equity (Total Equity)	0.45	0.82
3	Debt Service coverage ratio (times)	Earnings Available for Debt Service	Debt Service (Interest + Principal)	0.22	(0.02)
Profitability Ratio					
4	Net profit ratio (%)	Profit or (Loss) For the Year	Revenue From Operations	(0.53)	(4.85)
5	Return on Equity Ratio (%)	Net Profit After Tax	Average Shareholder's Equity	(1.63)	(21.64)
6	Return on Capital employed (%)	Earnings Before Interest & Tax	Capital Employed (Average Total Equity + Long Term Debt)	7.19	(3.38)
7	Return on Investment (%)	Earnings Before Interest and Tax	Average Total Assets	1.74	(1.12)
Utilisation Ratio					
8	Inventory Turnover Ratio (times)	Cost of Goods Sold	Average Inventory	2.10	5.28
9	Trade Receivables turnover ratio (times)	Revenue From Operations	Average Trade Receivables	3.06	4.03
10	Trade payables turnover ratio (times)	Cost of Goods Sold	Average Trade Payables	4.49	8.95
11	Net capital turnover ratio (times)	Revenue From Operations	Working Capital	(3.98)	9.21

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

for Doctrack Solutions Limited

CA R Sunderesan Aiyar
Partner
M. No.:043946
Place : Mumbai
Date : September 04, 2026
UDIN : 26043946KCWJVG4004

Paulson Paul Thazhathedath
Wholetime Director
DIN 02301881
Place : Mumbai
Date : September 04, 2026

Hans Albert Lewis
Wholetime Director & CFO
DIN: 02301853
PAN: ACOPL6883G
Place : Mumbai
Date : September 04, 2026

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : September 04, 2026

Juhi Tanna
Company Secretary
PAN: BAHPT5930L
Place : Mumbai
Date : September 04, 2026

NOTICE OF THE 09TH ANNUAL GENERAL MEETING OF THE COMPANY

NOTICE is hereby given that the 09th Annual General Meeting of the members of Doctrack Solutions Limited ("the Company"), shall be held on 30th September, 2026, Wednesday, at 02:00 p.m., at the registered office of the Company situated at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India, to transact the following business:

ORDINARY BUSINESS:

ITEM NO. 1:

TO RECEIVE, CONSIDER AND ADOPT THE STANDALONE AUDITED BALANCE SHEET FOR THE PERIOD ENDED 31ST MARCH, 2026, THE PROFIT & LOSS ACCOUNTS AS ON THAT DATE TOGETHER WITH REPORTS OF DIRECTORS AND AUDITORS THEREON:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the Provisions of Section 129, 134 and other applicable Provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force) read with Companies (Accounts) Rules, 2014, the Standalone Balance Sheet as at 31st March, 2026, the Standalone Profit and Loss Account and Standalone Cash Flow Statement for the financial year ended 31st March, 2026, along with the Schedules & Notes attached thereto and the Directors' Report and the Standalone Auditors' Report, as laid before the Shareholders, be and are hereby approved and adopted."

"RESOLVED FURTHER THAT pursuant to the Provisions of Section 92 and Section 137 of the Companies Act, 2013 any Director of the Company, be and is hereby authorized to file the adopted annual accounts, annual return and other returns, with the statutory authorities in connection with the said Annual General Meeting for the Financial Year ended 31st March, 2026 and to do all such acts, deeds, things and matters."

"RESOLVED FURTHER THAT copy of this resolution signed by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same."

ITEM NO. 2:

TO RECEIVE, CONSIDER AND ADOPT THE CONSOLIDATED AUDITED BALANCE SHEET FOR THE PERIOD ENDED 31ST MARCH, 2026, THE PROFIT & LOSS ACCOUNTS AS ON THAT DATE TOGETHER WITH REPORTS OF DIRECTORS AND AUDITORS THEREON:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the Provisions of Section 129, 134 and other applicable Provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force) read with Companies (Accounts) Rules, 2014, the Consolidated Balance Sheet as at 31st March, 2026, the Consolidated Profit and Loss Account and Consolidated Cash Flow Statement for the financial year ended 31st March, 2026, along with the Schedules & Notes attached thereto and the Consolidated Auditors' Report, as laid before the Shareholders, be and are hereby approved and adopted."

"RESOLVED FURTHER THAT pursuant to the Provisions of Section 92 and Section 137 of the Companies Act, 2013 any Director of the Company, be and is hereby authorized to file the adopted annual accounts, annual return and other returns, with the statutory authorities in connection with the said Annual General Meeting for the Financial Year ended 31st March, 2026 and to do all such acts, deeds, things and matters."

"**RESOLVED FURTHER THAT** copy of this resolution signed by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same."

ITEM NO. 3:

TO APPROVE AND RECOMMEND THE REAPPOINTMENT OF MS. MONINA ELIZABETH LEWIS (DIN: 10147743), NON-EXECUTIVE DIRECTOR, LIABLE TO RETIRE BY ROTATION AT THE 09TH ANNUAL GENERAL MEETING OF THE COMPANY:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

"**RESOLVED THAT** Ms. Monina Elizabeth Lewis (DIN: 10147743), Non-Executive Director of the Company who retires by rotation and is eligible for reappointment, be and is hereby reappointed as Non-Executive Director of the Company."

"**RESOLVED FURTHER THAT** any one Director or Company Secretary of the Company be and is hereby authorised to make the necessary filings with the Registrar of the Company and to do all such act, deed, things and matter as may deem necessary to give effect to this resolution."

"**RESOLVED FURTHER THAT** any one of the Directors or Company Secretary of the Company be and are hereby severally authorised to sign the certified true copy of the resolution to be given as and when required."

SPECIAL BUSINESS:

ITEM NO. 4:

APPROVAL OF RELATED PARTY TRANSACTION:

To consider and, if thought fit to pass, with or without modification(s), the following resolutions as Special Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 188 and other applicable provisions of the Companies Act, 2013 read with the Rules made there under (including any statutory modification(s) or reenactment thereof for the time being in force), the Company' Policy on "Materiality of Related Party Transactions and also on dealing with Related Party Transactions" and all other applicable laws and regulations, as amended, supplemented or re-enacted from time to time, and as per the recommendation and approval of the Audit Committee and Board of Directors of the Company, as amended from time to time, the consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company ("Board"), for entering into and / or carrying out and / or continuing with existing contracts / arrangements/ transactions or modification(s) of earlier/ arrangements/transactions or as fresh and independent transaction(s) or otherwise (whether individually or series of transaction(s) taken together or otherwise), with the related parties of the Company, as per the details set out in the explanatory statement annexed to this notice, notwithstanding the fact that the aggregate value of all these transaction(s), whether undertaken directly by the Company or along with its subsidiary(ies), may exceed the prescribed thresholds as per provisions of companies Act, 2013 as applicable from time to time, provided, however, that the said contract(s)/ arrangement(s)/ transaction(s) shall be carried out at an arm's length basis and in the ordinary course of business of the Company for the financial year 2026-27".

Name of the Related Party	Aumen Healthcare Private Limited	Augmentors Healthcare Limited	Chemolec Enterprises LLP
Name of the Director / KMP who is related and nature of their relationship	Paresh Jaysih Sampat	Paresh Jaysih Sampat	Paresh Jaysih Sampat
Nature of transaction as per	Transactions /	Transactions /	Transactions / Contracts

Section 188 of the Companies Act, 2013	Contracts / Purchase / Sale / of Goods / Services and availing or rendering of any services	Contracts / Purchase / Sale / of Goods / Services and availing or rendering of any services	/ Purchase / Sale / of Goods / Services and availing or rendering of any services
Amounts (in Rs.)	10,00,00,000	10,00,00,000	10,00,00,000

"RESOLVED FURTHER THAT any Director of the Company or the Company Secretary, if any, be and is hereby authorised, on behalf of the Company, to do all such acts, deeds, matters and things as may be necessary, proper or desirable and to sign and execute all necessary documents, applications and returns for the purpose of giving effect to the aforesaid resolution along with filing of necessary E-form with the Registrar of Companies."

"RESOLVED FURTHER THAT copy of this resolution certified by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same."

FOR DOCTRACK SOLUTIONS LIMITED

____

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLETIME DIRECTOR
DIN: 02301881

Date: 04/09/2026
Place: Mumbai

<u>Enclosure(s):</u>

1. Explanatory Statement - ***Enclosure – I***
2. Attendance Slip - ***Enclosure – II***
3. Proxy Form - ***Enclosure – III***
4. Route map – ***Enclosure - IV***

NOTES:

(a) A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of himself and the proxy need not be a member. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.

(b) In order for the proxies to be effective, the proxy forms duly completed and stamped should reach or must be deposited at the registered office of the Company not later than 48 hours before the time of the meeting.

(c) An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 relating to the special business to be transacted at the meeting is annexed hereto.

(d) Relevant documents referred to in the Notice and the accompanying Statement are open for inspection by the members at the Registered Office of the Company on all working days, during business hours up to the date of the Meeting. Additionally, copies of the relevant documents are available for inspection at the registered office of the Company and will also be made available at the Meeting.

(e) In accordance with the applicable MCA Circulars, SEBI Circulars, provisions of the Companies Act, 2013 ('the Act') and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the AGM of the Company is being held through Physical meeting and no e-voting facility would be provided for voting at the meeting. The venue for the AGM shall be the place as mentioned in the notice of AGM.

(f) Members are requested to update their Bank Mandate / NECS / Direct Credit details / Name / Address / Power of Attorney and update their Core Banking Solutions enabled account number with the Depository Participants with whom they maintain their demat accounts.

(g) Non-resident Indian Members are requested to immediately inform their Depository Participants about:
- the change in the residential status on return to India for permanent settlement;
- the particulars of the NRE account with a Bank in India, if not furnished earlier

(h) The Securities and Exchange Board of India has mandated the submission of the PAN by every participant in the securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participant(s).

(i) In compliance with the aforesaid MCA General Circulars and SEBI Circular dated 12th May, 2020, 15th January, 2021, 13th May, 2022 and 05th January, 2023, Notice of the AGM along with the Annual Report 2025-26 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. A weblink containing exact path where details of Annual Report is available for those shareholders whose email id is not registered with the Company.

(j) The Members are requested to register their e-mail address, in respect of demat holdings with the respective Depository Participant by following the procedure prescribed by the Depository Participant.

(k) Members may note that the Notice and Annual Report 2025-26 will also be available on the Company's website https://doctrack.co.in/, website of National Stock Exchange of India Limited at www.nseindia.com.

(l) Institutional/Corporate Shareholders (i.e. other than individuals/HUF, NRI etc.) are required to send a scanned copy (PDF/JPG Format) of its board or governing body Resolution/Authorization etc, authorizing its representative to attend the physical AGM on its behalf or to vote at AGM. The said Resolution/Authorization shall be sent to the Scrutinizer by email through registered email address to csvjobanputra@gmail.com with a copy marked to the Company at legal@docmode.com.

(m) The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and Register of Contracts or arrangements in which directors are interested maintained under section 189 of the Act, and any other relevant documents referred to in this Notice of AGM and explanatory statement and also referred in other reports attached with this notice, will be available physically for inspection by the members without any fee during AGM. Members seeking to inspect such documents, can send an email to legal@docmode.com

(n) In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

(o) Members who would like to express their views or ask questions during the AGM may register themselves till 23rd September, 2026, by sending request mentioning their name, demat account / folio number, email id, mobile number through their registered email to the Company at legal@docmode.com. Members holding shares as on the cut-off date shall be entitled to register and participate at the AGM. Members who are registered in advance will only be allowed to express their views or ask questions at AGM. The Company reserves the right to restrict the number of questions and number of speakers, depending upon availability of time as appropriate for smooth conduct of the AGM.

(p) The facility for voting through Ballot Paper shall be made available at the AGM and the members attending the AGM, who are otherwise not barred from attending the meeting, shall be able to exercise their right to vote at the AGM through Ballot Paper.

(q) The Members, whose names appear in the Register of Members / list of Beneficial Owners as on 23rd September, 2026, being the cut-off date, are entitled to vote on the resolutions set forth in this notice. A person who is not a member as on the cut-off date should treat this Notice for information purposes only. Once the vote on a resolution(s) is cast by the Member, the Member shall not be allowed to change it subsequently.

(r) The relevant details, pursuant to Regulations 26(4) and 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations") and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking re-appointment at this AGM is annexed as ***Annexure -1***.

(s) Details of Scrutinizer and result of e-voting:

a. The Company has appointed M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 | C. P. No.: 22293) to act as the Scrutinizer, to scrutinize the entire e-voting in a fair and transparent manner.

b. The Scrutinizer shall submit his report to the Chairman of the meeting or any person authorized by him within two working days of the conclusion of the AGM. The results declared along with the report of Scrutinizer shall be placed on the website of the Company https://doctrack.co.in/ and on website of NSDL immediately after declaration of results by the Chairman or person authorized by him in this behalf. The Company shall simultaneously forward the results to National Stock Exchange of India Limited where the shares of the Company are listed.

c. The resolution(s) will be deemed to be passed on the AGM date subject to receipt of the requisite number of votes in favour of the resolution(s). The Results declared along with the Scrutinizer's Report(s) will be available on the website of the Company at https://doctrack.co.in/ and the communication will be sent to the National Stock Exchange of India Limited.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013, READ WITH REGULATION 36 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015:

The following statement set out all material facts and details relating to Item No. 4 mentioned in the accompanying Notice.

ITEM NO. 4:

The Members are hereby informed that the provisions of the Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, does not apply to the company as being SME. However, the provisions of Section 188(1) of the Companies Act, 2013 governs the Related Party Transactions for entering into any contract, transactions or arrangement with the related party(ies), the Company obtain the approval of Shareholders by way of a resolution as prescribed in Rule 15 of the Companies (Meeting of Board and its Power) Rules, 2014. The Company proposes to enter into certain related party transaction(s) as mentioned below, on mutually agreed terms and conditions, and the aggregate of such transaction(s), may cross the applicable materiality thresholds as prescribed in rule 15 of the Companies (Meeting of Board and its Power) Rules, 2014.

Accordingly, the prior approval of the members is being sought for all such arrangements/ transactions proposed to be undertaken by the Company. All the said transactions shall be in the ordinary course of business of the Company and on an arm's length basis. The Audit Committee has, on the basis of relevant details provided by the management, as required by the law, at its meeting held on 30th May, 2026, reviewed and approved the said transaction(s), subject to approval of the Members, while noting that such transaction shall be on arms' length basis and in the ordinary course of business of the Company.

The Board of Directors in the meeting held on 30th May, 2026, and the Audit Committee has, in the meeting held on 30th May, 2026, under Section 177, provided Omnibus Approval for certain Transactions with companies who are related parties of the company in the following matters under Section 188 (1) of Companies Act, 2013 which are repetitive in nature, at arm's length and in ordinary course of business for the financial year 2026-27:

Name of the related party and its relationship with the listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise)	Aumen Healthcare Private Limited Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director	Augmentors Healthcare Limited Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director	Chemolec Enterprises LLP Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director
Type, tenure, material terms and particulars	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the shareholders is being sought for entering into an transactions mentioned

	shareholders is being sought for entering into an transactions mentioned under "Nature of Transactions" during FY 2026-27	shareholders is being sought for entering into an transactions mentioned under "Nature of Transactions" during FY 2026-27	under "Nature of Transactions" during FY 2026-27
Nature of transaction as per Section 188 of the Companies Act, 2013	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services
Value of Proposed Transactions (in Rs.)	10,00,00,000	10,00,00,000	10,00,00,000
The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction (and for a RPT involving a subsidiary, such percentage calculated on the basis of the subsidiary's annual turnover on a standalone basis shall be additionally provided)	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.
If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary:			
i) details of the source of funds in connection with the proposed transaction;	NA	NA	NA
ii) where any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments, • nature of indebtedness; • cost of funds; and • tenure;	NA	NA	NA
iii) applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security; and	NA	NA	NA
(iv) the purpose for which the	NA	NA	NA

funds will be utilised by the ultimate beneficiary of such funds pursuant to the RPT			
Justification as to why the RPT is in the interest of the listed entity	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies
Any valuation or other external report relied upon by the listed entity in relation to the transactions	NA	NA	NA
Any other information that may be relevant	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice
Material terms of the contract or arrangement including the value, if any	As per agreed terms	As per agreed terms	As per agreed terms
Advance paid or received for the contract or arrangement, if any	Nil	Nil	Nil
Manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of the contract	As per the Market Price	As per the Market Price	As per the Market Price
Whether all factors relevant to the contract have been considered, if not, the details of factors not considered with the rationale for not considering those factors	Yes	Yes	Yes
Any other information relevant or important for the Board to take a decision on the proposed transaction	Nil	Nil	Nil

Accordingly, the members are requested to review the above-mentioned related party transactions under Section 188 (1) of Companies Act, 2013 which the Company may enter in the financial year 2026-27. Since the aforesaid sections requires approval of the Shareholders of the Company by way of passing resolution, your Directors recommend the resolution set out in Item no. 4 for your approval.

Except Mr. Paresh Jaysih Sampat and his relatives, none of the Directors, Key Managerial Persons (KMPs) of the Company or any relatives of such Director or KMPs, shall be considered to be concerned or interested in the proposed resolutions, except to the extent of their shareholding.

FOR DOCTRACK SOLUTIONS LIMITED

____

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLETIME DIRECTOR
DIN: 02301881

Date: 04/09/2026
Place: Mumbai

ATTENDANCE SLIP

(to be presented at the entrance)

Members attending the Meeting are requested to complete the Attendance Slip and hand it over at the entrance of the meeting room.

I hereby record my presence at the 09th (Nineth) Annual General Meeting of the Company at 30th September, 2026, Wednesday, at 02:00 p.m., at the registered office of the company situated at 201, Kalpataru Plaza, Rambaug, Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India.

Folio No/ DP ID No.: _____________

Name of the Member(s): ____________________________ Signature: ____________________

Name of the Proxy holder(s): __________________________ Signature: __________________

Note:

1. Only Member(s)/ Proxy holder(s) can attend the Meeting.
2. Member(s)/ Proxy holder(s) should bring his/ her copy of the Notice for reference at the Meeting.

Enclosure – III

Form No. MGT - 11
PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: L74999MH2017PLC297413
Name of the Company: Doctrack Solutions Limited
Registered Office: 201, Kalpataru Plaza, Rambaug, Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India.

Name of the member(s): ________________________________
Registered address: ________________________________
____
E- Mail id.: ________________________________
Folio No. / Client Id.: ________________________________
DP ID.: ________________________________

I/We, being the member (s) of _______________shares of the above-named company, hereby appoint

1. Name: ________________________________
Address: ________________________________
E-mail Id: ________________________________

Signature: _______________, or failing him

2. Name: ________________________________
Address: ________________________________
E-mail Id: ________________________________

Signature: _______________, or failing him

3. Name: ________________________________
Address: ________________________________
E-mail Id: ________________________________

Signature: _______________

as my/our proxy to attend and vote for me/us and on my/our behalf at the 09th (Nineth) Annual General Meeting of the Company, to be held on 30th September, 2026, Wednesday at 02:00 p.m. at the registered office of the Company situated at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India, and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

1. To receive, consider and adopt the Standalone Audited Balance Sheet for the period ended 31st March, 2026, the Profit & Loss Accounts as on that date together with reports of Directors and Auditors thereon;

2. To receive, consider and adopt the Consolidated Audited Balance Sheet for the period ended 31st March, 2026, the Profit & Loss Accounts as on that date together with Reports of Directors and Auditors Thereon;

3. To approve and recommend the reappointment of Ms. Monina Elizabeth Lewis (DIN: 10147743), Non-Executive Director, liable to retire by rotation at the 09th Annual General Meeting of the Company;

4. Approval of Related Party Transactions.

Signed this ______ day of _________ 2026

Affix Revenue Stamp

____
Signature of shareholder

____
Signature of Proxy holder (s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Route Map to the venue of Annual General Meeting